var title_f31_33_32272="Rash in infectious mono";
var content_f31_33_32272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rash in infectious mononucleosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 252px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD8AYEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0xY84IHHarEMZZgRwO/tSQrvIOcKKuooUHjgexNeizkBIcYCntxmrGzaDke1IoAIHf/69SbCed2akYzygx+YH2Ap3kip0TYBkcj1p+wnJbgUXEZdzEpJO0jHINdLaSb1jJ4JArCux+9RQD7471t2CsAuduQOcZNTIpFTx/pR1jwhqNvGpa5jTz4cDnenzDH1wR+NeG6fdERx4LnK8HjoRX0pABgZ5HfPpXzv4n0xdC8VanYf8so5i8PzbQI3+ZR+GSPwrz8TG6uehg52fKy7bSMIGww2gjIB/z7VpLLKxjdmd9wIwO47+/XpWHbFTGQTnccZAxx2OK0LWUgqrBVAwOT2/xrzz00dJaiI4mVjIgPMbdS3bit+0uFeESyx5ZvkCdc8cfXpXL6XcoZirDB4zgnGP5VpyTeZKpbPld0DDA9PrVxZEtXZm4b0zRBZCdu35QpI+X2HeommYS7MZJABU8Egde/P+NULSOWR0IkKKTjZnjP8ADj8B39OtakSKrfPu54GT9319+/T3rVMl2RBGu+ZRIoJyGbj+vap7mFX+YeW23nBPJ7cev0qsZFjYgA8DgA/fbI7+3P8AKq907pGh5XIwGU8g9/r+vvQ0Du2Z91jIjiIA2glugH1/p6VkzMSjROf3QOSSe/8AntV+5be5OWOexXjjOfw5BrLucxoFBUZ+YKDk9uTWbLQ+dEgtd6DhepHf1rEuX85ZhH0cfLgdOf8AIrRnmZIG3ruPJ9M/hmsi7l2wr5I+XGQD6f1NJE8pzmooVQrsG3kZPeuZu02lH29Dk5HauxvWaeJgv+sPJX2rm7uJ1XEi8lTnHPHc/wCfStYMxqK6OTliENxJGPuqePcdqWNRzyef0qfUBuKSYycmMk+3I/rVdHPBGRW5wtWZ6P4BusBFJOQcV7VoNzwmWyB6185eDrsw34U8A17r4buA0S9eRziuqnqiJaHommpInnPFctud9yRlQI0GPugD+fU1pC+ERC3i+TngOTlD/wAC/ocViafIPlBJ5/KtkS7l2tgqRzkcGplEEy8CDyKWsU2LwsX0u5a3bGfJcF4j+HVf+AmobjxENMwNbtntE/5+VBeA/wDAhyv/AAICoasO3Y6CqsxUXUakMSwOdvoMdfz/AFqO01axu4hJa3UM0Z6NG4YfpTLhPtMwEkjLE4KKFyMjqfmHToKaQmU0uQdWhtLDMiRbhNJn5UwOhPdskcdsVtxKEQBemT/OuU0W4h/t3WY7NUENiI4CQu1d5GXOPXgflXQm5jSILv3ADrxTeobFkvjPqKRnwjnBYDsKz3vU7EH3oF9GYJiDyFzj1o5RmiWAQ5OeKYWWSLaCFJ4BxnB7ViyakBEcuOlQ2+o7tvzdDnrRygaUshFtOIgHkIC/KMF2IPbp71yXiCzivpLKyjzNb2eqWtwXPO4lmLD6DGa6pGL3EMynYu4uxK5DHG0DP4/pXJa9eJp/iK1iQfuru1PzAbR5itkHHb7xp+ole+h0l9eJBu5GSSc1lwXL3UobJKgc+9YiC41Ccs7FYievqK2wI7eJVQfKMVogtYkDnzCCenFK8wUVzeq+JrOyufskQlvdRfhLO0TzJT9QOFHuSKqf2J4g19WOuXn9i6e3/LnZOGncekkvRfov51PN0RSj3JfEPjW0sboadp8U2qas33bO0G5h/vkcKPrWcnhPVvEcq3HjW8Edsp3Jo9k5Cev7xx94/Suu0XR9O0G1Nvo9nFaxnlig+dz6sx5P4mr6DcVI4I9PShQv8Qc9vhMb/hFvD3/Qvaf/AOA5/wAKK2fKT+7/AOPGirsieZ9zl42AyAPyHSrCsQe9JHDtBJyR7Uu0bsKCO1bnIPV2LcDn2q1EGz8zYz0FNhhwOn/16tLGe/6UhkkakgAEc9anC8cD/wCtUUfXjP0xVLUZZnaSFN6KMEleppDRIVLXBYn+LAresFAUA5/wrGtoy0ilQRGBkseMV0dvGEUEkAdc1EnoNItRqewryn446WUOm6yi43H7HMB15yyE/wDjw/4EK9XWWMPtyeQDnHHPvWN4vsF8Q+HNS02ACRpYmCSBhhZRymD6hgK5prmVjopy5WmeA2IDOq/Kr4BGR+Va8Y27vNyFGeeoFc5YyvsilQhd4BKnpnvn0rUs5NxCuoPOMnOB9fWvLkrM9mLurm1ay+VKAAozkqOw5+lb0MoikYxnkrtjfAAI56VzcDeSTtwOMrj6/wCeK14ZmMccmwkKeACQRwePzzSQ5amwly0iLIyLHnGVY89O/qatxuMF0wXTqueSvfI+g/KsaB2uJmBjdVzxtIPHrz1rTtFCQhQx39cjjcM9P5H6fSt0yHoiYyGdpCqebt4YA+/GfXP9KjaPbujYncFIY44B9KvoihVaNRsPUk4z649ce9VtTWOSEofnzgccBsYHOPQdafmTfWxiXX3hliuDtC9MD+WP61n3SjPALM52gDJyM8HNaFwDICzFS27KJngjHqfeqStIAyAkLgEhgOAPb+ntWTNLlI25mX958qgZOe+fSsa/Xy1ypLbcgnsR/j0rpr2Mg5VSMkNz6fX9awpLcYfzWAYdf65pXEpdWc/Jbktvyu1V4wfSsnUIywyeTz09K6C+YBmVMKrcAehrEuAORyHU8fSrizOae5yV/EWimGMEjcuOeQc/yzWWGOMjOK6C72pKrhcqp5H+PtzXPyp5M8sW7hTwfUev5V0RehxVFZl7S7jyb2JiO+DXu3g67WSBOfevnxWKkEcV694Avt8EfPOK6KL1sYy2PbNLk4BzW0p4Bz71y+kTbkXPf3ro4ZMxg57de1bMzJwxyCeSDn6GpfMypB57EHofqKrK4BAPWgyZJI71LQ0zGuPBmiT6ib2KIafcAENJbt5YcHrkdM+/WtmZrfTtMH2F1ka3UmJRJkcg8sckkdyTUU8pIxgY7g8ivPfFPgj+0Y3GmX8lornJtpCTCT7Y6fSocLapF83No2cxF8TbfQ1vorexuLtrgszyiQKC54LDPUdaZpvxVuhCiXenbguFDRTZJHbIPtWLefDbxFEzeZaRyxkhRLBKGHJ9OtdhY/BsTwJ9o1J7e6HDIIs8evJHFc69rfQ3aprcqT/FbT4k33MN9GGOBhA3OPY0/QPiloup2OqXH28WZjCxol5iMvk5LKMnIHSsj4jfCk6Z4OuryHUWmubd4mij2bd7F9pU+g2nOfY1zNr8LtVnvYtMjltZJvJS5uZQxMcKsTtXP8THBOB2quaotGibR6M9Gg8YaJJAGk12yZiM/wCtrY0TXLfVMNpUrXiF/LDQoXG7GcZHoOa4pfgrN5if8TeHyyBvPkndn2Fek/D3wi/hKyurW01R7iOaUXG2WIAI4XacY9RjP0rSPtHurEy5UrpnapHdRwrEgaONIwMpguz57Z4weeteU/FDWLCz8QW0d3fDzIY/NBVSxJZs8AccYrovEUyWFncXer6teJtwW+YIqHngAZyTjge9eZab4S1zxjfjVPs6W2nt8sL3RwNg+7hRyfc9zSm3stwgluzqtH8TXuuIV8OaNdXm3hppWEEQPux5/IVuxeFtU1IZ8QawYYCebPTSUz7NKfmI+mK1/CmhJ4d0RLGJ1llHzO4G1WY/0rYcrzk1qot7k8yWxnaVpen6PbtDpNnDaRN1ES4Zv949SferDdcnvzUj+/PGKjHQ84z2z1q0ib3G/wBKQpjGR7UE5A9KVWG35c5NMQuf9k/nRTfn/wCen6UUwMcQl++M9eamit8dR24+lPXg8jj1qUHGQePTtWpzDwoCgY/GnYHQGkLYxjrSBdz8rz60gJE54P6d6Lm2WaIlTiQDKsvY1KiE9T/9anF1jB34HGBz1pDPLNT8aeJNJvLm2u9NtWWEgQuxwJAepxVI/E7xM5g+zaXpsEi58yR5GfI7YAAxxWl8WpvMutPUqq/IxOB15rhYlIYDOM1yV5yi7JnZQpxlFNo66x8e+NFMjSXumSM5yEe0O1Bnthgf/wBVB8TeKdVY/bvEEtvGqn5dPiWHJ9ycmufgm6r+Cg96vM4SPYMZ6deprjlOT6nWqcV0MW4C291Iu/zFZt4Ynls56/iTV2ymVi2QAehPXPpxSaxb5tIp1PzKdrALxtP/ANf+dUraV92SRz0x0rOequb03ZtG6HR4wQWBz1bp71v6b5LLHtJ3A5wDyOP5Hj8veuVjkOMBs54wO34VuaXd4WQKBkrkLvwNvpWKNZXtobi24EYkDlCx6DAHHOf/AK3vV+x2Sz/OzeYwy2RnIzwf07VlI73UfyjGzBbuWIyQeO/0qaFmEZZBiNSCxcfdz2OBz061rFkbqxrrNGsnG5X4Jw2VU9P6CoZnaQsRt2cjAHU9+Py59zUDb43DqwbA3Z6kAd8dKmkZ4irIAXB6jLL0/LGPz9a0EZ7bmLrHuZjzuJHUdfp1qOMxxguAOTgHqCOnPvip3Y28JjLncSQGC8beeT/OqIdkZgOue/Oe9ZsrcSe6QFMKSp4wex/w/nWffCKQN5RA34apbmOR7oFWJxkDA79ifw4qIwRqC3XcMdckZrMTSWphXULuwJDYYgkdAD7ViahG0bMeclehHTpXVag2wFypLY7n07fTrXP3eLhN4+UcDHcU0wbvuctewgggZKtwB0rntSQh45COSNpx0OP/AKxFdRMjNuGBnnBPrWJqEZlDRqPnUhhjr6GuiDOSrEyVJJ68emK7j4fX/lz+Wx6HjPpXGm2mB3mNsD09uuRWn4YuDBqcfOAfet6btI5mj6X8Pz7lU/jXWW5+XqK878K3O6GMg131i2F9M+vauxmJbz603Pt+NGR3PGKYTgAt9T70gEbkkNke1Rccg07ccinxpuf0460wH6XCTdIyHjdz7it1mMZd2cbeODxj8agtIDBCWVQXxwP/AK9VNQvLK0gF1qJVbYqQWkPAYZyCvQk44rGTuUjxf4s2WoTXmltqF9IdHiuC8SxAqJo8H93jPzOSQMnj0r0Lwzp0ulaGlzdQM01yI2kUfe3sQqxj0VBgV5n8VfGQur7TZRbF7GyHniEEKxJIVS2eO3T0r0jwjqms+K4bXUb6CCw023IKwh97yOOhJI6DPA96yhJczsayT5UdGYd8s8QwrQlQ+fcZGKieFskFlIIwQR1qzpKPLf6zLJn5rgRqD02qoHH5mpbiIAtwQf51vGVzNqxy1z4d0ue6imuLUusJ3pAXJhD/AN4p0JrZa5bIHA7Djge1OkTg5GTUXku7EIrn3UZxVWSE3ceZs56jPvzTS/zdeajSGVAoljO8Dn5cZqR4iWZMHeBkqoztHuegpiuNLEj5Rkd8dKiYnJwATXA+O/ippfhyU2ejMmp6ky4kMMuY7cDoNw4LE5JAzWVpHxntrlR/ammXcQzzIn72MDvyBuGPxrP28E7NmipTaukeqqd2c84/DNKoOQF4I6Y4rj3+JHhhbXz0vo2yCVjBySB39h25qnqHxO0uz0B7/wA+weWRf3FulxvnJPQbAOPfNV7SC6iVOT6Hom+L/npB/wB9CivCv+Fs3/8A0J1n/wB8t/jRWX1mHc09hP8Aqx7AjZXk4A5z2FSqecEHmsi2vY2Gc8/pV6C4BJ5/Ou04C8FFWFQqM43VBHMignBPGfXNT+cmTlhnrtB5+tJghXJC5HFU5HJfhuntVkxtPyW49B6U8Wu3jjJ+lF0gPJ/ikCNZtFJ5FuD19Sa4+D5mPTA6j1rsviqpXxHCjcf6MnU+5rjYHKuQO1cOI+I9DD/ATRAoqEj5ieK0LeJCQZCC5PAqlHzPk8gfzq2d+QCMEjH4Vxs60y+8aXFq3mHETKUyo7eormnLwTFX4dCVOP5100MisRGeAoH0x71keIYglxHcRjbFKuD/AL49fw/lQtVYL2dxlu7GQljjuSKvwEh03YHHcDkelY9uxUhT26ke9asMpaNCQoxwB049awZ0p6HU2d2hDBSVYHO5h82eMVPdXSRzlBGxHUkcZ/zz061zlu7rsUkE7hnB/l/nNaEd7I0qAk5boTjjHX9OlUmTya3RrRTdmzz8xY5AA7HA/lUyuwcq0ZGDkFieQDyP8/rUdiYFVsA4PJzgZ4yMVde4SKEFFLR9ANvOB6GtUQ5a2KMp+SfymwwyRu6jsRVWdApmQ5JGVHGPmPXj6Y/OrckpRgFkALNg9OuO2O/+NU3VzJudTnBIHQD3/l+VDsUitAzBiSAMjcCeQD0/Gs2+K732ckAEEdTzV+bjMTvuIfIyeM+pxxxz+NZ10pjOWxuI+ZR1welZMtblC7k8yRfmbHdRxWRdKzK7LkKRkg9hW4+w3Kjb8wGCAeMf5/Ws+6jCKQoBDDv2pJibOauCoXGCSOSfUVj3Me6VdzH5/lLexGM/rW9dRlpdwxggc9hz/wDWrHuk5IB4K1rBnPUR5/8A2tPDeqtypL28hX5TjkHvXQaL4khm1OFbiKCOHozMuCPcEVjeKLLGoeeAR9oUOf8AeHDf4/jWQkRVuBkfzrfbY47M+u/CCRS20MmnySXEZTcTt/XivQtO5AA+ufavjrwnq+p6d5bafqV1abOgif5R+ByK948F/FS5ihSPxBamcIBtubJB5hHfch4I9x+VdCrx2ZDpSautT18qQCDxtGKhxjiuavvip4QtdPtrxr8hFLZtmt2Nw7D+EIRkcnOenHFdD4a8RaT4p0ptQ06WJ7YJuKY2vGQMkOD90g5/nVKomQ4NbjguePf0q3bRfOuOnSsmw1KG4vtSs1V0uLGfyZVb3AZWHsQQa15TIbGUQMUlK7VYDlc4Ga0b00J6k17eDyZIYxJuwcbepA6n+nrXB+K3TX9Z0Pw7BIYgga5ulT5liKgALn+8Bnj3zVXxxHfPrNjpOn39x59zC7vG77VyGAySBnb1ra8E+G4NEiknncXGpyghpM/LGvXant6nqay+LS2he2tzxrxhp00+p62SNzSRhkGOBtYLj9B+dfQ/gvSl0nw7a2rMHkKh5T2LHrj2rzfxPp2dXuQg5k3Lx6MVb+hr1yz4gi542j+VZwjZyNJyukRXE0dioQYM00h8pOm5jzRMWyqzAeYV3fKfzx+Yq66KxUlQWXlSR0qm7I1yxZA00abQPZjz/IVaZmQTIoDny5XK9FjGdxHUe341y+veKNN8L2BuPE0qxTOdsdpBIZJCeoG1SMDGOe9cx8f/ABBqmn6DDbaVdtawTOYrnapWR1PQK3YeuK8Bs7PUdaupZk8y4mbAeWVsk4GBkn0GKyq13F8q3NqdHmV2eq+LPjQkh8rw3p0igAgTXLYUkjr5YOeO2TivN9R1vxH4pkMVxd3VyjHJhiykQPuq4H510mi+CrZI92osZZe6qcKK6mytobUeVbQxxxoONo4JrmlUnPdnTGlGOyPPtP8AA0zBW1GRYl/55J1+hNdha6ZFbWSW8CiJP9gfzqXUZ2WUBWXJ6EcZqIX22MOwwOgBqNDazsVrrRrKVQJLGGU55OzDGq1pp1jBJlbK3jCnh9gz7HNaQugeUZcNwKFkaR2jI2swIDf3SR29eTQF3Ybl/b/voUVnf2ddf9BOX8qKq5Nj1BrcjkfKRUsUjoPmH6YrpzYht2VXn8KrvpxJ6Cvd5jwjMgvCpH9a0Ibld+flBOM8dvSo2048jqfpULWMiEFRjHoaQG7bzKzYU7fp0q+pG3hifQ1yi+bDj5ia0LW+5AbPTrSaA87+MAMfiWHjG62TH5muHWQiTp6/hXafFhvM8Q20gO7Nsv8AM1xbbeWUAn1rgr7noUPhRYtWBbBHI5Bq3GxU5Ayf1qkrjIVcYB5Aq15m1cEZ4woH865GdS1LVvHI8gGPlHNWL62N5ZSWyjDj94j+jD0+tQRTiKISTDAxySf51oIcowUgZHXvUp2Y3rocjA37lWUqTkKV7irlvKB94EgcNt4OMdvz/SodSiS1vZHK7Vl+ZSOhOfm/z70kbk7SBtBzjn2pVF1NKcujNlZQZApIKZIJJHzf54q7EQZCvC4OegBOPr169Kx4HBRASCH9c9P8itCwbdJw5CnAGG/r9azTNTYgJOSuA4II5HPpWmJ/LiZAxwBjKr35PU+lYcbkZfYCOnK4UfX2Oav20isqgbmI6dx9M1rFkSL8kxbkjYR/EQDuwe+OfQYpLlmlQGMtKQcZxwWz2+lRQfvB5alVDEbtp5YZ475PpWgIyrFU+6q8YIxjHp/npVGbaRgTrtwWU7j3x09/TNQXFvGyGZ9wBYkjPQeldBcgcI7A4ABwOnvWTfn9yoIVMADaDkj/APUO9ZtFKVzDfyoZDnGTwcHjHX/Cs29Ie2BRhnnGRyeavSom51dhx0I69aqhUK7U4xwfofeoLempgyIRH8oHJ/mKx9TiCeYVGM889jXRXoVcEBVc/ofese/VCp5Jwcc1cWZyVzkPEMG+yZ1AxE4cZ6gHg/riuZC8dc9q7a8VZImib7rAqePwz/KuKYNGzIwIZTg/hW6OOaszY0N8SbT0zXdaVuyNg4xXnOlS7J1yMZrv9GuAArAnI7j+tTI0pPodNuNw6h0AeMYBxkmuh8Ma/daNOkaJBLps0oN3DLGD5gyPmJ6kgDgdK5Vbw7DnB7ip4pCo3Zz3471Ck4u6NpRurM9v0TX/AA5fXt3rEdxErXMaLciUeUyuuQpYHA6HbkegrdtL9DPEzxCPT5498crtx9OeuRzn/GvJNK8W+HktdJstf0uWW3tImiLPAJossfmO0HI6AkkE5PGMV1Gi+L9M1y+gXT7tLi5aJpzbSxkNCo4IYYwO2K9CnNSVrnn1IOL2H+MvEGmw+L/DMtpfWrKs7W06g5ZEcY3EjjaCoHXuPeukupfKlyp4+vWsjw/YaVbmeTU7WEXc4YJuT5cZ3YI6Ej5cnsabf3Y3Pz3wMdq0gn1M3boZPiS9Eeo2dwfutdRxHp/ECK9Xt+LeJSeVUCvnv4paidN8Ki9HDW13bXBPsJQMfzr3vTr2HULKC4hbKyIrLz1BGajqy3okaG4Z61katLPa3O+GNHEy4O5tpBUEgCtJR83XOKLmOOaJklUMv6j3o2YjyH4o6ba694QubZpTHqVrG9xbjztwdx87Rknjpg+uK858IskPh63MbeYXXK4HQ+ldf8bom8O6BHb6bbKscsxmad3LAEjYVC9shuc9cVyPg+JP+EYtQqkNg4PPrXJXa5mduH0jqbsbzGNhkHIoVfs8BLn8AajSNvLYu2C3cUzdHvKKNx9e+awOhjZAkyBmXB6Dvim7EHCqNvv0qXC4wAx+v+FROeTzhQOcdqoV2MDwnhAuQeOOaryRSOwKsQoPWmgIk/DdsjmpUOH3ZJOcYI4pLUezF8uT/nqf++aKTMvr/Kii67Ae+WzKQMsTzVry1PP41zMF4y5+b24rWt77coDcnrkGvaaPBNEwrxwCSetI9krjkEfSkik3DhwP6DNXVk3AY6VDbQ0jLk07k4AOfWqcumHllwM9q6MD5egx1xUbJkY/HrQpg4nh/wAUYGttXg3HkwD8OTXE5yMDNej/ABlTbrVmMfet+n/AjXmfzsx2DseT0rmr6u520H7qLEbqH5XsSKtxFiVxgg44FUULRsN3UHBNWbYYKljznvxXG0daZpQklWDhXGc7Wqytxt+cLuZeQBwSazAxD7VJyTgmtGJfMUKVB2/n9agq3cNYt/7R01mjj2yxfOmOuehH0xXMJOGjBz8o7k12VswRN2SSM7Vzw1clrFqbPUnXaqRy/vE9PcZ+v86pe8rC+Fl2xkV9zjnuTjpj0q9CoKkwuoQZzk9/5Cuft52BAJJPGPf3rTxsi3AnaThl559c+n1rFqxsmbdq4ILyNlCCpBGcCtCUbVL7w8JckkDGR6Y/zmsO2EqSr5jqOcjD43DA/wA/Wtq3vUETB+gXngAH0z68mrQpPW6L1upRRcuByM4Azg4/LP8Ahz3qV7lvKdzvLMPkAwCcdP59qSNVaPodmB97r7Z5qvKCskhiiVsrsDE4AB64xjJz+FaLQhNN6kj3eA8jMsZ3DavqMcmsu5lLnfknd3xgdPar6W7NzMw3McnPHYnk+p96p6nFIIwEBIC7hnnK+nsBUstNXMdsyQ5xgIPvAd/SqTsYo3UNuLfp61sKIxalHYMqtnr1x0I/Ss24CSKvABYfKcceoJrJml77mLODlUIOMcn3rPvosgquB7HtWzqBIkBAzJ6A+1Zlwu58jggY2nnNCIl3OdukxuJ4I9R+BrktdjCX5kH3ZBu/Hof8a7W9Xl1+8OwP865nXYAbUOPvRHOP9k9f1xXRF6HJURjWzbXB5612mizKVUk5yK4VWweldNodxkAHnA4FNkQdmd/ZneT8mVIBNWGZDgKepz6Gs/TZG8pCSxz0q07KAS+evGOtZM6dyO4dsfLkjocVHHdSxbmtLme3mAwJIXKMOc9Rz1H6U64O5flbk8Z6VTY4UHqw9DQtNg3Vi1rPinxFcRhVvAsqReVFNkrIhyCXyOrHHJOc5r0Lwh4hm8TeHxNdeW2q2q7LkLxvI6NjtuHI9wRXlDjdk9faptA1mfw7rUN/brvX7k0X/PRD/UdR7iuilXal7z0MalFNe7udP8Z7hLrwRqscbboysAUj/eya9E+A3ika/wCBNOLlVvbNBbToD/d4VvxUD8c15/8AFiGE6Hcm3VfIuJ8ED+CQZyD9eo+tcd8Gtfk8OrbXi7mhDGK5jH8SZ5/EdRWyqcs2mYOnzJWPsi2uRIvVQePutnNF5dw2ltJcXMixxRrudm7AVmaZcwT2kU1o6NA6h42ThSuODxXH+MtfmVrdYNuSWaBHAIyOPOYegOdoPU89q1laKuzKKcnZGH8RL1NWltbG6UFppFupoTz5Uag+VGfdsl2H0rnPNWFo41UCMD7oHSnCSN5pWaRpJyxZ5WOSzHqT6moRGEVmlI3HqR6V585czuejCKikhbhZCr7SNnYDtTLMJ5b9C4OM+tKvBI3kbfelklCx7lXnPIFSXfoMumxEcd+9VY9o3BtxGMipnZpYQdoUc5yajEexF2MTnrQF7KwwQgsCBtA5AFIJkaQrkj696kMuGC57YzioXRAwKsc57UBvuSYHp/48KKj85/8AnjLRSA9eKlWA9eaVZHR8rnHpWjLGpf8Ahz/KqrweozXvHhIns77GFc89Oa2LW8Xu2e49q5l4SGqSKSSPOMgdKTSYHZJcK4x/OpQQec9eBXJRaiU4fIrRttTjPBfp71m4DucD8agE1fTWJI3QMM/Rv/r15wg28hiwB6D0r0H40yCa50mRDnMMi8f7wrziKXY5XsRxXNV0ep2UfhRNdxs6CQKAhO7P1pIcMy4X1Iz15ptxO0ghiTn1wKcrKrBP1B5xXJI643LqEgblyzYz/SrkSPtUHlern09qp2sqySEZ+UDqa0YiRkKB06Vky1oTQsnncqd3QAetVfEFuL6wIXm6iO9dvqOq/lVmCN9hGQuehPrVuOEJGwztwvUcmhaA7Hn1q4DKzF9snXaK10/eRY3AkdO2BVLXbQafqbR/MIpR5iHtk9R+dMt7jC4z8vAII9+DROPUqBt2dxtfIYEsT0Tnp78Vq28EQVirOVOBiQ7s8dP1rnoH2ENnDA5I6j8xzWjb3IKmMAA4B5J457VCNGr7HSRrujiVdygAg7OpP97Hfn6UqStHIY5XLSHCgcA9uhHp61n6feYLYMjREkEY6YPY5q7O6+dG3EhcngdB7bf0rVMztZ2HTzSxqoTcF28FyMAeuMZ7celMEMrWzB2O58Dd0+oFXIHJtfn4fO0EryM+9QXF0AzBDsjLBzvOMnvj2602rgm9kUZbOIWpy2FBOQBjP/1qyZ4FeMsEPLY61sNceZayu6hQCCS+cEH1rJZgbwozFVGcZ9M//WrJouNzInPkkKVyAccj7xqlcxtwQ3bIOOa2btIi/wB3cwyT+P8A+qs6VQoDEZHce2akJO5z17CiuQvTr1rCvY1YSRvwCCu71B71u32TLuHHX3rEuATkn3rWDMaiOLkR0kZGHzKdprT0a42SgY5NQawoS8ZsACQbuOnoajsn2XCkdDWhy7M9M0mUMqhyAMcZ7VduGcggngjp1rC0ZwwG7HuTW7C+8H2OM1mzqi9LkfO0Z6gYqpK+xic9auvldwPT+VV5EVRnHTJ/GkO5Tx1K5Ht6VDMnmZXJwRirDKAGwcA9KrHOecHFAM7vV9V0nV/hXdme5jh1i3mgIgZsNI6jZuA7grzXlvgiUJcXlsc5jlJHt3q9chSGyBn1rN8MRGPXtRbPB2HH1/8A1VpKfPuZKHK1Y9u8G+KW0vSLrTr0zG0OHiaMfMuT8yD0z2PbJqvPei5nnuWwpkOQqkkIOyD2A4rm9PJeNsnAPfNaMQMMO0DdxjgVMqkpJJmipRTbW5djGzBQ5DdzSYLSA849Ae9Mt5hJGxZdqjjmlguNwJ6HOKhFu4XCMi5jT5T1AoTGzc3BPGKSSZUUBSWZjzSPFJhwXJJGelUISWYqVKR7h3x0xSsQcgg47imwQtFu65OOc54qKVnAbaNzZ4GMigLX2HscgjJ/E1C3PzA49zRHEQjGTqedvp71WljZFIU8HkDJoHYfv9m/IUVRxN6v+dFFyrPufTBtlAOQCegNNaxYdxjjHtUpJPqcVZjlLIM8lT0r2btHgmY9jgc56kVCbQ8fKcfSt2IBjycCnCIEuu3auBg7v6UcwWOXltOvBHoPSqU1r6A/hXXT2m4cngcZrPurN1wQBzVKQM8r+IkTLHZF2yPnA/Q1wp4Pzc8c16V8SbaQWluzrhRIwB+orzZ+MjmuXEfEddB+6EZIkHH9KnQKZSz4CD35xUSDYRg4ods7uu3qSO9cTOyOpdtmRZmYngDj61p2owrMeSTyf6VmxqBGCf4hnP8AjV+I7o8rzgZwD2rMtl1CwOAvQ9AOKs25OcYA45PfNV0ywVnJ3DnBPP0p6AsGlkyHZcbQcYpIEVvFNgL/AEssoH2iIh0OcZ9V+pGfxriUY8srAqexr0pV8wBWBAyCK4TxHYf2Zrc0WM20+ZYuM/7w/A5rRaqxKdmJBIcADt61ctWkKApkNnjHfPasaNiUyD1xnmti1OIefu46e5/w9awasdF9DZsbhInG5wCCMMp5z3z/AI1pxiOSNwVJUDPHVWPqO/8A9euVQsWGdqrgYB6Vr6fcmMdQwTgAZP8AKqiyZR7G4gC221A6LjAOeCOmOarh40VPNUxkD5Ezkk+/tkdfalguiIsuABuJ3KnB4quuJCuwg5wAdvIPTqe+fyrVErzIXuiRtjbch6sR1OOuD2/pVYREzvKoBC4BxyT64qxcSId4hO4sTxu6856/z5qrLC0MDgqZCRjI4xms5I06FW5hLXO4uoX+vbNUpuY9vGPTHvWgiyJbHzOScZHf/PFZc7F5WQfKM9T0/wA5rNhuZF1Aqo5z7g471h3CfIB2FbtyGVWVznnK5PQVj3Iy4Bzj0q4mc0czrkBe0LoCWibOPY9f6GsFG2uD2rsbhAxYMMhsgg/lXHXEZgnkjbqjEf4GtlqcklqdfoV0yxqT8x9K6+0KyRZIIbrXnOh3O1whru9On3Rhgcgc9OtTJGlN6WLcgAkwc/zANQtnGcjB4INOeXzADj2PYio2dckA5FQaMrzdCV49qqtnZzVjfkMD29utVZpCD2GeaLDK0x46g84qlpLiPxFIpPyyQA/k3/16tytkYA471mIwj1+wYnh98R49sj+VNESZ6Bbs23YASvtWrDIyRkt1PTNYVnMc4GTjFaqyDYGyfX6VLRrc0YpBgHAPNCOwJCgDqetUreTMbMTwKsRydB83Iz9KaBk/IIKAcZJ4psLybsuQWPaohIQ2OSR0J/lT/lMgkJPHAGaYr9xs9y6lQpAQfrT/ADOz8Ke3Y1Wnk/fDdjI4PtTrqLfGCpHGR70x2Q92AGVPUd6pB3eVgxJXvUrTbSgIycY3DrUE0nUNlh3pCH7z/eH5j/Ciqm+b+4tFFx2PpxudrH7w9e3vSSPJFGzQRrLKB8qPIUUnPc4OOMnoabvyMr16YxQxycZwPTPX6fhmvaseEi4zFXynPoamjZgDk54qkG6LjvmrKnA5GQP85qRlnfnIyKUANw2MCq7PgHHf2qJpWU8HilYLnH/Fu3z4ZinUfcuR09wRXikvC8dfSvdfiM/n+D79WH3Ckgz2wwrwiT5mO7se9ZVkdNB6DkwQTjAHFKnIGOg5PHWoQQFA7frQMopOeD+lcUjtiaiOWDKc8naPpV+3kjjQheQDjBNZVu+EUHGSMcmp1AV1wBjPPGcmsTTyNiCQMV354Xk96Vgzn5XB3k4YdgD/APrqlCSZ2BztKjHPT61dgwkQ3MFUKQfr2ouNaGjGRIrIrbCe/XFUfEth9v0eRF+WW3bzYSTjcwHI/EcflSwN5bF2JOBu31a81pJAVzuOMcZJbrmriS4nmkcuVBBODyOOa0rcs8YywGT0PVqb4psG03VeF/0W5Bmjx90ZPzKPof51SWUh85Jz3xUziVCXQ17cjbukDNg5z1P1x3q5EqAbw+FB6KeR6H6VQtZWdFUHORhQTmrEjptwrLgnOAP8/wCTWaLvqamnSFyfmKFeFxzgngYB/r6VZnUBGXcVDEAgcKex5/8ArVmWZcsswyuD6fL/AJxWpZmQTDcw+Q8Kev5/jWiYm7AUEJOSWbtHjP8Anp/nFTtkrIwYkuAxbGcfT/69VJZdymK32SoQflAbIHdTz/n1qf5poQBt3qM+gx/+umSynctESETjJJLZ+97VjXkYl2Ntxgg89KvzrI92HwFAGFAGFNZ91KWkwpIyecelZs0S7GTfEtI29Tsz0HpWdcf6z5k7YzW5fxhYtyAZIJ61kzLIeWB6454pIUtUYV0PmIAGM4rltfTEqzAElvkYj1HT9M/lXZ3UZIfAB7/hWHqFuLi2kiI5I+U56Hsa2izlqIwNPl2Tduld5pM2UQHH515tExV/RlNddo91uUANg+lVJEwep1zsItnQ5445qJwAhwAM85FM3ZiUHrjj2qPzCGKnnjGPWszot1DGDjqTVKY9QOccirAbhhkZHeqxyr8cN70CIJSNrYPTtWRfN5U9pL3S4Xk+h4/rWvM2VUY5xWLq4Is3bPzJtcevBB/lQtyJbHdafITEfX1zWnEDtAPI9qw9LlBjBX7pGfzrWViSgLAfU/rSZotS+hABCnA9KlIYxllx8g5btVVRtILMW3HJ9qnMoTCnv1FIfUnXeY1Bx04PrUigYOclgOlVndE2jdjuOKehy7MD7DI6VSEEtv5j5yMjt0P0oyVjPpilkY846VTlL5IDYwMnimNakrAkAlRg8VDKgRd5PI6U9SfL38tkdvWo9rE/e+TH8Q5pAV/tZ9B+VFS5/wCmaUUiuZH0huG7ADcDdnjGfSnqxLY4PfpxVdZstnHHvUgPT165r3DwS4jZzjqOhFTxtlSDkY4FUEYYx82f896f5p5OO/HNKwGgD7Z9s9KVk3Hr9az/ALQeMUfbGXgZpWYFXxTYtP4b1dMZBt3YD0wM/wBK+dpiPLAHUjNfSU155tpNE3PmROhz7qRXzTOSgwR93jB9qyrJ2N8O9WRsTuVRg+uKnVsgb8kdM+9QYJYc9sU+L7owe+7NcEjuiy1asQ7bhjB4x16VdiJI5GWDfT8qz0dQ2VHAOPxqzFLhwCCABnn2FYs1RoySBMELwSAcflVqWbdtRjhWGc+mKzlcmTEnGMYIbvVtudvBIGc+nHt1oKXQ0onRlEknCL19c/57VbTMaAqpZyBgdvYVRikDoN6YXrk+tXRMhYEkbdvX/CriQyn4t0xtT0mZECfaYgZ4tvBLAcgexGR27V5qk++MM3KlcZ7161JclSJAAzY9OnoMetea+JdP/s3WZY1Vlt5/3sJ9M9QPoc1ctUSrrUZGWkVdhBYKOnANaCupiUnJ2gA5PWslHRNgJ9sdcVdglLEqo+v48Cudmqdzchumgh2quGccgHr2z7VeiuDuCZ+dsH7vDe3+fesaK4VANrfdAJXHIJz0NaEEu5ELAB85HTj2561SYPuXFZYm2LtVSpLBhzyP5Zq2rkIpGx3cDJ9GH6dzWfGhllDSHrkfKcH6+/r2/Gp4YX2L5uAnYA/dP4/nVidivEryHc4CIV4xn5ucY5rNntpHmVWbAJLnbwD61rXUhWVgFIJ5Jxnt/L/9dUZ2kI37SpYZz9KhouNzMv8A92GBCkhcrnPP+eKyZ5ciTjLEbvxrXldmhBkU5Xvgis9oRuYyLjPGKgppW1MaYgxAqfmJ7Csq8UKBgY9MVtToqSAL9316Vm3iZfHAGP09auLMZo4nWIPIvN4BVZfm44we/wDj+NXNCmAYA8Yq3rFt9ot3VV+ZPmX/AOt9RWBYz+XMrD7prbdHLsz0aBxLHjPOPWpio47Y6VlaXcBlXnrWqwBA5+orNo3jK6GMMbsDn0NVmfIIxx61I2Spz1ziqzAhCFHHekMglO5gR2rO1Rd9rKvUmNh9TitByQcYPSqdyu4YPWglmx4cl83S7ZgeWjXP5VvxMDtODuHSuR8Gy50m2Xvgr+RxXUwuO/bnkUSWpdN6I00cnPHy9xUmFJ3Ed6qRuAcAHHarMfAxjPHQGpK2HtGrSBmByOBinbiMbVyWHA7Uh3EYHUHoKfuwMKcf/XphcajsWAYEn8s07JffuGOw70xxzgccnJp2crzhSDjmqC4jdgc+lQl9o6nPr0p0yHeG3Hgc1WmuPLUgZPy8EjqfegESeYv979aKyfl9X/I0UrBc+m0BznPXtUobkHjgdKrIcgkD605HPOAc9Oa908MuBu/4daCxK5PGeeagSQ5HXI6ZpwcHoMfhmkBLz0qNgDzzilZuh/nTXYfxA47UwGDO8Y9a8D1+E22rXsI6pO64+hr31vnGQvNeH+PojbeKtRRhtzJv/MA/1rGuvdNqD94wSxD8D3oB3LzwQe1MZsbjnocUgfAweAvNedJHfEuROqoOhI5qzC/EgbgE849KzI3VndWOMHOT7mrLnapCDrwfzrBm6NWNlZlcE5UE8jPtmrEMpcE7mC9Rxzn1rMimIO1SBz+dXBIpj2qoAXnHTJzSKNOaVZLbcvoMc+55q5GPlj2gBSfvMcDmqNm2VRQAeOjAZP8AnFPgmJlAPz8jaT/nrmtER5GjFvD5Ayy5G1c81m+MLH+0dJcxHM9uxkiHXOByv1P9BitC3kLs0ik7RnB6ZP8Aj/Orn3WZ/kBACsSN2c9sf56VsloRI8hjcFT1K44/z61pQkurMrBcDkjr09aj1+w/s3W5rdcrE37yIFSOD/D+Bz+VRwEsSG5GKwmrFRZo6c5O0sA3/wBfkcdTWtC5DDYApBNYKAqxcEgY7nA/z14q+J9qBozjgdDz+H+FZmj1NoSpGqmJg8npipLW5kJcHIRVJX1yTz9f/wBdYiTmRQ+4vkc4ODyP5VbSdNqLxuAJPJ9OMVomPl0Nljtj5KsRgfLxyT1zVGaXDHIJYjLA9c9hj069Kg+2LKCkcj7cfMcYDEentTUXP7zcW3EADsT6dKGJRtuQXYWROXwCM8Hr9KzLuKVpl2jAU9+/v+NackicAjOTwBwev8qrToWJ+cEKOgrNlbGLqEIBxg5bkEVmXERdi/Ib0rcuSxfa3HG0fWs24UlumDn1oRMtjn54wQSoII5/GuQ1CE2944UbUY7lx6eld7dhQx+UA9/euX122LwMyrueI7uD/D3reDOWpEk0a5ygHUiuljlDgc89a4DTpzFNx0NdfYSb0BzwKJIKbNGQ7yD07j2qFmwCe4pS3p0pbfaW+YAj0qdzRsryDPIH+NUbjAIGc81rywRsx2kr+NUbixYjh1znPP8A9am4Mm6KvhB8Wbr3jmcfrXYQkkDIxxyK5HQLO4tGukdQN8pdSpz8tdWoaIRiRJIwwG0uhUEeoz1pSWtyqe1i/G2W6c561ajIT5c89wDVW3QnkEZA7VJAcbiDuyeT3rM0LJPJycHtinNtww5B68dajbjdgcetKNwAIH0A71Qh6nJK8kY4OaUja+QSzHng8Uq/d56/TihvubgfbNUAxSGbkk+2Kzb6QMGjjIaRm5XI4qHXroWjITPIPMXBjVuCM+nqemfQVmWOoRuzggxBVJLZGF468VcablqZyqKOhp/Zk/57D86Kg+0P/cuf+/VFV7Jh7VH0qhGOOtSKucdTnjrUOcD2p+4nGTzXrHkFg9jTiRuG2oQ4xz364FKjA8E96AJRnH0PShmz6Y9aQdueaUNhcZFAC9uCcmvH/ivF5XiosAMSQRN1z2x/SvXweO/NeX/GSPGo6VMq43wMufcN/wDXrOqvcZpSdpnnEjZOGxz70gbjPJoYnPtnrUeTswefrXmyPRgTQcsNxPJ5rT4APbIxx3rNjA2nHBPXPWrySYjAYHdngk9BWDNdy7byKHVnQFycgE9PerCEuzmQYbPcVnwAFgz/AHgMjNTjd5qHPA6gUrlJGtFIsl1kMdyDGen+TV+JE6oQCzlienzdayAPMRt3yjcCSfarsLO5wHO08J2znk1cdxWNi1WOQ5UsVY7Tx93jg1dfzG53DZweT/T/AD+JqlZjaqqQ0ZXAbB6HtgZ5qdMkO8SHCtnYMjJ+vpnvW6MXuc7450z7RpRuo1Jksh5i5PJiJw3H6/hXCQy5Bx94eleuy7UhLumRjbIGHy4PBHv19u1eRarZtpeqT2pYsitmJv7yHlT+X8qioiossRzFYuD8vrnP4VejZXXcrbQAOetY8LHy/m+90HtV63C7cDhSMHNYWNrl4IGAy27AOct2q5b8ugYguCRjtjH61n27Rh9pUt6MR0PtVhIwSBlgR15/Wgq/Q0hGhUgLl885x+Y9/apQAqli0jEcHecZPSqali2/kjGAOn+e9TxsGUqNpOzn5zzj09P/AK9USLKMISrZc/xEYA+n61m30rxvsTHUr92tBMcr8uRgHaeMf0qjfKu4tHtIAByM4HbrSaKjuZ14HMqswIJ4OPzqpJ8yEDAb0Pf/AAq+SzDd82Mg5PY1Umj+bgYGMj3qQZlXcYYcgkdC3oax72MfxdD6d63bv5oSq45PGayrmM7DuB6dPSriYTRwl3EbW7dO2cqSOord0e73ABjVTXYMxiVR8ydf93/9dUtMm8ubBOAa13Rzp2Z2qurKdv5UsHXCke/NU7WUNHgVLgDoTj8qhaM0vcsF3UkspPuOaiNwvQH86qlpkX5HDex4NQyXjIcTR7c+oq+ZE2Zv6CxfUoIiw2yEryMjGM4r6Qhe8UaJobT+bFc2ymS3lQFcFeFwRxgelfLOj6haHUbYrOIisgJIbkD6V9If2zFd/EXSJYZIBBbRohcS7Uc7D3OcdQMV20Lcpz1NyfTdG0eaZ4L/AEHTZFTIDjdC/wCJU81X1/wb4etbSS5gs7qzfH7vyr0SID9GycV02j6raRzyR6iZrS5LF28yIPGwzxtxyfyrlfir4nt1it7CycXCiTzJWjiKj5RwuDzjJyT3q5wh1QRnO9kzg9VitLW6ljs7oyxKvymVQGY+nFZouskYCH0ANVL6982SZnDbnOclMVSW4UMPTPpXFKEb6HWpM31n2sNyHHfBqzcW8kFn9suImjtwC5LHBC+tY9gsV5fxQb03SMFGW249Tk+1bXiG7tr8/YrMk6bEVyzEkOV6bR6A4570OnFR5n8g55N2RxxgbUro3LwTSb+hC8BewGatDTIBkSw+XuG0krtyPc1uReWWCBG54+tTjg5HIxWamy+RdTA/sa2/57N/39P+NFdHlf8AnnH/AN8//WorTnZHs0ezA9M556+1PxxweKaMnjIJHWlVcEAHmvUPKJAVCncD+dSJkk/zqMDj19utOUe/B/OgCUnHbNAyONpzjvSE8Z/KkDcd8dxnqKAHluAAM1wHxih3aNptzjmOdozx0DLn+ld9kdF7etcl8ULYz+D53xzBNHLn0Gdp/nUzV4sqDtJHihACgEnpxSR/dYNxzSTH5uABgU0H7vJ4968yaPRgycHyzkdSeaswvl9z7gmM49e1VWHyLwD7dadISwCqvzDr7VzyRvE0kYI3sxwPrVlZQIyy4O7p6jmspyXVfm6HJz3NX4diIox+n6VNii7BN50YEh++TkdumK07Jdnlh8kDgEtn6YrnpnkYsIuChrW0mVvKBlG1wc+3t/StIBJWV0bZvH4VxtVWznrnrx+daUZafcQHKAZO7PX/AD+dYEytIgcE4OPm7L6YrSimErLkxsrgDlSCTxn8OD+dbxMWtCzdXEckYjBdH3E4IOH6ccce/wDOuD8d2yO0V4iBHiHluOckEnBP0Jx9DXYurFn3OhCnpnLMMY6ex5/KsPVUW9SZHXyVkHlMuclR78nP1zRLYpRRwkEh3BSOM8+1XEL7SYz8o5wP8KoGOSCZ4pP9ZGxQ47n1qwsrJJ82cEDn/wCtWDQ4sv2zP5gfJGAPx+lWluCjkPuwcnjgfh+VUop2DBXLe/09a0LaQTR78E4PQDmpNbl9NrAN8p+vAH1/OnRyFmYkrtAKkEAAY9fWqs8vlEHOH6k4/wA9aSMGaOT5gcjqCM/56UDS0NBrhWk2qCGXGeM9v881R1HbynLDPy/L27EfSiOGTrPJuOck56n2/CpbiRmjKRRxhGG3c2Dx9e31471QJWehQTEmAQ3HY9/eq8xTeVJAYnB9M1bhbahZm3SJkA44P4/kazrhW80sz8Zxjv8AT9KloqxTmx8/XjnJHFZt0OTtAAP59K3LmSNgYwqnPJJFZs0OWZse4B7GgykjnL6EbGDDKkc5965FlaCYo33kODXd30RJ4zt6gY6VyWtxbJlk7H5T/StoM5Jq2ppaXOCoOee9apPy8cDr/wDXrlNPm2OFz34zXRQyfKCD2pNWCLJD1OfXiq9wQyEHpmpm5Oe2e9V5hgdTipZRztzbtJqUaIu4svFdDp2kXYQFVAHpuNUISU12zb1V1rtbOUKATTbukKEbtlvRb/xLpQVNO1O5jUfwGTeo/wCAtkUXFxrdzMJblnmlbnccc1YhlBXIJB44x0q3HJjaSce2aXO7WubcivsZDNqIH72ByPZaiWecSKnkNvOBgjFdEkwXMjOQo6g9qWHNw4eUnA+4vYChSfcfKira2cjANMmc9gOBV7DiMALgewq6sBZCZGEYHf0FOzH5hUEEDjmm/MpK2xDbAKpIJJ44PSmyMFjGWAU+3BqcKVwwYc9QR0qtKoIbDHDdOn6UB1GfaF9U/wC+j/jRVfyx/wA9R+QopBoe+IBu42jPX1JqQLxnkj2qOMAYHepQQuOuP5V7R4hIg5BweTn6U8IPTH0pgfGc0quG4OOaBiHJYDOPfFOAIPuP1pdw6DnnBprEjkDv6UAKuGIzuFZPi+3Nz4W1eHqTbMw9yOf6Vq7sYABJPqKJohPbTQtj96hjz65BFAtj5lkPIwOCM8+lRbjnH6VLMhiJVvvIdpHuOKix+8PXPXivNmj0YsVHPUfdxk1YSQyNu7EdqgERwpP44qZQex249K5pHQi1C2TuHLDoKtKUYE5GcAn8Koo2GQYIz26Zqxh1TIIDMBnNQWkWYcyQu3cn2rVs3xsQDLMcKpPXp/hWYG8lE2gFuOD3rRjKuqbl+bAIPcGqiNl+JzuYM2ArZYZP5cdsGtJWMbx7HVwSV6gE++fTr1xWZbqpPynDMauQly7K2RkEDuB/kVvEzaJQ21l8plKjPBTHtxnp1+nNU7oZjdii4XJIYfd9unXnNa8cgZSGCNGzYAboTx2P1qjfK0Qbht4JJ29FPB498/19KpoE9Th/E1r5EyXijMc2EkGMEMOhP4cfgKzMeYy7cmMHd9K7HU7N77TnilC4YcMD90gZBP4iuHtWaFhG/BB2kE9CDWLWgLc1YQuflHI7Dt61LE6oMRDDAnknB5/ziqyPn5hnOevr6/SnRKzMXBGffvioaNIs1LSYsAGB479fxp6xJ5pZs9OnY1FYybEVQdpY9M4xVn7yAgAEnOBz09KQ76j3BkzsbAH3Suc+/wCH+e1D+aBtcHYQAwJ79QfamSzGNVMeX+U5I7e9RRiWSJXkYhAASCOT700UMuB5S7EDAnJyv6gms6XYoXBHJOQeT9f6VtSFWO2X94MZJC4xVOeMMgWPAbOAMc/jQxpmabZt5OTuznGOv+c1HcJtGGHz9TntWmF7r8wB+nPP6VWlhDHzX4zz6Z+n5UiXruYF6gC8n5hweOK5zWLXzIpEBUkgkex6iuslQk4PcnPvWPew564x/LiriznqROCjbDZHGK3tPuMouTWPfxeTdOBgAncKmsJCrgHpWj11OaOmh0m4kdc/WoZjkge9ELZHNNmPy/54qGaIz5TjVNPbj/WEfpXYWwDY561xd1gX1jnjE39K7OzOAueT3pPZFQ3ZpxbQx5znrj1qYFmkChSVPQg1WiIGBkc9M1cXnKxj95kBfQe9SdHmKqiSUr/AnLH1b/61dBZW7bV2hduM4I6VV06yUKEUZPdj3NbVpbspUk4B4Oeh/wDr/lVpCEeHALYOOuPWqbRksSuM+n8q0JRhh5jFSOcDo2agLp8wIxn8+KbHqim+eRyCTkntVZ32DrlSMjA5q1KojRVGencc9c9KzpGTc20fvMZ3ZxSuIZ5sX9xv++aKXzD/AHkopWFc96Vdq8/jT8nPFLhducH6GgL0J6ehr2zxgTdnHPHvTiF25wN3WlVflwecdPanJF3JNIBmWxgDI/KgMx7HPvUsaYB9e+e9P8rOSSc5zx2FAFdWOMMc569s0CQ7hjtUskJGcBiPbv7VG0bbFbaUJUMVOCQfTimI+ffFlsbTxFqcDAgpcvjHoTkfoax2PBNdr8VbRoPFLysvFxAjggYBIG0/yriN+OOpINcFZWkzupO6Q8EqSRnk9qmGcYP6VAjfKQx/+vUsTFjjjkda45HXHUnTADEcn0PFXUbCopyT0Bx3qkpG9VOemAPSp0fDliPx9fSoaLLxPGSvToMdKktZXVuCSMZAHeqqSFy4IJIx3zkVd0994xjaV45PX/PSnEeyNawYBSDg7V3Bhz+NX1iWdSQ2zdySRnI69+9ULfzEuEcYCLjPH3c+mKuQPuusIrEnIxt6fh3FbxIe5agaNggJGxeiueFyOPx6/TFPYSeQxyuN2duM7ee3TJORTbZVADNnaWJOepPp/n3ply7SxlU2upKguQVKjPp656/pV9CbXM+5mVZmQoAx7qc9sVxviKyMN6JsL5c5PIHG72x2x/Ku2e3yWaUgt1UhMDA9f896yfENqJLQwqV4AKH/AGvb8jms2VbsctAyAYYt6Z9f/r1dtmU4BPzdSRxjH+elUIxkdCCOM46VctchlBByD+dZNWAvL5ald+7IydxHJ/H8eKnMi4HlkN1+XP8AkVCiLhiMYI5bPU+/pTwgVCm7GMZwOv8AjSKRMNoCuxIHXJHFHmRfISwKg9gWIprKNxAAZGOMc4Pv9aXaMuknyhTwSKCkWMB8yEEn0Pr346mqju7sVVPlznJ6/hU4UhcAHOOxJ/yaaE53FckdfX8vrQBAyhlA2ggnPPHHsPSqkyl1GflC8bRxk88fnV3GwHIJHU7fWq1wv7oBc7+pJ5xSGZrqpxkcAYLHjFYt3HkEFQGPUVumEDgnKgdqoSxggnI9c49+v400zOSOC162OPMAwVOfwNY8TFXB967vVrQFWyM54wetcTNbmGZo8dOR7jtW0X0OWUbM1rWbKjp0qwx+X6VmWTYABPI6VoKdydR71LBGdenMtmeoEyiu0thuIC9zz7VxWqHbHGR/DKp/Wu2sTkg+2aT2Lh8RqwQCQ9iT0zWtpVqZZiwGVX5Rz+f+faqVshOCD8xOB9TXX6VaLEigc8VKOhiW1qVRtuQ2BgL/AI1cYqNiqrFh1A6//rq7sVAFOME4Ht61GQmAUypboc8H/wCv9apMaIJFVj5hGOcMOgA/z3qhLArkZX5mBXd0IB5/pV/yypO3BxgEE4OO2ao3rEAsR1HfvyeB6UmC1MmcuHBjZtp5xj8OvrWY0i7jnI9q1JkLseduOqt/Ksy6wJGyoyOvekgkR+YPV/0oqLzj/e/SinYzPo2CLUv+Wmlc9MR3KNg/jirsKXZ4/sqcj2mjP9aLed9u7j6elWY7qTIAIH0Feyzx0MjiuR97S7gAd96Y/nThBLyWsLwcdNqkfzqVbmXOdx4xSQTyvECzsThT19eaWpRCUuOo0+7Ix0KqP61IEuOP9BZex3zoP604sSACTg8daiY/MvA5p6iJQkoXBt4c9h9pXio5d4GPIB47TIcVBI5K9hUJO5CSAefSnYDgPjDZiUaXcJE6lfMhbcOOxGCPxryOePbLtGSAOa9p+JSKvhsyhRvSePH45BrxW5Yvctn1xXNiI2Omg7oI1X5gCc9fpUsabhjOOMZqsGOMDpUiOWMfYyFVJA6Z9K8+R3RLcOWOAoyehqwqEE8cjpiqyuwNwpOSm3DHryKttI2xDn+DNZ2NL32JoIiE6YHUn0q7Yf6xiflxznP61n20rMpyfbH41owfdB9P8KENs04GdVVX9eo69asom9S+84GDnoP/AK3FUIWYxAliTjOfxxUqSt5qJgbWO0gjNbIjc20XAKuSyqMH5c//AK+9MYnbtLgd03KM9ePqf5CobUtgrvbGA2c9TxU6EhnXJwDxk5rQnZkRw7OJCcA5z9ByPpVTUIwd7MMN1G7HNaFwAskS4DBk5yOevr+tUr9BJEgJI3E5x7cVLVhp6nDX6FLmTOfm+bJ4570kJyQq/Lxu56D1q5qsS/Zy+PmEmKzI+Du9R0rMb0Zq20q4AI2Fj36D2qYSdlAKnGecc1UtVDtg+hqa2AZUJA+U7AMdjUDJlYhxs5KnDZHQVKGyVKqdxP5CqbSH5c4wBjGPQipB0UdiM0kUTs/Iy3C+3I/D3pSygADOcc55qr5jGRgT+v0qXGQvbccHH0p2Ac4yAAQRnIJ9RmoZwAVOMZJyT2PvUwG5yMkcdqrXLFRweoyc9+tFgTImCMWHGMducjvWbdOrPtVSucnHpx0q+q7+GZsYY8H0qlJ+7lJHbB5+lCQMyrwbwR685Pr9PpXIeIItnlyqOF4P0PT/AD7119zGAOrHLDqfxrC1GJJGKuNwJwc9xVxOeocvDMVk4NacNwXXgVhY2s4BPysRzVy1diB9M1pKJhF3JdUYfY2PoQf1rstMcMkbA84B/SuI1Pm0ceuBXXaOc28JPdVzz7VLXulwdpHZ6R++ueSMRj9TXY2kqW8fzYDnGM84Fcd4c+5I/fd/XFb0pPlF8nIH50kjrjrudA00crRqpJJxtx1J+n41JKArHY6IW4JLE9+Mgisdi0EblWYsFxksQTwOuMetSmWQsoLtknrnkc9PpVNW0HfsWrwrCiBmUn+E7vXgfUdvWsm7dN69eOB6E5z0+vFS3x2hSABwGxjuTWPcyMHfBxtUMPzqJKzsAsrq+4bQFP3vy4rJuHVc8k/X9Kklc+aw6YJHH0rEvZG2vk5zk4/OlYiTJ/tX+cmisT7TJ/s/lRTM+Zn/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A generalized, erythematous, maculopapular eruption is often seen in patients with infectious mononucleosis after the administration of ampicillin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32272=[""].join("\n");
var outline_f31_33_32272=null;
var title_f31_33_32273="Diffuse panbronchiolitis Lung";
var content_f31_33_32273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse panbronchiolitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Collection of foamy macrophages in alveolar spaces adjacent to a bronchiole compromised by diffuse panbronchiolitis (hematoxylin and eosin stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32273=[""].join("\n");
var outline_f31_33_32273=null;
var title_f31_33_32274="Clinical microbiology review: Gastrointestinal infections";
var content_f31_33_32274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical microbiology review: Gastrointestinal infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32274/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32274/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32274/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32274/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/33/32274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the Gram's stain is a first step in the examination of most specimens, only rarely can it be used to distinguish enteric pathogens from normal stool flora. Thus a variety of culture media, biochemical reactions, serological grouping, and other tests must be used to identify the bacteria which cause gastrointestinal infection (",
"    <a class=\"graphic graphic_picture graphicRef63042 graphicRef58979 graphicRef71759 \" href=\"mobipreview.htm?3/42/3747\">",
"     picture 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Microscopic examination, on the other hand, is the principal method for diagnosing intestinal protozoal and helminthic infection (",
"    <a class=\"graphic graphic_picture graphicRef58729 \" href=\"mobipreview.htm?7/13/7391\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 4 year-old girl has fever and dysentery. What does the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    stain of stool show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef54162 \" href=\"mobipreview.htm?27/53/28496\">",
"     picture 3",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef62877 \" href=\"mobipreview.htm?29/20/30016\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 24 year-old man develops fever and diarrhea. What does the Gram's stain of stool show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef82723 \" href=\"mobipreview.htm?11/38/11887\">",
"     picture 5",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef62098 graphicRef72909 \" href=\"mobipreview.htm?33/47/34545\">",
"     picture 6A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CASE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 72 year-old woman from a nursing home presents with abdominal pain and bloody diarrhea. What does the stool culture on sorbitol-MacConkey agar show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef68990 \" href=\"mobipreview.htm?37/10/38062\">",
"     picture 7",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef82227 \" href=\"mobipreview.htm?19/23/19839\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CASE 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 23 year-old man presents with severe watery diarrhea two days after ingesting inadequately cooled shellfish in Louisiana. What does the stool culture on TCBS agar show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef58998 \" href=\"mobipreview.htm?5/51/5951\">",
"     picture 9",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef73856 \" href=\"mobipreview.htm?7/40/7823\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CASE 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 72 year-old man presents with secondary peritonitis following a ruptured cecal carcinoma. What does the Gram's stain of this peritoneal fluid sample show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef81575 \" href=\"mobipreview.htm?27/3/27711\">",
"     picture 11",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef66936 \" href=\"mobipreview.htm?29/6/29807\">",
"     picture 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CASE 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;What does the wet mount of stool show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef70523 \" href=\"mobipreview.htm?31/28/32192\">",
"     picture 13",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef53646 \" href=\"mobipreview.htm?33/60/34752\">",
"     picture 14",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CASE 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;What does the wet mount of stool show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef65371 \" href=\"mobipreview.htm?40/53/41808\">",
"     picture 15",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef73134 \" href=\"mobipreview.htm?42/10/43168\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CASE 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;What does the wet mount of stool show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef52124 \" href=\"mobipreview.htm?36/62/37856\">",
"     picture 17",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef63910 \" href=\"mobipreview.htm?38/39/39536\">",
"     picture 18",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CASE 9",
"    </span>",
"    &nbsp;&mdash;&nbsp;What does the wet mount of stool show? Question: (",
"    <a class=\"graphic graphic_figure graphicRef75712 \" href=\"mobipreview.htm?25/1/25617\">",
"     figure 1",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef50369 \" href=\"mobipreview.htm?26/30/27105\">",
"     picture 19",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CASE 10",
"    </span>",
"    &nbsp;&mdash;&nbsp;What does the wet mount of stool show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef66192 \" href=\"mobipreview.htm?32/63/33777\">",
"     picture 20",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef78000 \" href=\"mobipreview.htm?35/9/35985\">",
"     picture 21",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CASE 11",
"    </span>",
"    &nbsp;&mdash;&nbsp;What does the wet mount of stool show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef57012 \" href=\"mobipreview.htm?2/30/2529\">",
"     picture 22",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef68716 \" href=\"mobipreview.htm?3/38/3681\">",
"     picture 23",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CASE 12",
"    </span>",
"    &nbsp;&mdash;&nbsp;What does the stool specimen show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef76436 \" href=\"mobipreview.htm?30/25/31120\">",
"     picture 24",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef55444 \" href=\"mobipreview.htm?31/35/32304\">",
"     picture 25",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CASE 13",
"    </span>",
"    &nbsp;&mdash;&nbsp;What does the wet mount of stool show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef67190 \" href=\"mobipreview.htm?29/22/30063\">",
"     picture 26",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef82347 \" href=\"mobipreview.htm?31/29/32223\">",
"     picture 27",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1268 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32274=[""].join("\n");
var outline_f31_33_32274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CASE 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASE 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CASE 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CASE 5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CASE 6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CASE 7",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CASE 8",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CASE 9",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CASE 10",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CASE 11",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CASE 12",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CASE 13",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1268\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1268|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/1/25617\" title=\"figure 1\">",
"      Stool sample 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1268|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/21/30046\" title=\"picture 1A\">",
"      MacConkey agar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/34/38446\" title=\"picture 1B\">",
"      Salmonella Shigella agar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/36/11854\" title=\"picture 1C\">",
"      Salmonella Shigella agglut",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/13/7391\" title=\"picture 2\">",
"      Stool ova and parasites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/53/28496\" title=\"picture 3\">",
"      Methylene blue stool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/20/30016\" title=\"picture 4\">",
"      Methylene blue stool answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/38/11887\" title=\"picture 5\">",
"      Gram stain stool 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/46/14063\" title=\"picture 6A\">",
"      Gram stain stool 1A with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/28/35278\" title=\"picture 6B\">",
"      Gram stain stool 1B with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/10/38062\" title=\"picture 7\">",
"      SMAC agar stool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/23/19839\" title=\"picture 8\">",
"      SMAC agar stool with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/51/5951\" title=\"picture 9\">",
"      TCBS agar stool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/40/7823\" title=\"picture 10\">",
"      TCBS agar stool with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/3/27711\" title=\"picture 11\">",
"      Gram stain peritoneal fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/6/29807\" title=\"picture 12\">",
"      Gram stain peritoneal answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/28/32192\" title=\"picture 13\">",
"      Stool sample 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/60/34752\" title=\"picture 14\">",
"      Stool sample 1 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/53/41808\" title=\"picture 15\">",
"      Stool sample 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/10/43168\" title=\"picture 16\">",
"      Stool sample 2 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/62/37856\" title=\"picture 17\">",
"      Stool sample 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/39/39536\" title=\"picture 18\">",
"      Stool sample 3 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/30/27105\" title=\"picture 19\">",
"      Stool sample 4 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/63/33777\" title=\"picture 20\">",
"      Stool sample 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/9/35985\" title=\"picture 21\">",
"      Stool sample 5 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/30/2529\" title=\"picture 22\">",
"      Stool sample 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/38/3681\" title=\"picture 23\">",
"      Stool sample 6 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/25/31120\" title=\"picture 24\">",
"      Stool sample 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/35/32304\" title=\"picture 25\">",
"      Stool sample 7 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/22/30063\" title=\"picture 26\">",
"      Stool sample 8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/29/32223\" title=\"picture 27\">",
"      Stool sample 8 with answer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_33_32275="Sorbitol: Pediatric drug information";
var content_f31_33_32275=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sorbitol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"    see \"Sorbitol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/16/12548?source=see_link\">",
"    see \"Sorbitol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Hyperosmolar",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Osmotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"      see \"Sorbitol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Constipation, chronic:",
"     </b>",
"     Oral: 70% solution: 1-3 mL/kg/day in divided doses, usually twice daily (NASPGHAN, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hyperosmotic laxative, intermittent use: Note:",
"     </b>",
"     Usually as single dose, at infrequent intervals:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 2-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral: 70% solution: 2 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Rectal enema: 25% to 30% solution: 30-60 mL once daily as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral: 70% solution: 30-150 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Rectal enema: 25% to 30% solution: 120 mL once daily as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Toxic ingestion, adjunct with charcoal:",
"     </b>",
"     Children &ge;1 year and Adolescents: Oral: 35% solution: 4.3 mL/kg;",
"     <b>",
"      Note:",
"     </b>",
"     Current guidelines recommend limiting use to a single dose administered with the initial charcoal dose of 1 g/kg (AACT/EAPCCT, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:0em;\">",
"     <b>",
"      Hyperosmotic laxative (as single dose, at infrequent intervals):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:2em;\">",
"     Oral: 70% solution: 30-150 mL",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:2em;\">",
"     Rectal enema: 25% to 30% solution: 120 mL",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:0em;\">",
"     <b>",
"      Transurethral surgical procedures:",
"     </b>",
"     Irrigation: Topical: 3% to 3.3% as transurethral surgical procedure irrigation",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, genitourinary irrigation [preservative free]: 3% (3000 mL); 3.3% (2000 mL, 4000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 70% (30 mL, 473 mL, 480 mL, 3840 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15054204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze; below 15&deg;C (59&deg;F) cloudiness and thickening may occur; warming will restore clarity and fluidity without affecting product quality",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irrigation solution: Store at 25&deg;C; brief exposure to 40&deg;C does not adversely affect the product. Avoid excessive heat.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Hyperosmotic laxative; sweetening agent (OTC product: FDA approved in ages &ge;12 years and adults); has also been used as humectant; facilitate the passage of 	 charcoal-toxin complex through the intestinal tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rectal: Hyperosmotic laxative (OTC product: FDA approved in ages &ge;12 years and adults); has also been used as humectant; facilitates the passage of  charcoal-toxin complex through the intestinal tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irrigation solution: Genitourinary irrigant in transurethral prostatic resection or other transurethral resection or other transurethral surgical procedures; irrigant for indwelling catheter to maintain patency (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F222447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid and electrolyte losses, hyperglycemia, lactic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, diarrhea, dry mouth, nausea, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Management of ingestions (poisonous): Absent bowel sounds, recent abdominal/rectal trauma, recent bowel surgery, intestinal obstruction, intestinal perforation; volume 	depletion, hypotension or significant electrolyte imbalance (AACT/EAPCCT, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irrigation solution: Anuria",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15054203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in infants; other causes of constipation should be evaluated prior to initiating therapy. Use with caution in patients with renal impairment, severe cardiopulmonary disease, and in patients unable to metabolize sorbitol.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15054202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Large doses may cause fluid shifts and electrolyte imbalances. For the management of acute ingestions, administration of sorbitol with charcoal is not routinely recommended and if used, therapy should be limited (eg, single dose) to prevent excessive fluid and electrolyte losses; excessive amounts of activated charcoal with sorbitol may cause hypernatremic dehydration in pediatric patients. Current toxicologic data does not support the use of charcoal/sorbitol combination to reduce the bioavailability of ingested drugs nor improve the outcome of poisoned patients (AACT/EAPCCT, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Sorbitol may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Sorbitol may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluid status, serum electrolytes (changes may be delayed due to slow absorption)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A polyalcoholic sugar with osmotic cathartic actions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, rectal: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Mainly in the liver to fructose",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists, &ldquo;Position Paper: Cathartics,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2004, 42(3):243&ndash;53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32275/abstract-text/15362590/pubmed\" id=\"15362590\" target=\"_blank\">",
"        15362590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Clinical Toxicology and European Association of Poison Centres and Clinical Toxicologists,&ldquo;Position Statement and Practice Guidelines on the Use of Multi-dose Activated Charcoal in the Treatment of Acute Poisoning,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1999, 37(6):731&ndash;51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32275/abstract-text/10584586/pubmed\" id=\"10584586\" target=\"_blank\">",
"        10584586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Charney EB and Bodurtha JN, &ldquo;Intractable Diarrhea Associated With the Use of Sorbitol,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1981, 98:157-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32275/abstract-text/7452390/pubmed\" id=\"7452390\" target=\"_blank\">",
"        7452390",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James LP, Nichols MH, and King WD, &ldquo;A Comparison of Cathartics in Pediatric Ingestions,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 96(2 Pt 1):235-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32275/abstract-text/7630676/pubmed\" id=\"7630676\" target=\"_blank\">",
"        7630676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar A, Weatherly MR, and Beaman DC, &ldquo;Sweeteners, Flavorings, and Dyes in Antibiotic Preparations,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1991, 87(3):352-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32275/abstract-text/2000275/pubmed\" id=\"2000275\" target=\"_blank\">",
"        2000275",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, &ldquo;Evaluation and Treatment of Constipation in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2006, 43(3):1-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32275/abstract-text/16954945/pubmed\" id=\"16954945\" target=\"_blank\">",
"        16954945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12801 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32275=[""].join("\n");
var outline_f31_33_32275=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049964\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049961\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222403\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222389\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15054204\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049966\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222447\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049970\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15054203\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15054202\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300074\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223042\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222399\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079771\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049963\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049960\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049969\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12801|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=related_link\">",
"      Sorbitol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/16/12548?source=related_link\">",
"      Sorbitol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_33_32276="Overview of muscular dystrophies";
var content_f31_33_32276=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Overview of muscular dystrophies (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/33/32276/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32276/contributors\" id=\"au2018\">",
"       Basil T Darras, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/33/32276/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32276/contributors\" id=\"se5269\">",
"       Jeremy M Shefner, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/33/32276/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32276/contributors\" id=\"de6967\">",
"       John F Dashe, MD, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/33/32276?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      MUSCULAR DYSTROPHY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Muscular dystrophy is an inherited disorder that causes progressive muscle weakness (myopathy) and atrophy (loss of muscle mass) due to defects in one or more genes required for normal muscle function. Some of the genes responsible for these conditions have been identified.",
"    </p>",
"    <p>",
"     There are a number of different types of muscular dystrophy (",
"     <a class=\"graphic graphic_table graphicRef61217 \" href=\"mobipreview.htm?18/32/18957\">",
"      table 1",
"     </a>",
"     ). The primary symptom for most types is muscle weakness, although some dystrophies also cause heart disease or reduced mental ability. The diseases are distinguished from one another by the type of symptoms and the nature of the genetic abnormality causing the disorder.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      MUSCULAR DYSTROPHY GENETICS",
"     </span>",
"    </p>",
"    <p>",
"     The genetic defect that causes muscular dystrophy is passed from one or both parents to a child by a specific pattern of inheritance that varies from one type of muscular dystrophy to another. A brief explanation of how genes are inherited will assist in explaining how children develop muscular dystrophy.",
"    </p>",
"    <p>",
"     In the process of reproduction, a male's sperm and female&rsquo;s egg each contributes one sex chromosome. Males have XY sex chromosomes while females have XX sex chromosomes; the male can contribute the X or Y chromosome, while the female must contribute one of their X chromosomes. A male infant results if the male contributes his Y chromosome while a female infant results if he contributes his X chromosome (",
"     <a class=\"graphic graphic_figure graphicRef76396 \" href=\"mobipreview.htm?38/57/39825\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Duchenne and Becker muscular dystrophy and some types of Emery-Dreifuss muscular dystrophy are caused by mutations on one of the X chromosomes carried by the female parent. These muscular dystrophies affect 50 percent of male infants of mothers who carry the genetic defect; this is called X-linked recessive inheritance. Females who inherit their mother's defective X chromosome (called carrier females) are usually disease free, although mild symptoms can occur occasionally (",
"       <a class=\"graphic graphic_figure graphicRef54604 \" href=\"mobipreview.htm?3/38/3684\">",
"        figure 2",
"       </a>",
"       ) (see",
"       <a class=\"local\" href=\"#H8\">",
"        'Female DMD carriers'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       Myotonic muscular dystrophy, facioscapulohumeral muscular dystrophy, some types of congenital muscular dystrophy, one type of Emery-Dreifuss muscular dystrophy, and some types of limb-girdle muscular dystrophy can develop if",
"       <strong>",
"        either",
"       </strong>",
"       of the parent's chromosomes carries the defect and is passed to the infant; this is called autosomal dominant inheritance.",
"      </li>",
"      <li>",
"       Most types of congenital muscular dystrophy, a rare form of Emery-Dreifuss muscular dystrophy, and some types of limb-girdle muscular dystrophy develop if",
"       <strong>",
"        both",
"       </strong>",
"       the mother and father pass a defective chromosome to their infant; this is called autosomal recessive inheritance.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      MUSCULAR DYSTROPHY MUSCLE FUNCTION",
"     </span>",
"    </p>",
"    <p>",
"     Normally, electrical signals travel from the brain through the spinal cord and into the nerves that lead to the muscles. From there, the signals are transmitted into the muscles, where they stimulate muscle tissue to contract. Along the way, the nerves must be in good working order, and the muscles must be able to accept the impulses and generate a response.",
"    </p>",
"    <p>",
"     Problems can occur anywhere along this route. If the brain, spinal cord, or nerves are damaged or diseased, the electrical signal may not be generated or get through. If muscles are inflamed or abnormal, they may not be able to respond properly to a nerve impulse.",
"    </p>",
"    <p>",
"     Diseases of muscles that cause weakness are called myopathies. With myopathy, nerve impulses usually reach the muscles without any problem, but the muscles are unable to respond in a normal way due to the disease.",
"    </p>",
"    <p>",
"     Many things can cause myopathy to occur, a few of which include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Inflammation of the muscles",
"      </li>",
"      <li>",
"       Inherited conditions, particularly muscular dystrophies",
"      </li>",
"      <li>",
"       Problems with certain hormones that affect muscle function",
"      </li>",
"      <li>",
"       Chemical imbalances in the body",
"      </li>",
"      <li>",
"       Drugs and toxic substances",
"      </li>",
"      <li>",
"       Infections",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      MUSCULAR DYSTROPHY TESTS",
"     </span>",
"    </p>",
"    <p>",
"     A number of tools can be used to diagnose muscular dystrophy, including genetic testing, blood tests that identify the signs of muscle damage, electromyography (EMG), muscle biopsy, electrocardiogram (ECG),",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     echocardiogram (ECHO), which is an ultrasound of the heart. Tests are chosen based upon the type of disease that is suspected. This is particularly true of genetic tests, which must be tailored to search for specific abnormalities.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Electromyography",
"     </span>",
"     &nbsp;&mdash;&nbsp;Electromyography (EMG) is a test that evaluates the electrical activity of muscles both at rest and during voluntary movement. Abnormalities in this activity can indicate the presence of a muscle or nerve disease.",
"    </p>",
"    <p>",
"     A small needle is inserted through the skin into a muscle in several locations (usually the arms and legs). The needle is connected to a recording device that displays the muscle's electrical activity at rest and in response to contraction. The electrical activity may also be heard as a static-like noise through a speaker.",
"    </p>",
"    <p>",
"     The size and pattern of electrical activity recorded from different muscles is analyzed by the physician who supervises the EMG test to determine whether the muscles and nerves are functioning normally.",
"    </p>",
"    <p>",
"     The test generally takes about 30 minutes. A patient may feel some discomfort as the needle is inserted, and the muscle may feel sore or bruised for several days. EMG is very useful in determining whether there is weakness due to muscle disease. However, it does not provide a specific diagnosis; genetic testing or muscle biopsy may be more useful if muscle weakness is obvious.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Muscle biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A muscle biopsy is a procedure that removes one or more small piece(s) of muscle from either an arm or leg. Muscle biopsies can sometimes provide a specific diagnosis. However, muscle biopsies are done less frequently than previously because of the increased availability of genetic testing.",
"    </p>",
"    <p>",
"     The biopsy may be done by making a small incision and removing a piece of muscle or by using a thick needle (called a punch biopsy), which removes a small cylindrical piece of muscle. The type of biopsy used will depend upon the physician's preference and need to examine the muscle directly before biopsy. Both types of biopsy can be done in an office or clinic setting, usually with local anesthesia (medication is injected to numb the area).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      DUCHENNE MUSCULAR DYSTROPHY",
"     </span>",
"    </p>",
"    <p>",
"     Duchenne muscular dystrophy (DMD) is caused by a defective gene located on the X chromosome. This gene is responsible for producing a protein called dystrophin, which normally functions to protect muscle fibers. Without dystrophin, muscles are broken down by enzymes, which cause degeneration and ultimately weakness of muscles.",
"    </p>",
"    <p>",
"     DMD occurs in about 1 in 3500 (0.02 percent) of all males. It is primarily seen in boys, and occurs in all ethnic groups.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Female DMD carriers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most female carriers of the abnormal dystrophin gene have few or no symptoms of their disease. Muscle weakness develops in 2.5 to 20 percent of females. Symptoms may present early in life and become progressive (worsen) in certain situations.",
"    </p>",
"    <p>",
"     Women who have no symptoms but who have a family history of muscular dystrophy and want to become pregnant can consider specialized testing. This can help to determine if the woman is a carrier of the defective gene. However, testing is not always accurate in identifying female carriers. As an example, some female carriers may have the defective X chromosome only in a fraction of their eggs and not in their blood or other somatic cells. Thus, a blood-based genetic test will be negative even though the woman is a carrier of the gene mutation. Any woman with a family history of muscular dystrophy should consider genetic counseling to discuss the probability of having an affected child.",
"    </p>",
"    <p>",
"     If testing confirms that the woman is a carrier, she can consider preimplantation genetic diagnosis or other options to avoid passing the defective gene to her child. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=see_link\">",
"      \"Preimplantation genetic diagnosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms of DMD usually appear in children between age two and three years. Children are usually wheelchair bound by age 12 to 13 years. These ages represent the average for all patients with DMD; individual patients may develop symptoms earlier or later in life.",
"    </p>",
"    <p>",
"     Weakness starts near the trunk, and spreads to the extremities, affecting the legs before the arms. A child may have difficulty running, jumping, and walking up steps, and may use their hands to push upright from squatting or sitting (called Gower's sign).",
"    </p>",
"    <p>",
"     DMD may also cause heart problems, including enlargement of the heart tissue (dilated cardiomyopathy) and irregular heartbeat. Abnormal curvature of the spine (scoliosis) combined with muscle weakness can lead to problems with lung function. Fractures involving the arms and legs are frequent, usually caused by falling. In many cases, affected children have some degree of mental impairment, although some children have average or above-average intelligence. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/17/44305?source=see_link\">",
"      \"Patient information: Dilated cardiomyopathy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Management of DMD",
"     </span>",
"     &nbsp;&mdash;&nbsp;Early identification of children who are affected by DMD is important to prevent complications and prolong life. Recommendations for managing and preventing problems in these children include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pneumococcal vaccine (given once) to help prevent pneumonia, and annual influenza vaccine for children six months of age and older. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"        \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Screening (usually by echocardiography or cardiac MRI) and early treatment for cardiomyopathy, starting at the time of diagnosis or at around age six years. Female carriers may be screened beginning in the teens. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/17/44305?source=see_link\">",
"        \"Patient information: Dilated cardiomyopathy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Lung treatment while sleeping (nocturnal noninvasive ventilation) or respiratory assistance during periods of lung infection is recommended. Lung function testing should begin around age 9 or 10 years, before the child becomes wheelchair bound, and should be repeated several times per year when lung function worsens or the child requires a wheelchair.",
"      </li>",
"      <li>",
"       Bone density should be maintained to reduce the risk of fractures by ensuring that the child has a diet rich in calcium and vitamin D. Parents should monitor their child's weight to avoid excessive weight gain and obesity; a nutritionist can assist with food planning.",
"      </li>",
"      <li>",
"       Physical therapy can help to maintain muscle function and prevent joint stiffening (contractures). Leg braces can assist with standing and walking. X-rays are taken periodically to monitor for changes in the bones.",
"      </li>",
"      <li>",
"       Surgery can help correct joint contractures, especially at the ankle. Lengthening and transferring tendons can return the joint to its normal position and prolong walking with, and sometimes even without, braces. Spinal fusion operations have been very effective in correcting scoliotic deformities and maintaining upright sitting position in a wheelchair.",
"      </li>",
"      <li>",
"       Scoliosis, or curvature of the spine, is a common complication of DMD. When severe, it can cause breathing problems, so that surgical treatment may be necessary. In less severe cases, braces may be effective.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Treatment of DMD",
"     </span>",
"     &nbsp;&mdash;&nbsp;Steroids (such as prednisone or deflazacort) are the primary treatment for DMD and are generally offered to boys who are over the age of five years. Steroids have been proven to significantly increase strength, muscle function, and lung function.",
"    </p>",
"    <p>",
"     Regular visits with a healthcare provider are needed to monitor the benefits and potential side effects of prednisone treatment. Side effects can include weight gain, swelling in the face, decrease in height, osteoporosis, long bone and vertebral bone fractures, acne, excessive hair growth, gastrointestinal symptoms, and behavioral changes. The dosage can be adjusted if excessive weight gain occurs.",
"    </p>",
"    <p>",
"     Treatments other than steroids have not been extensively studied or proven to be effective and safe.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Prognosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;In early studies, most patients with DMD died in their late teens or twenties as a result of respiratory infections or cardiomyopathy. However, later studies have reported a median survival to age 35 years. Thus, survival appears to be improving with advances in respiratory care and cardiac care. Again, these ages represent the average for all patients with DMD; individual patients may have complications earlier or later in life. (See",
"     <a class=\"local\" href=\"#H25\">",
"      'Life with muscular dystrophy'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      BECKER MUSCULAR DYSTROPHY",
"     </span>",
"    </p>",
"    <p>",
"     The pattern of inheritance of Becker muscular dystrophy (BMD) is the same as DMD, with the abnormal gene carried by the mother. It also occurs mainly in boys. BMD is also caused by problems with the dystrophin gene, although people with BMD often have partial production of dystrophin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Female BMD carriers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Female carriers of the abnormal dystrophin gene that causes BMD are similar to those that carry the DMD gene (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Female DMD carriers'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Compared with DMD, the age of onset for children with BMD is usually later and symptoms are usually milder. Children can usually walk until they are approximately 16 years old, with some people continuing to walk as adults. Mental impairment is less common than with DMD. Similarly, heart problems are not common; when they occur, they can be more severe in patients with BMD than in those with DMD.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Management of BMD",
"     </span>",
"     &nbsp;&mdash;&nbsp;Management of patients with BMD is similar to that of DMD (see",
"     <a class=\"local\" href=\"#H10\">",
"      'Management of DMD'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Treatment of BMD",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prednisone may be used for treatment of BMD, although little is known about its effect on the symptoms and disease progression (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Treatment of DMD'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Prognosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;On average, patients with BMD usually survive into their mid 40s. The most common cause of death is heart failure from cardiomyopathy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      BMD/DMD OUTLIERS",
"     </span>",
"    </p>",
"    <p>",
"     Some patients are found to have the genetic abnormalities of the dystrophin gene, but, clinically, have symptoms between those of DMD or BMD. These so-called \"outliers\" may be thought of as having mild DMD or severe BMD. They usually become confined to a wheelchair between the ages of 12 and 16 years.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      EMERY-DREIFUSS MUSCULAR DYSTROPHY",
"     </span>",
"    </p>",
"    <p>",
"     Emery-Dreifuss muscular dystrophy (EDMD), also known as humeroperoneal muscular dystrophy, can be caused by a number of inheritance patterns. It can affect both boys and girls.",
"    </p>",
"    <p>",
"     Symptoms of muscle weakness and loss typically begin in the arms between 10 and 20 years of age. Leg muscle weakness follows and, in some cases, mild facial weakness is also seen. The disease tends to progress slowly. Contractures of the elbows and neck are sometimes the first sign of disease. Involvement of the heart is also common, and can lead to serious problems with the regulation of heartbeat.",
"    </p>",
"    <p>",
"     EDMD is usually diagnosed based upon signs and symptoms, family history, and genetic testing. Treatment is focused on preventing death from heart disease. A pacemaker can be lifesaving in patients with arrhythmia. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     .) Physical therapy is useful in preventing contractures.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      MYOTONIC DYSTROPHY",
"     </span>",
"    </p>",
"    <p>",
"     Myotonic dystrophy is the most common form of adult-onset muscular dystrophy. It can affect both boys and girls. Symptoms typically occur in adolescence or adulthood, although a newborn form does occur. There are two genetic forms of myotonic dystrophy, type 1 and type 2.",
"    </p>",
"    <p>",
"     Myotonic dystrophy affects multiple body systems, causing muscle loss and weakness, especially in the facial muscles, arms, and legs. In addition, myotonic dystrophy can cause heart problems, cataracts, problems with glands, and abnormal intellectual functioning. In some cases, there are joint problems or difficulty swallowing. Excessive daytime sleepiness is found in about one-third of patients with myotonic dystrophy.",
"    </p>",
"    <p>",
"     Myotonia, or delayed muscle relaxation after contraction, is also seen, but this problem typically does not require treatment. Pulmonary function tests, swallowing studies, and heart tests are often used in the management of myotonic dystrophy. People with myotonic dystrophy are treated as symptoms develop. Leg braces are often used as weakness in the legs and feet worsen.",
"    </p>",
"    <p>",
"     Life expectancy appears to be reduced for people with myotonic dystrophy. Respiratory and cardiac diseases are the most common causes of death.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      LIMB-GIRDLE MUSCULAR DYSTROPHY",
"     </span>",
"    </p>",
"    <p>",
"     Limb-girdle muscular dystrophy (LGMD) is a group of disorders that have a number of inheritance patterns. It refers to dystrophies that affect the shoulder girdle (or area surrounding the shoulder), the pelvic girdle (the area surrounding the hips), or both. Low back pain may be a prominent symptom.",
"    </p>",
"    <p>",
"     The age of onset varies from early childhood to adulthood. The course is usually slowly progressive. Cognitive (brain) functioning is usually normal. However, cardiac involvement does occur in certain forms of LGMD.",
"    </p>",
"    <p>",
"     Treatment of LGMD focuses on the prevention of contractures. Stretching exercises are often recommended after diagnosis, and are useful to prevent disabling symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY",
"     </span>",
"    </p>",
"    <p>",
"     Facioscapulohumeral muscular dystrophy (FSHD) can affect boys and girls. It is usually progresses slowly, but is extremely variable in its severity and age of onset. It is usually inherited in an autosomal dominant pattern, which means that a parent with the disease has a 50 percent chance of passing it to their child.",
"    </p>",
"    <p>",
"     In the infant form, symptoms appear within the first few years of life. Most children require a wheelchair by the age of 9 or 10 years. There is profound facial weakness, with an inability to close the eyes in sleep, to smile, or to show other facial expressions. The weakness rapidly progresses to include the shoulder and hips. There may be marked weakness of the wrist or ankle. Children with early onset FSHD may have epilepsy, reduced mental ability, and severe hearing loss.",
"    </p>",
"    <p>",
"     In the classic form, symptoms usually begin between 20 and 30 years of age. Progression is slow, and the life span is near normal. The facial muscles are involved initially, with inability to close the eyes tightly, smile, or whistle. There may be a pouting appearance to the face. The facial weakness can be mild and may remain mild for many years. The muscles of the shoulders and upper arms are usually involved.",
"    </p>",
"    <p>",
"     In some of cases, the disease progresses rapidly in middle age, leading to significant disability. There may be problems with vision or hearing. The heart's rhythm can be affected in some patients.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      CONGENITAL MUSCULAR DYSTROPHY",
"     </span>",
"    </p>",
"    <p>",
"     Congenital muscular dystrophy (CMD) refers to cases of muscular dystrophy that are apparent at birth. There are several types, including a classic form, Fukuyama type (seen primarily in Japan), Ullrich congenital muscular dystrophy, merosin-deficient or merosin-positive congenital muscular dystrophies, Walker-Warburg syndrome, and muscle-eye-brain disease.",
"    </p>",
"    <p>",
"     Symptoms of CMD are usually seen at birth, and include lack of muscle strength (\"floppy baby\") and multiple joint contractures (arthrogryposis). No definitive treatment is available for CMD.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      LIFE WITH MUSCULAR DYSTROPHY",
"     </span>",
"    </p>",
"    <p>",
"     Many children and adults with muscular dystrophy can lead active lives. However, the diagnosis of muscular dystrophy can be overwhelming for a parent and a child. Support and education from healthcare providers and community organizations can help a family to provide their child with the best possible care. Organizations such as the Muscular Dystrophy Association (",
"     <a class=\"external\" href=\"file://mda.org/\">",
"      mda.org",
"     </a>",
"     ) have a large network of support services and information available. A week-long summer camp is available in many locations throughout the United States.",
"    </p>",
"    <p>",
"     Parents are often unsure about how to discuss muscular dystrophy with their child. Because it is a slowly progressing disease in most cases, parents are not obligated to discuss their child's long term prognosis until the child is mature enough to understand the implications of their diagnosis. Most children have an understanding of death by the age of 7 years, but even before this point, children want and deserve to know basic information about their disease and treatments that may be needed. In the terminal stages of illness, adolescents and young adults may want to participate in the decision making processes about end of life care, resuscitation options, and the location of their care.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498601998\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11169580\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/13/34001?source=see_link\">",
"      Patient information: Muscular dystrophy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11169597\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/17/44305?source=see_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=see_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/16/1290?source=see_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21415?source=see_link\">",
"      Emery-Dreifuss muscular dystrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/14/41192?source=see_link\">",
"      Oculopharyngeal, distal, and congenital muscular dystrophies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15881?source=see_link\">",
"      Limb-girdle muscular dystrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19882?source=see_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26666?source=see_link\">",
"      Treatment of Duchenne and Becker muscular dystrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=see_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/musculardystrophy.html\">",
"      www.nlm.nih.gov/medlineplus/musculardystrophy.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/md/md.htm\">",
"      www.ninds.nih.gov/disorders/md/md.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Muscular Dystrophy Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.mdausa.org/\">",
"      www.mdausa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gene Reviews (discusses genetic testing)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=dbmd\">",
"      www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=dbmd",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/33/32276/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 27, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/33/32276?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32276/abstract/1\">",
"      Emery AE. The muscular dystrophies. Lancet 2002; 359:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32276/abstract/2\">",
"      Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004; 170:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32276/abstract/3\">",
"      Moxley RT 3rd, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64:13.",
"     </a>",
"    </li>",
"    <li>",
"     Darras BT, Miller DT, Urion DK. Dystrophinopathies. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1119/ (Accessed on May 27, 2012).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_33_32276=[""].join("\n");
var outline_f31_33_32276=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           MUSCULAR DYSTROPHY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           MUSCULAR DYSTROPHY GENETICS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           MUSCULAR DYSTROPHY MUSCLE FUNCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           MUSCULAR DYSTROPHY TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           DUCHENNE MUSCULAR DYSTROPHY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           BECKER MUSCULAR DYSTROPHY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           BMD/DMD OUTLIERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           EMERY-DREIFUSS MUSCULAR DYSTROPHY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           MYOTONIC DYSTROPHY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           LIMB-GIRDLE MUSCULAR DYSTROPHY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           CONGENITAL MUSCULAR DYSTROPHY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           LIFE WITH MUSCULAR DYSTROPHY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/57/39825\" title=\"figure 1\">",
"           Gender determination PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/38/3684\" title=\"figure 2\">",
"           Muscular dystrophy inheritance pattern PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/32/18957\" title=\"table 1\">",
"           Muscular dystrophy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_33_32277="Sodium nitrite and sodium thiosulfate: Pediatric drug information";
var content_f31_33_32277=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium nitrite and sodium thiosulfate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/838?source=see_link\">",
"    see \"Sodium nitrite and sodium thiosulfate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/37/34387?source=see_link\">",
"    see \"Sodium nitrite and sodium thiosulfate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11566635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11460129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nithiodote&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F14505426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F15589619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     Refer to Infant, Children, and Adolescent dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F14505445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/838?source=see_link\">",
"      see \"Sodium nitrite and sodium thiosulfate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cyanide poisoning: Note:",
"     </b>",
"     Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate. Monitor the patient for 24-48 hours following doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Step 1:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer's labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants, Children, and Adolescents: I.V.: Initial: 3% solution: 0.2 mL/kg; maximum dose: 10 mL (300 mg); if repeat dosing is necessary due to symptom return, use 50% of the original dose;",
"     <b>",
"      Note:",
"     </b>",
"     Presented dose equates to 6 mg/kg of sodium nitrite or 6-8 mL/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     of the 3% solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adults: I.V.: Initial: 3% solution: 10 mL (300 mg); if repeat dosing is necessary due to symptom return, use 50% of the original dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate dosing: Hemoglobin-dependent dosing: Infants, Children, Adolescents, and Adults: I.V.: For patients who are unable to tolerate significant methemoglobinemia (eg, patients with comorbidities that compromise oxygen delivery, such as heart disease, lung disease, etc), dosing may be based on hemoglobin levels (when rapid bedside testing is available) to prevent fatal methemoglobinemia; see table (Berlin, 1970):",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Dosing Based on Hgb Level",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hemoglobin Level (g/dL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose of 3% Sodium Nitrite Solution",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Maximum dose: 10 mL)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.19 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.22 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.27 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.3 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.33 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.36 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.39 mL/kg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Step 2:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Sodium thiosulfate: Note:",
"     </b>",
"     Dosing information provided based upon contents of Nithiodote&trade; kit. Sodium thiosulfate is also available as an individual product; see sodium thiosulfate monograph for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants, Children, and Adolescents: I.V.: Initial: 25% solution: 1 mL/kg; maximum dose: 50 mL (12.5",
"     <b>",
"      g",
"     </b>",
"     ); if repeat dosing necessary due to symptom return, use 50% of the original dose.",
"     <b>",
"      Note:",
"     </b>",
"     Presented dose equates to 250 mg/kg of sodium thiosulfate or 30-40 mL/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     of the 25% solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: I.V.: Initial: 25% solution: 50 mL (12.5",
"     <b>",
"      g",
"     </b>",
"     ); if repeat dosing is necessary due symptom return, use 50% of the original dose",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, renal elimination of sodium nitrite and sodium thiosulfate is significant and risk of adverse effects may be increased in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13165159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [combination package]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nithiodote&trade;: Sodium nitrite 300 mg/10 mL (10 mL) and sodium thiosulfate 12.5 g/50 mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14505447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer both components undiluted via slow I.V. injection as soon as possible after diagnosis of acute, life-threatening cyanide poisoning. Administer sodium nitrite first at a rate of 2.5-5 mL/minute, followed immediately by the administration of sodium thiosulfate over 10-20 minutes. Decrease rate of infusion in the event of significant hypotension, nausea, or vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11566791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Hydroxocobalamin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F14505439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Protect from direct light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14505429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute, life-threatening cyanide poisoning (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F11566786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, cyanosis, flushing, hypotension, palpitations, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, coma, confusion, dizziness, fatigue, headache, lightheadedness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site tingling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sodium thiosulfate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Disorientation, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, salty taste, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding time prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Warmth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14505433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium nitrite, sodium thiosulfate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15589603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with G6PD deficiency; increased risk for hemolytic crisis following sodium nitrite administration; monitor for an acute drop in hematocrit. Use caution with concurrent use of antihypertensives, diuretics, phosphodiesterase-5 enzyme (PDE5) inhibitors, and medications known to cause methemoglobinemia.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14505435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium nitrite may cause methemoglobin formation and severe hypotension resulting in diminished oxygen-carrying capacity and even death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; serious adverse effects may occur at doses less than twice the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation; ensure patient is euvolemic. Use with caution in patients with pre-existing diminished oxygen or cardiovascular reserve [eg, smoke inhalation victims, anemia (dosage reduction in proportion to oxygen carrying capacity is recommended), substantial blood loss, and cardiac or respiratory compromise], in patients at greater risk for developing methemoglobinemia (eg, neonates and infants &lt;6 months or congenital methemoglobin reductase deficiency), and in patients who may be susceptible to injury from vasodilation; the use of hydroxocobalamin is recommended in these patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain; however, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Treatment of cyanide poisoning should include decontamination and supportive therapy. Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate. Monitor patients for return of symptoms for 24-48 hours; repeat treatment should be administered if symptoms return. Consider consultation with a poison control center at 1-800-222-1222.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fire victims may present with both cyanide and carbon monoxide poisoning. Carbon monoxide poisoning leads to carboxyhemoglobinemia which decreases the oxygen-carrying capacity; use of sodium nitrite which induces methemoglobinemia may worsen oxygen-carrying capacity. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. Due to the slow onset of action of sodium thiosulfate, may consider using hydroxocobalamin alone or in combination with sodium thiosulfate (Howland, 2011). The presence of sulfite hypersensitivity should not preclude the use of this medication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12608847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11566640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11566641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed following maternal exposure to high concentrations of sodium nitrite in drinking water. Teratogenic effects were not observed in animal reproduction studies of sodium nitrite or sodium thiosulfate. Embryotoxic and nonteratogenic effects were observed in animal reproduction studies of sodium nitrite. Methemoglobin reductase is lower in the fetus compared to adults and may result in adverse effects due to nitrite-induced prenatal hypoxia. There are no adequate and well-controlled studies of Nithiodote&trade; in pregnant women. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14505449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for at least 24-48 hours after administration; blood pressure and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO2 gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F15589638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptoms associated with blood cyanide levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flushing and tachycardia: 0.5-1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Obtundation: 1-2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coma and respiratory depression: &gt;2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Death: &gt;3 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14505441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium nitrite: Promotes formation of methemoglobin which competes with cytochrome oxidase for the cyanide ion. Cyanide combines with methemoglobin to form cyanomethemoglobin and frees the cytochrome oxidase, allowing aerobic metabolism to continue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium thiosulfate: Serves as a sulfur donor to increase endogenous rhondanese-catalyzed formation of thiocyanate (much less toxic than cyanide).",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F15589604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Onset: Peak effect: Methemoglobinemia: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duration: Methemoglobinemia: ~55 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14505444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sodium nitrite:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metabolism: To ammonia and other metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Excretion: Urine (~40% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sodium thiosulfate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Thiosulfate: ~3 hours (Howland, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Thiocyanate: ~3 hours; renal impairment: &le;9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Elimination: Urine (~20% to 50% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Medical Management Guidelines for Hydrogen Cyanide (HCN).&rdquo; Available at",
"      <a href=\"file://www.atsdr.cdc.gov/MHMI/mmg8.pdf\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/MHMI/mmg8.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32277/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berlin CM, &ldquo;The Treatment of Cyanide Poisoning in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1970, 46(5):793-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32277/abstract-text/4320419/pubmed\" id=\"4320419\" target=\"_blank\">",
"        4320419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller RJ, Barthold C, Saiers JA, et al, &ldquo;Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(5):2146-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32277/abstract-text/17079589/pubmed\" id=\"17079589\" target=\"_blank\">",
"        17079589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia R and Shepherd G, &ldquo;Cyanide Poisoning and Its Treatment,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(10):1358-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32277/abstract-text/15628833/pubmed\" id=\"15628833\" target=\"_blank\">",
"        15628833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin For The Empiric Treatment of Cyanide Poisoning?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2007, 49(6):806-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/33/32277/abstract-text/17098327/pubmed\" id=\"17098327\" target=\"_blank\">",
"        17098327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011, 1519-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium Thiosulfate,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87297 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32277=[""].join("\n");
var outline_f31_33_32277=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566635\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460129\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505426\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15589619\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505445\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13165159\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505447\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566791\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505439\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505429\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566786\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505433\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15589603\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505435\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300061\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608847\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566640\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566641\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505449\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15589638\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505441\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15589604\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14505444\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87297|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/838?source=related_link\">",
"      Sodium nitrite and sodium thiosulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/37/34387?source=related_link\">",
"      Sodium nitrite and sodium thiosulfate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_33_32278="Bedbug vs bat bug";
var content_f31_33_32278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Bedbug versus bat bug",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral hairs behind the head are shorter in the human bedbug (A) than in the bat bug (B). Hairs shorter than the diameter of the eye are present in the bedbug. Hairs longer than the diameter of the eye are found in the bat bug.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32278=[""].join("\n");
var outline_f31_33_32278=null;
var title_f31_33_32279="Bipolar disorder in children and adolescents: Assessment and diagnosis";
var content_f31_33_32279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in children and adolescents: Assessment and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32279/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32279/contributors\">",
"     Boris Birmaher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32279/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32279/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32279/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32279/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/33/32279/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H190481122\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder in children and adolescents is characterized by recurrent episodes of elevated mood (mania or hypomania) that are above and beyond the child&rsquo;s developmental stage and are not better accounted by other psychiatric and medical conditions. Youth with bipolar disorder usually have recurrent episodes of major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bipolar disorder severely affects the normal development and psychosocial functioning of the youth and increases the risk for suicide, psychosis, substance abuse and behavioral, academic, social, and legal problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Youth with bipolar disorder frequently have variable course with rapid fluctuation in mood symptoms during acute episodes. These factors coupled with developmental issues influencing the clinical picture, the difficulties youth can have verbalizing their emotions, and high rates of comorbid disorders, account for the complexity and controversies in diagnosing children and adolescents with bipolar disorder.",
"   </p>",
"   <p>",
"    This topic describes the assessment and diagnosis of bipolar disorder in children and adolescents. The epidemiology, clinical presentation, course, and pharmacotherapy of pediatric bipolar disorder are discussed separately, as is bipolar disorder in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38791?source=see_link\">",
"     \"Bipolar disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7545?source=see_link\">",
"     \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link\">",
"     \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481581\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the serious consequences associated with bipolar disorder, identification of the illness and initiation of treatment occurs, on average, 10 years after its manifestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/4\">",
"     4",
"    </a>",
"    ]. Pediatricians and other primary care physicians should be alert to symptoms suggesting the possibility of the disorder. Diagnosing bipolar disorder in children and adolescents can be complex and has significant consequences. Unless a primary care physician has extensive experience with pediatric bipolar disorder, patients in whom the disorder is strongly suspected should have an evaluation by a child psychiatrist or other mental health specialist skilled in the diagnosis of this condition.",
"   </p>",
"   <p>",
"    Assessment of symptoms of mania, hypomania, and depression in youth requires carefully probing and in most cases longitudinal assessments. In addition to specific",
"    <span class=\"nowrap\">",
"     manic/hypomanic",
"    </span>",
"    and depressive symptoms, it is important to ascertain the frequency, intensity, number, and duration (FIND) of the depressive and",
"    <span class=\"nowrap\">",
"     manic/hypomanic",
"    </span>",
"    episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that lack of insight can be associated with mania or hypomania, it is imperative to obtain information from caregivers or other adults who know the child well in order to accurately assess symptoms and potential change in functioning. The child&rsquo;s chronological age, intellectual capabilities, and environmental factors need to be taken into account when assessing the level of functional impairment or improvement.",
"   </p>",
"   <p>",
"    Certain symptoms, particularly if they appear together and are episodic, should raise the clinician&rsquo;s suspicion with regard to the diagnosis of bipolar disorder in youth, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased activity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      silliness above and beyond what is expected for the developmental age of the child and not accounted by the situation or the presence of other disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of need of sleep, especially if the child is not tired or sleepy the day after having slept only three to four hours during the night",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inappropriate sexual behaviors without history of being exposed to sexual activity (eg, abuse, videos)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though it is not a symptom of mania per se, the presence of psychosis (hallucinations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delusions) should raise the question of whether the child has bipolar disorder.",
"   </p>",
"   <p>",
"    Mild or transient manic symptomatology that does not meet the diagnostic threshold for mania or hypomania may precede an episode of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/1\">",
"     1",
"    </a>",
"    ], highlighting the need to carefully probe for a history of manic symptoms in youth presenting with depression.",
"   </p>",
"   <p>",
"    Assessment of a youth for bipolar disorder should include close longitudinal observation of the child&rsquo;s mood symptoms, a history and examination for the presence of comorbid mental disorders, substance use, medical conditions, suicidal and homicidal ideations, psychosocial functioning, presence of family psychopathology, and ongoing negative life events (eg, family conflicts, abuse). In some cases, psychoeducational testing can be useful for a child with learning problems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=see_link\">",
"     \"Specific learning disabilities in children: Evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The appropriate intensity and restrictiveness of care (eg, hospitalization) should be determined through evaluation of the severity of mood symptoms, presence of suicidal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    homicidal symptoms, psychosis, substance abuse, agitation, child&rsquo;s and parents&rsquo; adherence to treatment, parental psychopathology, and family environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481588\">",
"    <span class=\"h2\">",
"     Assessment instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians&rsquo; assessment of mood and other psychiatric symptoms can be facilitated by the use of psychiatric interviews and rating scales. In contrast to the interviews, the rating scales below do not provide a diagnosis, but can report symptoms that may alert clinicians to further asses for bipolar disorder. Rating instruments can also be used to monitor the severity of symptoms over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481595\">",
"    <span class=\"h3\">",
"     Diagnostic interviews",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several structured and semi-structured interviews that can be used for the diagnosis of bipolar disorder, including Kiddie Schedule for Affective Disorders and Schizophrenia for school age children - Present and Lifetime version (K-SADS-PL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/6\">",
"     6",
"    </a>",
"    ]. However, these interviews are lengthy and time-consuming and are mainly used for research purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481602\">",
"    <span class=\"h3\">",
"     Clinician-administered rating scales",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two clinician-based rating scales are used for the assessment of manic symptoms and their severity in youth, the Young Mania Rating Scale (YMRS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/7\">",
"     7",
"    </a>",
"    ] and the KSADS Mania Rating Scale that was derived from the KSADS-P mania module (KSADS - MRS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Further studies are needed to evaluate the validity of these rating scales.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481609\">",
"    <span class=\"h3\">",
"     Youth and parent-administered rating scales",
"    </span>",
"    &nbsp;&mdash;&nbsp;It appears that parental reports are more effective in identifying mania than youth or teacher reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/7\">",
"     7",
"    </a>",
"    ]. The General Behavior Inventory (GBI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/7\">",
"     7",
"    </a>",
"    ], the parent version of the YMRS (P-YMRS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/7\">",
"     7",
"    </a>",
"    ], and the Child Mania Rating Scale for Parents about their children (CMRS-P) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/7,9\">",
"     7,9",
"    </a>",
"    ] have been shown to be psychometrically sound and useful for the screening of bipolar disorder symptoms in youth, but further studies to evaluate the specificity of these instruments for bipolar disorder are warranted.",
"   </p>",
"   <p>",
"    The Children Behavior Checklist (CBCL), a parent-report instrument used to assess general psychopathology, has also been used to screen for bipolar disorder in youths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/7\">",
"     7",
"    </a>",
"    ]. However, this instrument is not specific to assess mania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481616\">",
"    <span class=\"h3\">",
"     Mood timelines or diaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mood timelines or diaries describe the course of a patient&rsquo;s mood symptoms over time. Using school years, birthdays, and holidays as anchors, they can be helpful in the assessment of the onset and course of mood disorders. Timelines use simple scale showing daily changes in mood (",
"    <a class=\"graphic graphic_form graphicRef84011 \" href=\"mobipreview.htm?20/8/20621\">",
"     form 1",
"    </a>",
"    ). As an example, they can include a scatter line in which 0 is being very sad, 10 exaggeratedly happy and 5 is normal mood. A mood diary can include dosages of medications and stressors. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481623\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children and adolescents meet the full DSM-IV-TR criteria for bipolar disorder despite the fact that the diagnostic criteria were not developed or specifically adapted for use for pediatric populations. However, taking into account developmental issues, it is possible to apply the DSM-IV-TR criteria to children and adolescents. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97761136\">",
"    <span class=\"h2\">",
"     Disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of bipolar disorder and related conditions are described here; further information on their clinical presentation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38791?source=see_link&amp;anchor=H6530606#H6530606\">",
"     \"Bipolar disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97761106\">",
"    <span class=\"h3\">",
"     Bipolar I disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes of mania and often major depressive episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97761121\">",
"    <span class=\"h3\">",
"     Bipolar II disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes of hypomania and often major depressive episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97761092\">",
"    <span class=\"h3\">",
"     Cyclothymia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes of hypomania and depressive episodes which do not fulfill the criteria for major depression. In our clinical experience, children have been less likely to present with cyclothymia than adults. Some of these children may receive a diagnosis of bipolar disorder, not otherwise specified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97761085\">",
"    <span class=\"h3\">",
"     Bipolar disorder, NOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes of",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    and depression that do not fulfill the DSM-IV TR criteria for Bipolar I or II disorders. Children with subsyndromal symptoms diagnosed as bipolar disorder, not otherwise specified (NOS), usually have similar symptoms as youth with bipolar disorder I and II, but they have fewer symptoms for a shorter period of time (less than the four days required for hypomania or seven days required for mania).",
"   </p>",
"   <p>",
"    These youths have as poor prognosis, psychosocial difficulties comorbidity, and family history of bipolar disorders as those with bipolar disorder I and II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/3,11\">",
"     3,11",
"    </a>",
"    ], respectively. These youths have as poor prognosis, psychosocial difficulties comorbidity and family history of bipolar disorders as those with bipolar disorder I and II. Moreover, they are risk to develop the full blow disorders, indicating the need to recognize and treat them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/12\">",
"     12",
"    </a>",
"    ]. Unfortunately, there are no studies regarding the treatment of youths with bipolar disorder, not otherwise specified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97761178\">",
"    <span class=\"h2\">",
"     Episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes comprising bipolar disorder and its subtypes include mania, hypomania, and major depression. The distinction between these symptoms and normal behavior in children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38791?source=see_link&amp;anchor=H6530606#H6530606\">",
"     \"Bipolar disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481630\">",
"    <span class=\"h3\">",
"     Mania",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the DSM-IV-TR, a manic episode is defined as a discrete period of abnormally and persistently elevated, expansive, or irritable mood, lasting at least one week (or any duration if the manic symptoms caused admission to the hospital) that is above and beyond of what it is expected for the child developmental age and not mainly accounted by other factors (eg, comorbid disorder, use of substances, medical illnesses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the period of excessive mood elevation or irritability, at least three or more of the symptoms described below need to be present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflated self-esteem or grandiosity",
"     </li>",
"     <li>",
"      Decreased need for sleep",
"     </li>",
"     <li>",
"      More talkative than usual or pressure to keep talking",
"     </li>",
"     <li>",
"      Flight of ideas or subjective experience that thoughts are racing",
"     </li>",
"     <li>",
"      Distractibility",
"     </li>",
"     <li>",
"      Increase in goal-directed activity or psychomotor agitation",
"     </li>",
"     <li>",
"      Excessive involvement in pleasurable activities that have a high potential for painful consequences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further detail regarding the diagnosis of mania is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ) and described separately. These symptoms exist as a collection of concurrent symptoms and behaviors. Although some investigators disagree, the diagnosis of mania requires that they occur episodically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38791?source=see_link&amp;anchor=H6530613#H6530613\">",
"     \"Bipolar disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course\", section on 'Mania'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To make the diagnosis, the manic episodes must impair the youth&rsquo;s functioning and the symptoms must not be mainly accounted for by other psychiatric disorders, the use of medications, use of substances, or medical illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481637\">",
"    <span class=\"h3\">",
"     Hypomania",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the DSM-IV-TR, hypomania refers to an episode of at least four days of three or more manic symptoms associated with a change in functioning that is not severe enough to cause marked impairment (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/13\">",
"     13",
"    </a>",
"    ]. Sometimes hypomanic youths can improve their functioning, become more creative and &ldquo;sharp&rdquo;, work many hours, and become more social and outgoing.",
"   </p>",
"   <p>",
"    The diagnosis of hypomania may be difficult not only because the youth can function better, but also because the symptoms need to be differentiated from normal mood and behaviors usually observed in youths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481644\">",
"    <span class=\"h3\">",
"     Major depressive episode",
"    </span>",
"    &nbsp;&mdash;&nbsp;To be diagnosed with a DSM-IV-TR major depressive episode, a youth needs to have at least five depressive symptoms and at least one of the symptoms is either",
"    <span class=\"nowrap\">",
"     depressive/irritable",
"    </span>",
"    mood or loss of interest (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/13\">",
"     13",
"    </a>",
"    ]. The symptoms should be present daily or for most of the day, or nearly daily for at least two weeks and must be accompanied by impairment of functioning. Similar to the symptoms of mania or hypomania, they cannot be mainly caused by medications, drug abuse, or medical condition (eg, hypothyroidism), and should not be better accounted for by bereavement or other psychiatric disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The symptoms of depression may fluctuate more frequently and be more reactive in depressed children compared to adults. &nbsp;Often depressed children do not look or feel depressed all the time. They can be depressed at school, but feel or look happy when they are with their friends or playing games. To consider diagnosing a major depression in youth, it can be useful to evaluate what percent of the time (eg, in a week) they are depressed. Some investigators have suggested that to consider the depression as significant, they should be depressed at least 50 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481651\">",
"    <span class=\"h2\">",
"     Subtypes of bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtypes of bipolar disorder include manifestations with mixed episodes, rapid cycling, or with psychosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481658\">",
"    <span class=\"h3\">",
"     Mixed episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Youths with mixed episodes have symptoms of mania and depression at the same time. They may be very irritable, confused, anxious, labile, agitated, depressed, suicidal, and sometimes psychotic. It appears that youths tend to have more mixed episodes than the adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/3\">",
"     3",
"    </a>",
"    ]. This is important because the diagnosis and treatment of mixed bipolar disorder are more complicated than episodes of only mania or depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481665\">",
"    <span class=\"h3\">",
"     Rapid cycling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid cycling is defined in DSM-IV-TR as four or more cycles of mania, hypomania, and depression per year. The episodes may be consecutive (eg, after an episode of mania the child will experience an episode of depression) or the episodes can be distributed during the year. Similar to the mixed episodes, rapid cycling is associated with early-onset and poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some studies have documented that bipolar disorder youths have many more mood cycles per day or week than adults with bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/3\">",
"     3",
"    </a>",
"    ]. However, it seems that these studies are not referring to the DSM definition of rapid cycling; instead, they are describing rapid mood changes within any given episode. Similar to the mixed episodes, the frequent variations in mood in youths make the diagnosis and treatment of bipolar disorder more complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481686\">",
"    <span class=\"h2\">",
"     Diagnostic challenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate diagnosis of bipolar disorder in children and adolescents is critically important. A misdiagnosis of bipolar disorder may label children with a diagnosis that has lifelong implications and expose them to medications with risk of serious side effects and little benefit. Failing to identify a child who does have bipolar disorder leaves him or her with an untreated illness that may affect the normal development of the child, and may expose him or her to the adverse effects of medication for an inaccurately diagnosed condition. Variability in the clinical presentation of bipolar disorder can make diagnosis difficult. The diagnosis may also be obscured by the presence of comorbidities and overlapping symptoms with other psychiatric disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38791?source=see_link&amp;anchor=H6530606#H6530606\">",
"     \"Bipolar disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H190481693\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis of bipolar disorder in youth may be further complicated by the effects of development on symptom expression, children&rsquo;s difficulty expressing their symptoms, the social context where the bipolar disorder is developing (eg, the presence of family conflicts), and, if the child is on medications, their potential effects on the child&rsquo;s mood. Distinguishing manic and depressive symptoms from normal behavior in children is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38791?source=see_link&amp;anchor=H6530606#H6530606\">",
"     \"Bipolar disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481693\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main psychiatric conditions that can be difficult to differentiate from bipolar disorder in youth are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Attention deficit disorder (ADHD)",
"     </li>",
"     <li>",
"      Disruptive behavior disorders (oppositional defiant disorder and conduct disorder)",
"     </li>",
"     <li>",
"      Unipolar depression",
"     </li>",
"     <li>",
"      Pervasive developmental disorders (PDD)",
"     </li>",
"     <li>",
"      Schizophrenia",
"     </li>",
"     <li>",
"      Substance abuse disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Borderline personality disorder can also be difficult to distinguish from bipolar disorder; however, DSM-IV-TR only recognizes diagnosis of the personality disorder in individuals 18 and over, and its use in youth is controversial. Some teens, particularly those with bipolar II disorder, may be misdiagnosed as having this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481700\">",
"    <span class=\"h3\">",
"     ADHD and disruptive behavioral disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disruptive behavior disorders and ADHD are the conditions most likely to be confused with bipolar disorder. Tables list clinical features in youth helping to distinguish bipolar disorder from these disorders; symptoms occurring mainly in bipolar disorder include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Euphoria",
"     </li>",
"     <li>",
"      Grandiosity",
"     </li>",
"     <li>",
"      Decreased need for sleep",
"     </li>",
"     <li>",
"      Hypersexuality (in the absence of a history of sexual abuse or exposure to sexual activity)",
"     </li>",
"     <li>",
"      Hallucinations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the more important factors helping differentiate bipolar disorder from ADHD and the disruptive behavior disorders is the course of the symptoms over time. In general, chronic symptoms such as hyperactivity or distractibility should not be considered evidence of mania unless they clearly intensify with the onset of abnormal mood. Prolonged presentations of non-specific manic-like symptoms that do not change in overall intensity should raise the possibility of a psychiatric diagnosis other than bipolar disorder.",
"   </p>",
"   <p>",
"    Family history for bipolar disorder may support the diagnosis in the youth; however, offspring of parents with bipolar disorder may suffer from other disorders such as ADHD and oppositional defiant disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481707\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most depressed youths seen in psychiatric settings are experiencing their first episode of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/15\">",
"     15",
"    </a>",
"    ]. The presence of psychosis, family history of bipolar disorder, or pharmacologically-induced",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    may indicate susceptibility to developing bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, it is not clinically possible to differentiate between depressed youths with bipolar disorder and those with unipolar depression. These youths need to be followed longitudinally with ongoing assessment for the presence of manic or hypomanic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481714\">",
"    <span class=\"h3\">",
"     Schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizophrenia is very rare in children. If a youth presents with symptoms of psychosis, mood disorders need to be ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481721\">",
"    <span class=\"h3\">",
"     Developmental disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Youth with subsyndromal symptoms of pervasive developmental disorder or mild autism may have mood lability, aggression, and agitation, which may be misdiagnosed as bipolar disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481728\">",
"    <span class=\"h3\">",
"     Substance abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance abuse may also induce severe mood changes that may be difficult to differentiate from bipolar disorder. Youth with mood disorders are at higher risk for using illicit drugs or alcohol as a way to deal with their mood and daily problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481735\">",
"    <span class=\"h3\">",
"     Medication reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of medications such as antidepressants may unmask or trigger a manic or hypomanic episode in a susceptible individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/19\">",
"     19",
"    </a>",
"    ]. However, not every child that becomes agitated or giddy and excited with these or other medications has bipolar disorder. The SSRIs may induce disinhibition in children that is distinct from",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    (the child becomes more hyperactive, giddy, silly, talkative, and inattentive) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/2\">",
"     2",
"    </a>",
"    ]. These symptoms usually are not an indication that the child has bipolar disorder and the child typically improves quickly once the dose of the SSRI is lowered or the SSRI is discontinued. Family history and the severity, length, and characteristics of manic symptomatology may help to differentiate between bipolar disorder or agitation induced by these or other medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190481742\">",
"    <span class=\"h3\">",
"     Medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical and neurological illnesses (eg, head trauma, brain tumors, hyperthyroidism), and side effects of medications (eg, corticosteroids, bronchodilators, contraceptives) may be accompanied by mood fluctuations that may mimic bipolar disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190482045\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatricians and other primary care physicians should be alert to symptoms suggesting the possibility of the disorder. &nbsp;Diagnosing bipolar disorder in children and adolescents can be complex and has significant consequences. Unless a primary care physician has extensive experience with pediatric bipolar disorder, patients in whom the disorder is strongly suspected should have an evaluation by a child psychiatrist or other mental health specialist skilled in the diagnosis of this condition. (See",
"      <a class=\"local\" href=\"#H190481581\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain symptoms should raise the clinician&rsquo;s suspicion with regard to the diagnosis of bipolar disorder in youth, including (See",
"      <a class=\"local\" href=\"#H190481581\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased activity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      silliness beyond what is expected for the child&rsquo;s developmental age and not accounted by the situation or other disorders.",
"     </li>",
"     <li>",
"      Lack of need of sleep, especially if the child is not tired during the day despite less than four hours during the night.",
"     </li>",
"     <li>",
"      Inappropriate sexual behaviors without history of being exposed to sexual activity (eg, abuse, videos)",
"     </li>",
"     <li>",
"      Psychosis (hallucinations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delusions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of a youth for bipolar disorder should include a history and examination for the presence of comorbid mental disorders, substance use, medical conditions, suicidal and homicidal ideations, psychosocial functioning, presence of family psychopathology, and ongoing negative life events (eg, family conflicts, abuse). (See",
"      <a class=\"local\" href=\"#H190481581\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of bipolar disorder in youth should be made on the basis of DSM-IV-TR for [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32279/abstract/13\">",
"       13",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mania (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Major depressive episodes (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Youth with subsyndromal bipolar symptomatology diagnosed as bipolar disorder, not otherwise specified, have significant psychosocial morbidity, and are at risk to commit suicide, abuse substances, and convert into bipolar disorder I or II. (See",
"      <a class=\"local\" href=\"#H97761085\">",
"       'Bipolar disorder, NOS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of bipolar disorder in youth can be complex because youth with bipolar disorder frequently have a variable course with rapid fluctuation in mood symptoms during acute episodes, developmental issues that complicate the assessment of symptoms and behaviors, and difficulty verbalizing their emotions. In addition, bipolar disorder is accompanied by high rates of comorbid disorders. (See",
"      <a class=\"local\" href=\"#H190481686\">",
"       'Diagnostic challenges'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disruptive behavior disorders and ADHD are the conditions most likely to be confused with bipolar disorder. Other conditions in the differential diagnosis of bipolar disorder include unipolar depression, schizophrenia, substance abuse, medication reactions, and general medical illnesses (eg, head trauma, brain tumors, hyperthyroidism and side effects to corticosteroids, antidepressants, and stimulants). (See",
"      <a class=\"local\" href=\"#H190481693\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Birmaher B, Axelson D, Pavaluri M. Bipolar Disorder. In: Lewis' Child and Adolescent Psychiatry: A comprehensive textbook, 4th ed., Martin MA, Volkmar FR, Lewis M.  (Eds), Lippincott Williams &amp; Wilkins, London 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/2\">",
"      Pavuluri MN, Birmaher B, Naylor MW. Pediatric bipolar disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 2005; 44:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/3\">",
"      Birmaher B, Axelson D, Goldstein B, et al. Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study. Am J Psychiatry 2009; 166:795.",
"     </a>",
"    </li>",
"    <li>",
"     Goodwin FK, Jamison KR, Ghaemi SN. Manic-Depressive Illness: Bipolar disorders and recurrent depression, 2nd ed, Oxford University Press, New York 2007.",
"    </li>",
"    <li>",
"     Kowatch, R. A., Fristad, M., Birmaher, B., Wagner, K. D., Findling, R. L., &amp; Hellander, M. (2005). Treatment guidelines for children and adolescents with bipolar disorder: Child psychiatric workgroup on bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 213-255.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/6\">",
"      Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/7\">",
"      Youngstrom E, Meyers O, Demeter C, et al. Comparing diagnostic checklists for pediatric bipolar disorder in academic and community mental health settings. Bipolar Disord 2005; 7:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/8\">",
"      Axelson D, Birmaher BJ, Brent D, et al. A preliminary study of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children mania rating scale for children and adolescents. J Child Adolesc Psychopharmacol 2003; 13:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/9\">",
"      Pavuluri MN, Henry DB, Devineni B, et al. Child mania rating scale: development, reliability, and validity. J Am Acad Child Adolesc Psychiatry 2006; 45:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/10\">",
"      Diler RS, Birmaher B, Axelson D, et al. The Child Behavior Checklist (CBCL) and the CBCL-bipolar phenotype are not useful in diagnosing pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/11\">",
"      Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006; 63:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/12\">",
"      Axelson DA, Birmaher B, Strober MA, et al. Course of subthreshold bipolar disorder in youth: diagnostic progression from bipolar disorder not otherwise specified. J Am Acad Child Adolesc Psychiatry 2011; 50:1001.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/14\">",
"      Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/15\">",
"      Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/16\">",
"      Geller B, Fox LW, Clark KA. Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry 1994; 33:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/17\">",
"      Strober M, Carlson G. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch Gen Psychiatry 1982; 39:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/18\">",
"      Goldstein BI, Strober MA, Birmaher B, et al. Substance use disorders among adolescents with bipolar spectrum disorders. Bipolar Disord 2008; 10:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32279/abstract/19\">",
"      Martin A, Young C, Leckman JF, et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004; 158:773.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83083 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32279=[""].join("\n");
var outline_f31_33_32279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H190482045\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190481122\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190481581\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190481588\">",
"      Assessment instruments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481595\">",
"      - Diagnostic interviews",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481602\">",
"      - Clinician-administered rating scales",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481609\">",
"      - Youth and parent-administered rating scales",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481616\">",
"      - Mood timelines or diaries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190481623\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97761136\">",
"      Disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97761106\">",
"      - Bipolar I disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97761121\">",
"      - Bipolar II disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97761092\">",
"      - Cyclothymia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97761085\">",
"      - Bipolar disorder, NOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97761178\">",
"      Episodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481630\">",
"      - Mania",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481637\">",
"      - Hypomania",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481644\">",
"      - Major depressive episode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190481651\">",
"      Subtypes of bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481658\">",
"      - Mixed episodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481665\">",
"      - Rapid cycling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190481686\">",
"      Diagnostic challenges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190481693\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481700\">",
"      - ADHD and disruptive behavioral disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481707\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481714\">",
"      - Schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481721\">",
"      - Developmental disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481728\">",
"      - Substance abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481735\">",
"      - Medication reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190481742\">",
"      - Medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190482045\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/83083\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/83083|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?20/8/20621\" title=\"form 1\">",
"      Mood timeline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/83083|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38791?source=related_link\">",
"      Bipolar disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7545?source=related_link\">",
"      Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=related_link\">",
"      Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=related_link\">",
"      Specific learning disabilities in children: Evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_33_32280="Shoulder impingement syndrome";
var content_f31_33_32280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Shoulder impingement syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32280/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32280/contributors\">",
"     Stephen M Simons, MD, FACSM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32280/contributors\">",
"     David Kruse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32280/contributors\">",
"     J Bryan Dixon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32280/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32280/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32280/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32280/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/33/32280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder impingement syndrome (SIS) refers to a combination of shoulder symptoms, examination findings, and radiologic signs attributable to the compression of structures around the glenohumeral joint that occur with shoulder elevation. Such compression causes persistent pain and dysfunction. Shoulder pain is a common presenting complaint in primary care clinics, and SIS is likely the most common cause of shoulder pain in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much has changed in our understanding of shoulder function and dysfunction since Neer's original classification of these disorders decades ago [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/3\">",
"     3",
"    </a>",
"    ]. The diagnosis of SIS implies a spectrum of clinical findings, not injury to a specific structure.",
"   </p>",
"   <p>",
"    The pathophysiology, diagnosis, and management of SIS will be reviewed here. The approach to patients with shoulder pain, the shoulder examination, and conditions that may stem from SIS are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=see_link\">",
"     \"Physical examination of the shoulder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder pain is highly prevalent within the general population, second only to lower back pain. Studies suggest that shoulder impingement syndrome (SIS) is the most common cause of shoulder pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. However, epidemiologic calculations can vary depending upon how SIS is defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive activity at or above the shoulder during work or sports represents the main risk factor for SIS. As with many shoulder disorders, increasing age also predisposes to SIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. SIS is common among athletes who participate in overhead sports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. These sports may include swimming, throwing, tennis, weightlifting, golf, volleyball, and gymnastics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/15\">",
"     15",
"    </a>",
"    ]. Overhead work activities that can increase risk for developing SIS include painting, stocking shelves, and mechanical repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/6,16\">",
"     6,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Instability of the glenohumeral joint can lead to impingement. Such instability allows increased translation of the humeral head and predisposes patients to SIS, particularly if they engage in repetitive overhead activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scapular instability and dyskinesis, in addition to glenohumeral joint laxity, also predisposes to impingement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/17\">",
"     17",
"    </a>",
"    ]. Other risk factors may include upper extremity inflexibility, particular acromion anatomy, and acromioclavicular joint pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the pathophysiology of shoulder impingement syndrome (SIS) depends upon knowledge of shoulder anatomy (",
"    <a class=\"graphic graphic_figure graphicRef81764 graphicRef54102 graphicRef69995 \" href=\"mobipreview.htm?33/63/34810\">",
"     figure 1A-C",
"    </a>",
"    ). The anatomy of the shoulder is discussed in detail elsewhere, but aspects of particular importance to SIS are reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Movement of the humeral head within the glenoid and of the scapulothoracic articulation achieves motion in multiple planes (ie, flexion, extension, internal rotation, external rotation, abduction, adduction). This impressive range of motion can entail compression of structures within the shoulder, including the four rotator cuff muscles (ie, supraspinatus, infraspinatus, teres minor, and subscapularis), subacromial bursa, labrum, and biceps tendon (long head). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Compression can occur against the acromion, osteoarthritic change on the undersurface of the acromioclavicular joint, and the coracoacromial arch. The acromion is the lateral projection of the posterior scapular spine, and its morphology may play a role in impingement syndrome (",
"    <a class=\"graphic graphic_figure graphicRef53837 \" href=\"mobipreview.htm?7/33/7696\">",
"     figure 2",
"    </a>",
"    ). The acromion forms an articulation with the lateral clavicle, and this articulation is stabilized by the acromioclavicular, coracoacromial, and coracoclavicular ligaments. The coracoacromial arch is composed of the coracoid, anterior acromion, and the coracoacromial ligament [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The small surface area of the glenoid fossa makes the glenohumeral joint relatively unstable. Stability depends largely on surrounding ligamentous, capsular, tendinous, and muscular structures. Any weakness or dysfunction of these stabilizing structures can increase glenohumeral instability, allowing increased translation of the humeral head. This increased motion makes surrounding structures susceptible to impingement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder impingement syndrome (SIS) consists of a spectrum of clinical findings, NOT injury to a specific structure (ie, rotator cuff) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/19\">",
"     19",
"    </a>",
"    ]. This spectrum of disease was first described by Charles Neer in 1972, and consists of the following stages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/3,20\">",
"     3,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1: Edema and hemorrhage (patient generally &lt;25 years)",
"     </li>",
"     <li>",
"      Stage 2: Fibrosis and tendinitis (patient 25 to 40 years). Current term is tendinopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"       \"Rotator cuff tendinopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stage 3: Rotator cuff (RC) tear, biceps tendon rupture, bony change (patient generally &gt;40 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The underlying mechanism of injury occurs when the rotator cuff, subacromial bursa, and other soft tissues (eg, long biceps tendon) are compressed between the humeral head and the undersurface of the acromion, acromioclavicular joint, or the coracoacromial arch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/15,18,21\">",
"     15,18,21",
"    </a>",
"    ]. A number of anatomic and mechanistic factors play a role in this mechanism, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased translation of the humeral head",
"     </li>",
"     <li>",
"      Acromion morphology that predisposes to impingement",
"     </li>",
"     <li>",
"      Decreased distance between undersurface of acromion and humeral head",
"     </li>",
"     <li>",
"      Osteophytic change of the acromioclavicular joint",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weakness or dysfunction of the structures that stabilize the glenohumeral joint (eg, RC muscles) can lead to increased superior translation of the humeral head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/17\">",
"     17",
"    </a>",
"    ]. Increased translation can lead to compression of the subacromial bursa and RC tendons, causing injury. This extrinsic compression is one of a number of injuries that contribute to the development of SIS and rotator cuff (RC) tendinopathy. In addition, a decrease in the distance between undersurface of acromion and humeral head appears to correlate with clinical symptoms in patients with impingement syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between the anterior third of the acromion and subacromial structures accounts in part for compression and the development of SIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/3\">",
"     3",
"    </a>",
"    ]. Three acromion types have been described (",
"    <a class=\"graphic graphic_figure graphicRef53837 \" href=\"mobipreview.htm?7/33/7696\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type I - Flat",
"     </li>",
"     <li>",
"      Type II - Curved",
"     </li>",
"     <li>",
"      Type III - Hooked",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These acromion morphologies were originally defined by their relationship to RC tear, with type III acromions having the highest association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anatomic factors other than superior translation of the humeral head and acromion morphology can also contribute to the development of SIS. Osteophytic change of the acromioclavicular joint can cause compression and mechanical irritation of underlying soft tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The lateral band of the coracoacromial ligament has been implicated in impingement of the rotator cuff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/21,23,24\">",
"     21,23,24",
"    </a>",
"    ]. Scapulothoracic dysfunction may play a role in SIS, but it remains unclear if such dysfunction is causative or secondary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/17,25\">",
"     17,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Throwing athletes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throwing athletes suffer from a unique form of SIS. Impingement of the superior and posterior labrum and rotator cuff occurs with external rotation, extension, and abduction of the shoulder (ie, the cocking phase of throwing). This motion together with anterior translation of the humeral head causes impingement. Glenohumeral instability accentuates the anterior translation and subsequent impingement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. Repetitive use of the shoulder in extremes of rotation with throwing activities, combined with weakness of the rotator cuff and laxity of the glenohumeral ligaments, places athletes at risk for this form of SIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This form of impingement, sometimes referred to as posterior SIS, does not occur in all overhead athletes, but specifically in throwing athletes whose motion involves a cocking phase (",
"    <a class=\"graphic graphic_figure graphicRef71896 \" href=\"mobipreview.htm?10/57/11153\">",
"     figure 3",
"    </a>",
"    ). Such activities include baseball pitching primarily, but also tennis serves, American football throws, and javelin throws.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder pain is very common in the general population, and the differential diagnosis can be extensive (",
"    <a class=\"graphic graphic_table graphicRef53038 \" href=\"mobipreview.htm?9/20/9549\">",
"     table 1",
"    </a>",
"    ). This differential diagnosis and a discussion on how to approach the patient with undifferentiated shoulder pain are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain from shoulder impingement syndrome (SIS) may result from injury to a number of involved structures, including: the rotator cuff, subacromial bursa, biceps tendon, and labrum. The history and physical examination is used to identify the structures involved and direct treatment.",
"   </p>",
"   <p>",
"    It is important to distinguish SIS from rotator cuff tear and adhesive capsulitis, for which management differs. Rotator cuff tears frequently cause weakness in addition to pain, occur most often in older patients, and are associated with a positive drop arm sign and weakness with external rotation. Patients with adhesive capsulitis generally give a history of shoulder injury and manifest restricted active and passive glenohumeral motion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25991?source=see_link\">",
"     \"Biceps tendinopathy and tendon rupture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with shoulder impingement can concurrently develop cervical radiculopathy, emphasizing the importance of a careful neurologic examination in patients with shoulder complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Both conditions should be treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of shoulder impingement syndrome (SIS) are similar to those of rotator cuff (RC) tendinopathy. Patients complain of pain with overhead activity. The pain may localize to the deltoid area or lateral arm and often occurs at night or when lying on the affected shoulder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Throwing athletes complain of shoulder stiffness and a difficult or prolonged warm-up period. Pain occurs during the late cocking phase or the early acceleration phase of throwing. Initially, the athlete may not be able to localize the pain, but with time may develop discomfort at the posterior shoulder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9\">",
"     9",
"    </a>",
"    ]. Serving athletes (eg, tennis and volleyball players) may complain of pain at follow-through or terminal wrist snap before impingement becomes severe. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Throwing athletes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several structures may be involved in SIS, including the subacromial bursa, rotator cuff, biceps tendon, and labrum. Therefore, a number of shoulder examination techniques are used to ensure adequate sensitivity for detecting injury to susceptible structures. The overall approach to examination closely resembles that used to detect rotator cuff tendinopathy, and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Neer and Hawkins-Kennedy maneuvers are sensitive for SIS impingement (",
"    <a class=\"graphic graphic_picture graphicRef76237 \" href=\"mobipreview.htm?43/7/44149\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60425 \" href=\"mobipreview.htm?19/27/19891\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Performance of the shoulder examination, including special tests for impingement, is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=see_link&amp;anchor=H5844119#H5844119\">",
"     \"Physical examination of the shoulder\", section on 'Special tests for shoulder impingement'",
"    </a>",
"    .) Examination for SIS includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete neck examination",
"     </li>",
"     <li>",
"      Inspection for atrophy or disfigurement",
"     </li>",
"     <li>",
"      Evaluation of range of motion (including painful arc testing)",
"     </li>",
"     <li>",
"      Rotator cuff strength testing (including drop arm test and external rotation strength testing)",
"     </li>",
"     <li>",
"      Specialty testing (including the Neer and Hawkins-Kennedy tests)",
"     </li>",
"     <li>",
"      Bedside MSK US, if the technology is available and the examiner proficient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with SIS can manifest the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neck exam is within normal limits",
"     </li>",
"     <li>",
"      Tenderness present in the subacromial space or posterior shoulder",
"     </li>",
"     <li>",
"      Glenohumeral range of motion may be limited by pain (eg, positive painful arc)",
"     </li>",
"     <li>",
"      Reproduction of pain with specialty testing (eg, Neer, Hawkins-Kennedy, Yocum's)",
"     </li>",
"     <li>",
"      Atrophy of posterior shoulder musculature may be apparent with long-standing impingement",
"     </li>",
"     <li>",
"      Shoulder strength is normal, except in some cases of long-standing impingement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the throwing athlete, findings of SIS may include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymmetric muscle development",
"     </li>",
"     <li>",
"      Tenderness over the region of the posterior rotator cuff and capsule",
"     </li>",
"     <li>",
"      Increase in external rotation and symmetrical decrease in internal rotation compared with the unaffected (nondominant) shoulder",
"     </li>",
"     <li>",
"      Possible increased laxity of the glenohumeral joint (anterior translation)",
"     </li>",
"     <li>",
"      Positive posterior impingement sign",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To perform the posterior impingement test, place the patient's shoulder in 90 degrees of abduction, 110 degrees of extension, and maximal external rotation. The test is performed with the patient supine and is positive if it recreates the athlete's shoulder pain (",
"    <a class=\"graphic graphic_picture graphicRef58355 \" href=\"mobipreview.htm?24/49/25361\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, radiographs are unnecessary for the initial evaluation of shoulder impingement, and we do not routinely obtain them unless symptoms and function fail to improve with physical therapy.",
"   </p>",
"   <p>",
"    Plain x-rays may be useful in the following clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No improvement with conservative therapy",
"     </li>",
"     <li>",
"      Evaluation of acromion morphology (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Evaluation of the acromioclavicular joint (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Evaluation of distance between acromion and humeral head",
"     </li>",
"     <li>",
"      Evaluation for tendon calcification",
"     </li>",
"     <li>",
"      Anatomical evaluation prior to subacromial or glenohumeral joint injection (not essential prior to injection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Musculoskeletal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal ultrasound (MSK US) is an accurate tool for the evaluation of superficial tendon and muscle lesions, as well as bursitis, of the shoulder, and enables dynamic examination at the bedside. With experienced users, dynamic MSK US can often show the site of impingement and tendons involved. Its role in the evaluation of the rotator cuff is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging (MRI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An MRI is generally performed in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms and function fail to improve despite appropriate conservative therapy.",
"     </li>",
"     <li>",
"      The diagnosis remains unclear after initial evaluation.",
"     </li>",
"     <li>",
"      A rotator cuff or labrum tear is suspected based upon clinical presentation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"       \"Presentation and diagnosis of rotator cuff tears\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI can detect abnormalities associated with SIS, including inflammation of subacromial structures, compression of the supraspinatus tendon and subacromial bursa by bone spurs, acromioclavicular joint pathology, or a low-lying acromion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/8,22,29\">",
"     8,22,29",
"    </a>",
"    ]. A low-lying acromion can be further defined by measuring the distance between the acromion and the humeral head. For the athletic patient, MRI can be performed if rapid confirmation of the diagnosis is needed to determine whether return to sport is reasonable.",
"   </p>",
"   <p>",
"    MRI arthrography with gadolinium intraarticular injection may be useful when the diagnosis remains unclear following standard MRI. The study is generally obtained after consultation with sports medicine or orthopedic surgery. MRI arthrography can detect pathology of the labrum, undersurface rotator cuff irregularity, or small partial tears of the rotator cuff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;We refer patients for orthopedic evaluation if three months of conservative treatment, including appropriate physical therapy, fails to improve symptoms and function, or if a diagnosis of rotator cuff tear, labrum tear, or adhesive capsulitis is suspected.",
"   </p>",
"   <p>",
"    Surgical intervention should be individualized by age, comorbidities, and level of physical demand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/17\">",
"     17",
"    </a>",
"    ]. Surgical intervention may include debridement of the rotator cuff or labrum, acromioplasty with debridement, or rotator cuff repair. If laxity is present in the throwing athlete, a capsular repair may improve outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of shoulder impingement syndrome (SIS) is similar to that for rotator cuff (RC) tendinopathy. Some aspects of management are supported by evidence, but much is not. A description of the management approach and basic treatment for SIS follows. Issues related to the specific management of SIS, as opposed to RC tendinopathy, are discussed here; evidence for treatments used to manage both SIS and RC tendinopathy is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We approach patients with suspected shoulder impingement syndrome (SIS) in the manner described here, but recognize that evidence is limited and alternative approaches may be reasonable. We begin with a focused history and physical examination. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical presentation and examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If based on the history and examination, we suspect a clinically significant rotator cuff tear, a labral tear, adhesive capsulitis, or other significant pathology not amenable to conservative therapy; we generally refer the patient to an orthopedic surgeon. We maintain a lower threshold for referral in the case of high-functioning athletes. If we suspect a rotator cuff tear or adhesive capsulitis, but the patient has minimal weakness and reasonable motion, we generally embark on a course of conservative medical management, consisting primarily of physical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If we suspect acute SIS, we initiate conservative medical management, including the acute treatments described below and an appropriate physical therapy program. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Acute treatment'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Physical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The duration and success of physical therapy depends upon many factors, including underlying pathology, compliance with treatment, and the appropriateness of the program prescribed. We believe that whenever possible, it is important for patients to begin rehabilitation under the guidance of a knowledgeable professional (eg, athletic trainer or physical therapist with experience managing shoulder disorders).",
"   </p>",
"   <p>",
"    If function and symptoms improve over several weeks of physical therapy, we have the patient continue therapy and begin a gradual, stepwise resumption of activities, including sports. Should function fail to improve despite adequate rehabilitation, we obtain imaging studies. Musculoskeletal ultrasound (MSK US), if not performed previously, is obtained first. We perform a plain radiograph for persistent symptoms to assess for anatomic variants, such as a downsloping acromion or os acromiale, and acromioclavicular or glenohumeral osteoarthritis. We obtain an MRI if the MSK US is nondiagnostic, a rotator cuff or labral tear is suspected, or the diagnosis is unclear. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Radiographic findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Subsequent management depends upon the results of imaging studies. Alternative diagnoses are managed accordingly. We refer patients with rotator cuff tears, labral tears, and adhesive capsulitis to an orthopedic surgeon. For rotator cuff tendinopathy or subacromial bursitis, we continue conservative management. Some clinicians may choose to incorporate adjunct treatments, such as glucocorticoid injection, at this point, or earlier if pain is severe. Physical therapy may require several months before adequate shoulder function is achieved. We refer the patient to an orthopedic surgeon if, after six to nine months of conservative treatment, patient function and symptoms fail to improve significantly. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Indications for orthopedic referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research to direct management of SIS is limited, but the following is a generally accepted approach for acute symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryotherapy &ndash; Ice may decrease acute swelling and inflammation and provide some analgesia.",
"     </li>",
"     <li>",
"      Rest &ndash; This means avoiding activities that aggravate symptoms, including all overhead activities.",
"     </li>",
"     <li>",
"      NSAIDs &ndash; For acute injuries, we give a short course (ie, 7 to 10 days) of scheduled NSAID therapy. Thereafter, patients may use an NSAID for occasional analgesia if they find the medication effective. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"       \"Rotator cuff tendinopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although studies of physical therapy regimens for SIS are limited, available evidence and our clinical experience suggest that properly designed and performed physical therapy programs effectively treat most patients with SIS and should be implemented prior to surgical referral. Furthermore, several randomized trials have reported no difference in outcome between patients treated with physical therapy alone and those treated surgically with subacromial decompression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The physical therapy programs used most often for SIS closely resemble those used for rehabilitation of rotator cuff tendinopathy and these are discussed in detail separately. A randomized trial of 97 patients with SIS reported that those treated with such an exercise regimen had significant improvements in shoulder function and were less likely to undergo surgery than patients treated with standard exercises (20 versus 63 percent; OR 7.7, 95% CI 3.1-19.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link&amp;anchor=H22#H22\">",
"     \"Rotator cuff tendinopathy\", section on 'Physical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rehabilitation program for SIS should follow a progression from an initial focus on restoring mobility, to stability and strength training, and finally to integration of shoulder rehabilitation into overall functional training. A qualified therapist or trainer can help the physician to design and implement an effective rehabilitation program for SIS, which generally includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Range of motion exercises to improve motion in all planes (flexion, extension, abduction, adduction, internal and external rotation).",
"     </li>",
"     <li>",
"      Glenohumeral joint mobilization, including specific maneuvers for capsular structures.",
"     </li>",
"     <li>",
"      Strengthening exercises, focusing on the rotator cuff, scapular stabilizers, and core musculature. Eccentric exercises (application of a load during muscle lengthening) are included in the program.",
"     </li>",
"     <li>",
"      Biomechanical training to improve the throwing motion or other repetitive activity that led to injury.",
"     </li>",
"     <li>",
"      Exercises to improve the strength and stability of the core muscles and to integrate shoulder rehabilitation into patient-specific functional activities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overhead athletes should generally refrain from all throwing activities for two to four weeks, while performing physical therapy for the rotator cuff and scapular stabilizers. As symptoms resolve, athletes begin a graded return to throwing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9\">",
"     9",
"    </a>",
"    ]. Approximately 95 percent of throwing athletes return to their previous level of function if started early on a well-designed rehabilitation program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inconsistent diagnostic criteria, disparate outcome measures, small numbers of participants, and variable treatment protocols make studies of physical therapy for SIS difficult to interpret [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/4,34,35\">",
"     4,34,35",
"    </a>",
"    ]. Nevertheless, the available evidence suggests that stretching and strengthening exercise programs consistent with the guidelines listed above provide effective treatment for SIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/4,6,16,36,37\">",
"     4,6,16,36,37",
"    </a>",
"    ]. The addition of glenohumeral mobilization exercises to rehabilitation further improves outcomes. One small prospective study found that patients with less acromion-humeral narrowing showed greater functional improvements following physical rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Subacromial injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is little evidence to support the use of subacromial injection for the treatment of SIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/6,39,40\">",
"     6,39,40",
"    </a>",
"    ], a few small, randomized trials found a short term benefit from glucocorticoid injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Symptomatic relief gained from such injections may improve a patient's effort and compliance with physical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Alternative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clear evidence exists to support the use of the modalities listed here in the treatment of SIS, and we do not routinely use them in the care of our patients. Alternative treatment modalities may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrical stimulation, phonophoresis, and iontophoresis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"       \"Rotator cuff tendinopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Therapeutic ultrasound &ndash; No evidence supports the use of ultrasound for SIS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/4,6,36,45,46\">",
"       4,6,36,45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laser &ndash; As a single intervention, laser may provide greater relief than placebo, but studies suggest it provides no added benefit when used in combination with other conservative treatments (eg, physical therapy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/4,36,46\">",
"       4,36,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acupuncture &ndash; Some evidence suggests that acupuncture may provide some benefit when combined with physical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32280/abstract/4,47\">",
"       4,47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have patients return to clinic within two weeks of their initial assessment. This allows us to reassess our original clinical impression and to determine the effectiveness of interventions. Sometimes pain limits the initial physical examination, and rehabilitation programs may need modification.",
"   </p>",
"   <p>",
"    Monthly follow-up thereafter is appropriate. More frequent evaluation may be needed to facilitate efficient return to sport or work activity. If nonoperative therapy does not provide relief within three to six months, orthopedic referral is appropriate. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Indications for orthopedic referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated, chronic SIS can result in a significant loss of glenohumeral motion, possibly leading to adhesive capsulitis. This complication can be difficult to treat and may require surgical intervention. For the athlete, long-standing SIS can result in weakness, dysfunction, chronic pain, and the inability to perform effectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines are the same as those for rotator cuff tendinopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/35/26162?source=see_link\">",
"       \"Patient information: Shoulder impingement (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/49/8977?source=see_link\">",
"       \"Patient information: Shoulder impingement syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shoulder impingement syndrome (SIS) refers to a combination of shoulder symptoms, examination findings, and radiologic signs attributable to the compression of structures around the glenohumeral joint that occur with shoulder elevation. Repetitive activity at or above the shoulder during work or sports represents the main risk factor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SIS consists of a spectrum of clinical findings, NOT injury to a specific structure (ie, rotator cuff). Increased translation of the humeral head, acromion morphology that predisposes to impingement, and osteophytic change of the acromioclavicular joint all may play a role. Throwing athletes may develop posterior SIS. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to distinguish SIS from rotator cuff tear and adhesive capsulitis (frozen shoulder). Rotator cuff tears generally cause weakness, occur in older patients, and are associated with a positive drop arm sign and weakness with external rotation. Adhesive capsulitis is associated with a history of shoulder injury and restricted active",
"      <strong>",
"       and",
"      </strong>",
"      passive glenohumeral motion. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SIS complain of pain with overhead activity. Examination techniques for the shoulder are sensitive for the presence of SIS, but cannot reliably distinguish among specific causes of pain and dysfunction. In addition to general tests of shoulder motion and strength, the Neer and Hawkins-Kennedy impingement tests are useful. The neck and neurologic function must be carefully examined. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs are unnecessary for the initial evaluation of suspected SIS. Ultrasound often reveals the site of impingement and tendons involved. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Refer patients for orthopedic evaluation if three months of conservative treatment, including appropriate physical therapy, fails to improve symptoms and function, or if a rotator cuff tear, labrum tear, or adhesive capsulitis is suspected. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications for orthopedic referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Little evidence exists to guide management of SIS. Our approach is described above. Properly designed and performed physical therapy programs effectively treat most patients. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/1\">",
"      Cali M, Akg&uuml;n K, Birtane M, et al. Diagnostic values of clinical diagnostic tests in subacromial impingement syndrome. Ann Rheum Dis 2000; 59:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/2\">",
"      Hawkins RJ, Abrams JS. Impingement syndrome in the absence of rotator cuff tear (stages 1 and 2). Orthop Clin North Am 1987; 18:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/3\">",
"      Neer, CS. Anterior acromioplasty for the chronic impingement syndrome in the shoulder. A preliminary report. J Bone Joint Surg 1972; 54A:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/4\">",
"      Michener LA, Walsworth MK, Burnet EN. Effectiveness of rehabilitation for patients with subacromial impingement syndrome: a systematic review. J Hand Ther 2004; 17:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/5\">",
"      Schr&ouml;der J, van Dijk CN, Wielinga A, et al. Open versus arthroscopic treatment of chronic rotator cuff impingement. Arch Orthop Trauma Surg 2001; 121:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/6\">",
"      Faber E, Kuiper JI, Burdorf A, et al. Treatment of impingement syndrome: a systematic review of the effects on functional limitations and return to work. J Occup Rehabil 2006; 16:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/7\">",
"      van der Windt DA, Koes BW, de Jong BA, Bouter LM. Shoulder disorders in general practice: incidence, patient characteristics, and management. Ann Rheum Dis 1995; 54:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/8\">",
"      Ardic F, Kahraman Y, Kacar M, et al. Shoulder impingement syndrome: relationships between clinical, functional, and radiologic findings. Am J Phys Med Rehabil 2006; 85:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/9\">",
"      Meister K. Internal impingement in the shoulder of the overhand athlete: pathophysiology, diagnosis, and treatment. Am J Orthop (Belle Mead NJ) 2000; 29:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/10\">",
"      Lombardo SJ, Jobe FW, Kerlan RK, et al. Posterior shoulder lesions in throwing athletes. Am J Sports Med 1977; 5:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/11\">",
"      Walch, G, Boileau, P, Noel, E, Donell, ST. Impingement of the deep surface of the supraspinatus tendon on the posterosuperior glenoid rim: an arthroscopic study. J Shoulder Elbow Surg 1992; 1:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/12\">",
"      Bennett, GE. Shoulder and elbow lesions of the professional baseball pitcher. JAMA 1959; 117:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/13\">",
"      BENNETT GE. Elbow and shoulder lesions of baseball players. Am J Surg 1959; 98:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/14\">",
"      Jobe FW, Pink M. Classification and treatment of shoulder dysfunction in the overhead athlete. J Orthop Sports Phys Ther 1993; 18:427.",
"     </a>",
"    </li>",
"    <li>",
"     Hutton Ks, Julin MJ. Shoulder injuries. In: Team Physician's Handbook, 3rd, Mellion MB, Walsh WM, Madden C, et al (Eds), Hanley &amp; Belfus, Philadelphia 2002. p.397.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/16\">",
"      Walther M, Werner A, Stahlschmidt T, et al. The subacromial impingement syndrome of the shoulder treated by conventional physiotherapy, self-training, and a shoulder brace: results of a prospective, randomized study. J Shoulder Elbow Surg 2004; 13:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/17\">",
"      Mehta S, Gimbel JA, Soslowsky LJ. Etiologic and pathogenetic factors for rotator cuff tendinopathy. Clin Sports Med 2003; 22:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/18\">",
"      Dela Rosa, TL, Wang, AW, Zheng, MH. Tendinosis of the rotator cuff: a review. J Musculoskel Res 2001; 5:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/19\">",
"      Neviaser RJ, Neviaser TJ. Observations on impingement. Clin Orthop Relat Res 1990; :60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/20\">",
"      Neer CS 2nd. Impingement lesions. Clin Orthop Relat Res 1983; :70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/21\">",
"      Uhthoff HK, Hammond DI, Sarkar K, et al. The role of the coracoacromial ligament in the impingement syndrome. A clinical, radiological and histological study. Int Orthop 1988; 12:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/22\">",
"      Mayerhoefer ME, Breitenseher MJ, Wurnig C, Roposch A. Shoulder impingement: relationship of clinical symptoms and imaging criteria. Clin J Sport Med 2009; 19:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/23\">",
"      Sarkar K, Taine W, Uhthoff HK. The ultrastructure of the coracoacromial ligament in patients with chronic impingement syndrome. Clin Orthop Relat Res 1990; :49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/24\">",
"      Soslowsky LJ, An CH, Johnston SP, Carpenter JE. Geometric and mechanical properties of the coracoacromial ligament and their relationship to rotator cuff disease. Clin Orthop Relat Res 1994; :10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/25\">",
"      Kibler WB, McMullen J. Scapular dyskinesis and its relation to shoulder pain. J Am Acad Orthop Surg 2003; 11:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/26\">",
"      Cannon DE, Dillingham TR, Miao H, et al. Musculoskeletal disorders in referrals for suspected cervical radiculopathy. Arch Phys Med Rehabil 2007; 88:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/27\">",
"      Date ES, Gray LA. Electrodiagnostic evidence for cervical radiculopathy and suprascapular neuropathy in shoulder pain. Electromyogr Clin Neurophysiol 1996; 36:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/28\">",
"      Lauder TD. Musculoskeletal disorders that frequently mimic radiculopathy. Phys Med Rehabil Clin N Am 2002; 13:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/29\">",
"      Seeger LL, Gold RH, Bassett LW, Ellman H. Shoulder impingement syndrome: MR findings in 53 shoulders. AJR Am J Roentgenol 1988; 150:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/30\">",
"      Haahr JP, Andersen JH. Exercises may be as efficient as subacromial decompression in patients with subacromial stage II impingement: 4-8-years' follow-up in a prospective, randomized study. Scand J Rheumatol 2006; 35:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/31\">",
"      Ketola S, Lehtinen J, Arnala I, et al. Does arthroscopic acromioplasty provide any additional value in the treatment of shoulder impingement syndrome?: a two-year randomised controlled trial. J Bone Joint Surg Br 2009; 91:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/32\">",
"      Dorrestijn O, Stevens M, Winters JC, et al. Conservative or surgical treatment for subacromial impingement syndrome? A systematic review. J Shoulder Elbow Surg 2009; 18:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/33\">",
"      Holmgren T, Bj&ouml;rnsson Hallgren H, &Ouml;berg B, et al. Effect of specific exercise strategy on need for surgery in patients with subacromial impingement syndrome: randomised controlled study. BMJ 2012; 344:e787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/34\">",
"      Kromer TO, Tautenhahn UG, de Bie RA, et al. Effects of physiotherapy in patients with shoulder impingement syndrome: a systematic review of the literature. J Rehabil Med 2009; 41:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/35\">",
"      Kelly SM, Wrightson PA, Meads CA. Clinical outcomes of exercise in the management of subacromial impingement syndrome: a systematic review. Clin Rehabil 2010; 24:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/36\">",
"      Green S, Buchbinder R, Hetrick S. Physiotherapy interventions for shoulder pain. Cochrane Database Syst Rev 2003; :CD004258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/37\">",
"      Desmeules F, C&ocirc;t&eacute; CH, Fr&eacute;mont P. Therapeutic exercise and orthopedic manual therapy for impingement syndrome: a systematic review. Clin J Sport Med 2003; 13:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/38\">",
"      Desmeules F, Minville L, Riederer B, et al. Acromio-humeral distance variation measured by ultrasonography and its association with the outcome of rehabilitation for shoulder impingement syndrome. Clin J Sport Med 2004; 14:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/39\">",
"      Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev 2003; :CD004016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/40\">",
"      Hay EM, Thomas E, Paterson SM, et al. A pragmatic randomised controlled trial of local corticosteroid injection and physiotherapy for the treatment of new episodes of unilateral shoulder pain in primary care. Ann Rheum Dis 2003; 62:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/41\">",
"      Akg&uuml;n K, Birtane M, Akarirmak U. Is local subacromial corticosteroid injection beneficial in subacromial impingement syndrome? Clin Rheumatol 2004; 23:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/42\">",
"      Plafki C, Steffen R, Willburger RE, Wittenberg RH. Local anaesthetic injection with and without corticosteroids for subacromial impingement syndrome. Int Orthop 2000; 24:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/43\">",
"      Karthikeyan S, Kwong HT, Upadhyay PK, et al. A double-blind randomised controlled study comparing subacromial injection of tenoxicam or methylprednisolone in patients with subacromial impingement. J Bone Joint Surg Br 2010; 92:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/44\">",
"      Penning LI, de Bie RA, Walenkamp GH. The effectiveness of injections of hyaluronic acid or corticosteroid in patients with subacromial impingement: a three-arm randomised controlled trial. J Bone Joint Surg Br 2012; 94:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/45\">",
"      van der Windt DA, van der Heijden GJ, van den Berg SG, et al. Ultrasound therapy for musculoskeletal disorders: a systematic review. Pain 1999; 81:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/46\">",
"      Calis HT, Berberoglu N, Calis M. Are ultrasound, laser and exercise superior to each other in the treatment of subacromial impingement syndrome? A randomized clinical trial. Eur J Phys Rehabil Med 2011; 47:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32280/abstract/47\">",
"      Johansson KM, Adolfsson LE, Foldevi MO. Effects of acupuncture versus ultrasound in patients with impingement syndrome: randomized clinical trial. Phys Ther 2005; 85:490.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 240 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32280=[""].join("\n");
var outline_f31_33_32280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Throwing athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Musculoskeletal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Magnetic resonance imaging (MRI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INDICATIONS FOR ORTHOPEDIC REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Subacromial injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Alternative treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/240\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/240|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/20/33093\" title=\"figure 1A\">",
"      Shoulder anatomy anterior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/60/28613\" title=\"figure 1B\">",
"      Basic shoulder anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/6/27748\" title=\"figure 1C\">",
"      Basic shoulder anatomy posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/33/7696\" title=\"figure 2\">",
"      Acromion types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/57/11153\" title=\"figure 3\">",
"      Throwing phases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/240|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/7/44149\" title=\"picture 1\">",
"      Neers test for shoulder impingement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/27/19891\" title=\"picture 2\">",
"      Hawkins Kennedy test for shoulder impingement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/49/25361\" title=\"picture 3\">",
"      Posterior impingement test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/240|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/20/9549\" title=\"table 1\">",
"      Evaluation shoulder pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25991?source=related_link\">",
"      Biceps tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/35/26162?source=related_link\">",
"      Patient information: Shoulder impingement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/49/8977?source=related_link\">",
"      Patient information: Shoulder impingement syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=related_link\">",
"      Physical examination of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=related_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_33_32281="Secondary prevention for specific causes of ischemic stroke and transient ischemic attack";
var content_f31_33_32281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32281/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32281/contributors\">",
"     Karen L Furie, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32281/contributors\">",
"     Hakan Ay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32281/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32281/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/33/32281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the treatment of specific causes of both transient cerebral ischemia (transient ischemic attack or TIA) and ischemic stroke where the potential cause has been identified. There will be an emphasis on secondary prevention of recurrent cerebral ischemia and other vascular events. Risk factor management, which is appropriate for all patients with ischemic stroke or TIA, is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial assessment of patients with cerebral ischemia and acute therapy for ischemic stroke are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LARGE VESSEL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the secondary prevention of ischemic stroke or TIA caused by large vessel disease include revascularization (mainly for symptomatic internal carotid artery stenosis due to atherosclerosis) and multifactorial risk reduction including treatment with antiplatelet agents, antihypertensive drugs, and statins. The role of anticoagulation in this setting is quite limited, as noted below. Patients with large vessel atherothrombotic disease in anterior and posterior cerebral circulation sites other than the internal carotid artery and patients with the latter lesions who cannot undergo carotid endarterectomy benefit from antiplatelet therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some specific situations are discussed below for carotid disease, vertebral disease, intracranial disease, and dissection (a nonatheromatous cause).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Carotid stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid endarterectomy is beneficial for patients with recently symptomatic internal carotid artery atherosclerotic disease. This conclusion is based upon a number of randomized, controlled trials that have demonstrated the efficacy of endarterectomy in selected patients who have carotid atherosclerosis and symptoms such as a TIA or a nondisabling stroke. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Carotid endarterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carotid artery stenting is another potential option for select patients with symptomatic occlusive carotid lesions. Proponents of carotid stenting emphasize its less invasive nature (since it can be performed with local anesthesia and sedation) and the decreased likelihood of morbidity from coexisting coronary disease. Another group that may benefit from stenting consists of those with a \"hostile\" neck who are at higher risk for complications following standard carotid endarterectomy; included in this group are patients with radiation-induced stenosis, previous neck exploration, or tracheostomy. Nevertheless, carotid endarterectomy remains the preferred treatment for most patients with symptomatic carotid atherosclerosis (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Carotid stenting'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/66?source=see_link\">",
"     \"Carotid artery stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Carotid occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid artery occlusion may occur without clear symptoms, but it can be associated with TIA and stroke. The subsequent yearly risk of a stroke ipsilateral to the occluded carotid artery is 2 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal treatment of carotid occlusion remains undefined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/3\">",
"     3",
"    </a>",
"    ]. However, surgical revascularization is a viable option only when residual flow can be demonstrated in the internal carotid artery. In most cases, medical management is the only practical option in the setting of complete carotid occlusion. Many experts use short-term (three to six months) anticoagulation for acute symptomatic occlusion; the rationale for this approach is based on evidence that emboli may form and propagate from the stump of the occluded vessel after acute occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. An earlier randomized, controlled trial in patients with symptomatic carotid narrowing or occlusion found that surgical treatment using extracranial to intracranial bypass failed to reduce the risk of ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/6\">",
"     6",
"    </a>",
"    ], and the later COSS trial in patients with symptomatic carotid occlusion and hemodynamic cerebral ischemia also found no benefit for extracranial to intracranial bypass surgery compared with medical therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/7\">",
"     7",
"    </a>",
"    ]. Data from small retrospective studies suggests that recanalization can be achieved by emergent stenting of extracranial carotid artery occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/8\">",
"     8",
"    </a>",
"    ], or by intraarterial thrombolysis combined with stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/9\">",
"     9",
"    </a>",
"    ], but clinical benefit is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Extracranial vertebral artery stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, prevention of ischemic stroke and TIA due to extracranial vertebral artery stenosis is managed by intensive medical treatment and multifactorial risk reduction, including the use of antiplatelet agents, antihypertensive drugs, and statins. In addition, angioplasty and stenting is a treatment option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], and surgical transposition of the vertebral artery to the common carotid artery is another alternative for vertebral origin stenosis. However, efficacy for these procedures is uncertain. They are generally considered when maximal medical therapy has failed to prevent embolism or low-flow ischemic events.",
"   </p>",
"   <p>",
"    Guidelines for the prevention of stroke from the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    issued in 2011 reach a similar conclusion, stating that endovascular and surgical treatment of symptomatic extracranial vertebral stenosis may be considered when patients are having symptoms despite optimal medical therapies (eg, antithrombotic agents, statins, and other risk factor treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intracranial large vessel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of intracranial large artery atherosclerosis is reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/61/2010?source=see_link\">",
"     \"Intracranial large artery atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atherosclerotic stenosis of the major intracranial arteries (carotid siphon, middle cerebral artery, vertebral artery, and basilar artery) is an important cause of ischemic stroke, particularly in blacks, Asians, and Hispanics. The best treatment for intracranial large vessel occlusive disease is unclear.",
"   </p>",
"   <p>",
"    Randomized clinical trials, such as WARSS and WASID, have found no difference in terms of benefit between antiplatelet and anticoagulant therapy for ischemic stroke risk reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, the risk of major hemorrhage and death appears to be higher with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Results from the SAMMPRIS trial published indicate that aggressive medical management is superior to stenting for patients with recently symptomatic high-grade intracranial large artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of spontaneous cerebral and cervical artery dissection is reviewed here briefly and reviewed elsewhere in greater detail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21960?source=see_link\">",
"     \"Spontaneous cerebral and cervical artery dissection: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beyond the hyperacute period, antithrombotic therapy with either anticoagulation or antiplatelet drugs is accepted treatment for ischemic stroke and TIA caused by extracranial artery dissection, although there is controversy regarding the choice between the two. In addition, there is controversy regarding the use of antithrombotic agents for ischemic symptoms in patients with either intracranial dissection alone or intracranial extension of extracranial dissection because of the presumed increased risk of subarachnoid hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21960?source=see_link&amp;anchor=H28007410#H28007410\">",
"     \"Spontaneous cerebral and cervical artery dissection: Treatment and prognosis\", section on 'Antithrombotic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21960?source=see_link&amp;anchor=H28007438#H28007438\">",
"     \"Spontaneous cerebral and cervical artery dissection: Treatment and prognosis\", section on 'Choosing therapy for primary and secondary prevention of ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have ischemic neurologic symptoms caused by",
"      <strong>",
"       extracranial",
"      </strong>",
"      dissection who are beyond the hyperacute period or ineligible for thrombolytic therapy, we suggest treatment with anticoagulation, using unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin, followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for six months, rather than antiplatelet therapy. However, this approach is controversial, and some experts favor treatment with antiplatelet agents rather than anticoagulation in this setting.",
"     </li>",
"     <li>",
"      For patients who have ischemic neurologic symptoms caused by",
"      <strong>",
"       intracranial",
"      </strong>",
"      dissection, we suggest treatment with antiplatelet therapy rather than anticoagulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endovascular methods or surgical repair also have been used to treat dissection, mainly for patients who have recurrent ischemia despite antithrombotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21960?source=see_link&amp;anchor=H28007424#H28007424\">",
"     \"Spontaneous cerebral and cervical artery dissection: Treatment and prognosis\", section on 'Endovascular and surgical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SMALL VESSEL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small vessel disease that causes transient ischemia is a diagnosis of exclusion because of the importance of not missing a large vessel atherothrombotic lesion that can give rise to a sudden devastating stroke. The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in preventing recurrent TIAs or stroke in the setting of a small vessel (lacunar) TIA or lacunar infarction is uncertain. Over one-half of patients in the Warfarin-Aspirin in Recurrent Stroke Study (WARSS) had a small vessel stroke as their initial event and, as mentioned above, warfarin offered no advantages compared with aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4026?source=see_link\">",
"     \"Lacunar infarcts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other antiplatelet therapy is recommended, since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is potentially more hazardous and requires frequent monitoring. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to patients with large vessel disease, attention to serum lipids, hypertension, and other modifiable risk factors are additional means of preventing lacunar strokes in patients with small vessel disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CARDIOGENIC EMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral emboli from the heart and aorta behave the same way as artery-to-artery emboli that cause TIAs and stroke. Approximately 60 percent of all strokes in the NIH stroke databank are caused by embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/17\">",
"     17",
"    </a>",
"    ], and cardiogenic embolism is responsible for about 20 percent of ischemic strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distinction between artery-to-artery and non-artery-to-artery sources of embolism can be difficult. Suspicion of the former typically arises once vascular pathology in a large vessel has been identified (eg, with noninvasive testing). Repetitive spells within a single vascular territory are also suggestive of an artery-to-artery source, as is a normal echocardiogram. However, caution must be used in interpreting the results of a transthoracic echocardiogram (TTE). This study can exclude a cardiomyopathy and most atrial and mitral valve pathology, but may miss other potential embolic sources such as a patent foramen ovale, clot in the atrial appendage, mitral valve lesions, and aortic atherosclerosis. Transesophageal echocardiography (TEE) is better for identifying these lesions.",
"   </p>",
"   <p>",
"    We recommend doing a TTE with agitated saline contrast as a first test, and proceeding to TEE if there is a strong suspicion of a cardioembolic source and treatment decisions hinge on identifying one of the possible TEE findings. Cardiac monitoring is also an essential part of this evaluation to exclude atrial fibrillation.",
"   </p>",
"   <p>",
"    Definite cardiac sources of embolism for which antithrombotic therapy has proven effective include (",
"    <a class=\"graphic graphic_table graphicRef60843 \" href=\"mobipreview.htm?20/43/21181\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13,18-20\">",
"     13,18-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial fibrillation",
"     </li>",
"     <li>",
"      Left ventricular thrombus",
"     </li>",
"     <li>",
"      Dilated cardiomyopathy",
"     </li>",
"     <li>",
"      Rheumatic valve disease",
"     </li>",
"     <li>",
"      Prosthetic heart valves",
"     </li>",
"     <li>",
"      Recent myocardial infarction (MI) in high-risk patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of population-based observational studies found that an increased risk of stroke after MI was associated with older age, diabetes, hypertension, prior stroke, anterior location of index MI, prior MI, atrial fibrillation, heart failure, and nonwhite race [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minor potential sources of cardiogenic embolism include left ventricular regional wall motion abnormalities, severe mitral annular calcification, mitral valve prolapse, mitral valve strands, and aortic valve disease (",
"    <a class=\"graphic graphic_table graphicRef60843 \" href=\"mobipreview.htm?20/43/21181\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. The risk of stroke associated with these sources is uncertain, as is the efficacy of and need for treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation is a major risk factor for ischemic stroke. Anticoagulation is the most effective treatment to reduce stroke risk.",
"   </p>",
"   <p>",
"    However, it is not clear whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    should be started acutely in patients with atrial fibrillation who have a TIA or embolic stroke. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link&amp;anchor=H9#H9\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Atrial fibrillation and cardioembolic stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For secondary stroke prevention, virtually all patients with atrial fibrillation who have a history of stroke or TIA of cardioembolic origin should be treated with anticoagulation in the absence of contraindications. Guidelines issued in 2011 from the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    recommend anticoagulation with adjusted-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for a target INR of 2.5 (range 2.0 to 3.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ]. This recommendation is based primarily upon studies of patients with stroke, which have found that warfarin treatment can reduce the risk of stroke by approximately 70 percent, to a level similar to that seen in a population free of atrial fibrillation. For patients unable to take oral anticoagulants,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    325 mg daily is recommended. In addition, for patients with atrial fibrillation who require temporary interruption of oral anticoagulation and are at high risk for stroke (ie, those with stroke or TIA within three months, or a CHADS2 score of 5 or 6 (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 2",
"    </a>",
"    ), or mechanical or rheumatic valve disease), the guidelines state that bridging therapy with subcutaneous low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is reasonable.",
"   </p>",
"   <p>",
"    Of note, the 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ] were developed before regulatory evaluation and approval of the oral anticoagulant agents",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    . However, the guidelines observed that dabigatran, which lacks significant drug or food interactions and does not require coagulation monitoring, would represent a major advance for this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ]. Now that additional agents are available, they are options for patients with atrial fibrillation for whom anticoagulant therapy is chosen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/23\">",
"     23",
"    </a>",
"    ]. These issues are reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Myocardial infarction and left ventricular thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with left ventricular thrombus in the specific setting of an acute myocardial infarction have a significantly increased risk of embolic events. The 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines state that patients with ischemic stroke or TIA in the setting of acute myocardial infarction complicated by left ventricular mural thrombus should be treated with oral anticoagulation (target INR 2.5; range 2 to 3) for at least three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue of left ventricular thrombus and acute myocardial infarction is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=see_link\">",
"     \"Left ventricular thrombus after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in sinus rhythm with prior ischemic stroke or TIA who have cardiomyopathy characterized by systolic dysfunction (left ventricular ejection fraction &le;35 percent), the 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines note that the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has",
"    <strong>",
"     not",
"    </strong>",
"    been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ]. The guidelines conclude that either warfarin (INR 2 to 3),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (81 mg daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75 mg daily), or the combination of aspirin (25 mg twice daily) plus extended-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    (200 mg twice daily) may be considered for the prevention of recurrent events. The role of anticoagulation for individuals with heart failure and prior thromboembolic events is reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rheumatic mitral valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines consider long term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy reasonable for patients with ischemic stroke or TIA who have rheumatic valve disease, with or without atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ]. Antiplatelet agents should not be used routinely with warfarin. This issued is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other mitral and aortic valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor potential sources of cardiogenic embolism include mitral annular calcification, mitral valve prolapse, mitral valve strands, and aortic valve disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. The risk of stroke associated with these sources is uncertain, as is the efficacy of and need for treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines for prevention of stroke make the following recommendations for patients with mitral and aortic valvular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with mitral valve prolapse who have ischemic stroke or TIA, long-term antiplatelet therapy may be considered.",
"     </li>",
"     <li>",
"      For patients with ischemic stroke or TIA and mitral annular calcification, antiplatelet therapy may be considered.",
"     </li>",
"     <li>",
"      For patients with ischemic stroke or TIA and native aortic or nonrheumatic mitral valve disease who do not have atrial fibrillation, antiplatelet therapy may be reasonable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 guidelines from the American College of Chest Physicians (ACCP) suggest treating patients with mitral valve prolapse or strands and ischemic stroke or TIA with antiplatelet agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/24\">",
"     24",
"    </a>",
"    ], following the ACCP recommendations for noncardioembolic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/25\">",
"     25",
"    </a>",
"    ]. The ACCP guidelines make no specific recommendations regarding mitral annular calcification, but note that emboli in this condition may represent thrombus or calcific spicules, and the latter will not be prevented by antithrombotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/24\">",
"     24",
"    </a>",
"    ]. The guidelines state that it is reasonable to manage patients with mitral annular calcification who have thromboembolism with no other identifiable source in the same manner as patients with TIAs without mitral annular calcification (ie, with antiplatelet agents).",
"   </p>",
"   <p>",
"    The ACCP guidelines conclude that antithrombotic therapy does not have a role in calcified aortic valve disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitral and aortic valvular disease is reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2648?source=see_link&amp;anchor=H10#H10\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\", section on 'Transient ischemic attacks and cerebral vascular accidents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37801?source=see_link\">",
"     \"Mitral annular calcification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Embolic events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prosthetic heart valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;All mechanical heart valves require antithrombotic prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13,24\">",
"     13,24",
"    </a>",
"    ]. Antithrombotic therapy for mechanical and bioprosthetic heart valves is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important cause of embolic stroke and TIA for which anticoagulation is hazardous is infective endocarditis. Emboli from vegetations can cause focal neurologic signs which are fleeting. However, careful examination usually reveals evidence of a persistent deficit. Thus, endocarditis must be excluded in any patient with a TIA and other suggestive findings such as fever and a heart murmur. Treatment consists of antibiotic therapy for the infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33415?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with infective endocarditis\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     PFO and atrial septal aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patent foramen ovale (PFO) and atrial septal aneurysm (ASA) may be associated with increased risk of ischemic stroke, although the risk is uncertain. Evaluation and treatment of these entities remains unsettled, and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=see_link&amp;anchor=H8#H8\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Risk of embolic stroke'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     AORTIC ATHEROSCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data regarding the stroke risk associated with aortic atherosclerosis, which may in part be explained by methodologic differences across the studies. In longitudinal population studies with nonselected patients, complex aortic atherosclerosis does not appear to be associated with any increased primary stroke risk. However, most reports evaluating secondary stroke risk have found that complex aortic atherosclerosis is a risk factor for recurrent stroke. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9208?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and classification of stroke\", section on 'Aortic atherosclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal treatment for aortic disease is not clear, and no randomized trials have evaluated the role of antithrombotic therapy in patients with aortic atheroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/26\">",
"     26",
"    </a>",
"    ]. Nevertheless, secondary prevention seems warranted, especially since aortic plaques 4 mm or greater in size may be associated with an increased risk of recurrent stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2012 ACCP guidelines conclude that there is insufficient evidence to support the use of antithrombotic therapy for prevention of ischemic events in patients with severe thoracic aortic atheroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/24\">",
"     24",
"    </a>",
"    ]. The ACCP guidelines therefore suggest managing patients who have aortic atheroma and thromboembolism with no other identifiable source in the same way as those with no aortic atheromatous disease (ie, long-term antiplatelet therapy).",
"   </p>",
"   <p>",
"    Additional strategies for secondary prevention of aortic atheromatous disease include lipid lowering therapy with statins, antihypertensive treatment, and smoking cessation. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link&amp;anchor=H16#H16\">",
"     \"Embolism from aortic plaque: Thromboembolism\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link&amp;anchor=H23#H23\">",
"     \"Embolism from aortic plaque: Thromboembolism\", section on 'Summary and Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ARCH trial is an ongoing international randomized controlled study comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    with antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) for the prevention of stroke in patients with aortic arch atheroma that is either mobile or &ge;4 mm thick [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     BLOOD DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of hematologic disorders, including hypercoagulable states and sickle cell disease, can increase the risk of TIA and stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antiphospholipid antibody syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid syndrome (APS) is a hypercoagulable state characterized by recurrent arterial or venous thromboembolism, or pregnancy loss, in association with antibodies directed against plasma proteins that may be bound to anionic phospholipids. The presence of such antibodies may be detected as lupus anticoagulants, anticardiolipin antibodies (aCL) or anti-&szlig;2 glycoprotein-I antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This disorder has been referred to as primary APS when it occurs alone; however, it can also be seen in association with systemic lupus erythematosus (SLE), other rheumatic disorders, and autoimmune diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    and antiplatelet agents have been employed to prevent stroke due to APS. For patients with cryptogenic ischemic stroke or TIA and positive antiphospholipid antibodies, the 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines state that antiplatelet therapy is reasonable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ]. For patients with ischemic stroke or TIA who meet criteria for the antiphospholipid antibody syndrome with venous and arterial occlusive disease in multiple organs, miscarriages and livedo reticularis, oral anticoagulation with a target INR of 2 to 3 is reasonable. The 2012 ACCP guidelines conclude that subgroup analyses of secondary prevention studies have failed to find benefit of anticoagulation over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with antiphospholipid antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/25\">",
"     25",
"    </a>",
"    ]. Therefore, the ACCP recommendations for such patients follow the general recommendations for patients with noncardioembolic stroke (ie, long-term antiplatelet therapy).",
"   </p>",
"   <p>",
"    For patients with an otherwise cryptogenic ischemic stroke or TIA who meet criteria for the antiphospholipid antibody syndrome, we suggest long-term oral anticoagulation with a target INR of 2 to 3. This recommendation is similar to that of the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines.",
"   </p>",
"   <p>",
"    The management of APS is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Inherited thrombophilias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilias are hypercoagulable states that include a number of disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protein C deficiency",
"     </li>",
"     <li>",
"      Protein S deficiency",
"     </li>",
"     <li>",
"      Antithrombin III deficiency",
"     </li>",
"     <li>",
"      Activated protein C resistance",
"     </li>",
"     <li>",
"      Factor V Leiden as a cause of activated protein C resistance",
"     </li>",
"     <li>",
"      Prothrombin G20210A mutation",
"     </li>",
"     <li>",
"      Methylenetetrahydrofolate reductase (MTHFR) mutations associated with hyperhomocysteinemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions are thought to be rare causes of ischemic stroke in adults, but may be more important causes of ischemic stroke in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines recommend that patients with ischemic stroke or TIA who have an established inherited thrombophilia should be evaluated for deep vein thrombosis, which is an indication for short- or long-term anticoagulation, depending on the clinical and hematologic circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ]. In the absence of venous thrombosis, either anticoagulation or antiplatelet therapy is considered reasonable. For patients with an inherited thrombophilia and a history of spontaneous cerebral venous thrombosis or recurrent thrombotic events, the guidelines note that long-term anticoagulation is probably indicated.",
"   </p>",
"   <p>",
"    The evaluation and management of these conditions is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13176?source=see_link\">",
"     \"Protein S deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20743?source=see_link\">",
"     \"Prothrombin gene mutation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/16/9482?source=see_link\">",
"     \"Treatment and prognosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stroke is a frequent complication of sickle cell disease (SCD). In children and possibly in adults who have SCD, stroke risk can be reduced with transfusion therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link\">",
"     \"Cerebrovascular complications of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For adults with SCD and ischemic stroke or TIA, the 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines recommend general measures including traditional stroke risk factor identification and reduction as well as the use of antiplatelet agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"     13",
"    </a>",
"    ]. The guidelines also note that additional measures may be considered, including regular blood transfusions to reduce hemoglobin S to less than 30 to 50 percent of total hemoglobin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , or bypass surgery in cases of advanced occlusive disease.",
"   </p>",
"   <p>",
"    The management of SCD is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link\">",
"     \"Cerebrovascular complications of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/18/20772?source=see_link\">",
"       \"Patient information: Transient ischemic attack (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=see_link\">",
"       \"Patient information: Ischemic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491172207\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Options for the secondary prevention of ischemic stroke or TIA caused by large vessel disease include revascularization (mainly for symptomatic internal carotid artery stenosis) and medical therapy (mainly antiplatelet, antihypertensive, and lipid-lowering agents) for multifactorial risk reduction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Large vessel disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carotid endarterectomy is beneficial for patients with recently symptomatic internal carotid artery atherosclerotic disease. Surgical revascularization is a viable option only when residual flow can be demonstrated in the internal carotid artery. In the setting of complete carotid occlusion, Medical management is the only practical option. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Carotid stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, prevention of ischemic stroke and TIA due to extracranial vertebral artery stenosis is managed by intensive medical treatment and multifactorial risk reduction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Extracranial vertebral artery stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aggressive medical management is superior to stenting for patients with recently symptomatic high-grade intracranial large artery stenosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Intracranial large vessel disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antithrombotic therapy, with either anticoagulation or antiplatelet drugs, is used as treatment for the secondary prevention of ischemic stroke and TIA caused by cervical arterial dissection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dissection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Similar to patients with large vessel disease, medical management with antiplatelet therapy and treatment of modifiable risk factors is the mainstay for secondary stroke prevention in patients with lacunar stroke due to small vessel disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Small vessel disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definite cardiac sources of embolism (",
"      <a class=\"graphic graphic_table graphicRef60843 \" href=\"mobipreview.htm?20/43/21181\">",
"       table 1",
"      </a>",
"      ) for which antithrombotic therapy has proven effective include atrial fibrillation, left ventricular thrombus, dilated cardiomyopathy, rheumatic valve disease, prosthetic heart valves, and recent myocardial infarction (MI) in high-risk patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiogenic embolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virtually all patients with atrial fibrillation who have a history of stroke or TIA of cardioembolic origin should be treated with oral anticoagulation in the absence of contraindications. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Current guidelines support oral anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for the prevention of stroke in patients with left ventricular thrombus in the setting of an acute myocardial infarction, for patients with ischemic stroke or TIA who have rheumatic valve disease and, less strongly, for those who have bioprosthetic heart valves with no other source of thromboembolism. All patients with mechanical heart valves require antithrombotic prophylaxis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Myocardial infarction and left ventricular thrombus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Rheumatic mitral valve disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Prosthetic heart valves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patent foramen ovale (PFO) and atrial septal aneurysm (ASA) may be associated with increased risk of ischemic risk. Evaluation and treatment of these entities remains unsettled, and is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14328?source=see_link\">",
"       \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal treatment for the prevention of ischemic stroke and TIA due to aortic disease is not clear. The ACCP guidelines recommend antiplatelet therapy for patients with stroke associated with aortic atherosclerotic lesions, and oral anticoagulation or antiplatelet agents are suggested for patients with cryptogenic stroke associated with mobile aortic arch thrombi. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Aortic atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cryptogenic ischemic stroke or TIA and positive antiphospholipid antibodies, the",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines state that antiplatelet therapy is reasonable. For patients with ischemic stroke or TIA who meet criteria for the antiphospholipid antibody syndrome, oral anticoagulation with a target INR of 2 to 3 is reasonable. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Antiphospholipid antibody syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       AHA/ASA",
"      </span>",
"      guidelines recommend that patients with ischemic stroke or TIA who have an established inherited thrombophilia should be evaluated for deep vein thrombosis, which is an indication for short- or long-term anticoagulation. In the absence of venous thrombosis, either anticoagulation or antiplatelet therapy is considered reasonable. For patients with an inherited thrombophilia and a history of spontaneous cerebral venous thrombosis or recurrent thrombotic events, the guidelines note that long-term anticoagulation is probably indicated. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Inherited thrombophilias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children and possibly in adults who have sickle cell disease, stroke risk can be reduced with transfusion therapy. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Sickle cell disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24782000\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Philip Kistler for his contributions to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/1\">",
"      Cote R, Barnett HJ, Taylor DW. Internal carotid occlusion: a prospective study. Stroke 1983; 14:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/2\">",
"      Klijn CJ, Kappelle LJ, Tulleken CA, van Gijn J. Symptomatic carotid artery occlusion. A reappraisal of hemodynamic factors. Stroke 1997; 28:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/3\">",
"      Flemming KD, Brown RD Jr, Petty GW, et al. Evaluation and management of transient ischemic attack and minor cerebral infarction. Mayo Clin Proc 2004; 79:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/4\">",
"      Barnett HJ. Delayed cerebral ischemic episodes distal to occlusion of major cerebral arteries. Neurology 1978; 28:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/5\">",
"      Barnett HJ, Peerless SJ, Kaufmann JC. \"Stump\" on internal carotid artery--a source for further cerebral embolic ischemia. Stroke 1978; 9:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/6\">",
"      Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group. N Engl J Med 1985; 313:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/7\">",
"      Powers WJ, Clarke WR, Grubb RL Jr, et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA 2011; 306:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/8\">",
"      Jovin TG, Gupta R, Uchino K, et al. Emergent stenting of extracranial internal carotid artery occlusion in acute stroke has a high revascularization rate. Stroke 2005; 36:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/9\">",
"      Nedeltchev K, Brekenfeld C, Remonda L, et al. Internal carotid artery stent implantation in 25 patients with acute stroke: preliminary results. Radiology 2005; 237:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/10\">",
"      Coward LJ, McCabe DJ, Ederle J, et al. Long-term outcome after angioplasty and stenting for symptomatic vertebral artery stenosis compared with medical treatment in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. Stroke 2007; 38:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/11\">",
"      Jenkins JS, Patel SN, White CJ, et al. Endovascular stenting for vertebral artery stenosis. J Am Coll Cardiol 2010; 55:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/12\">",
"      Stayman AN, Nogueira RG, Gupta R. A systematic review of stenting and angioplasty of symptomatic extracranial vertebral artery stenosis. Stroke 2011; 42:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/13\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/14\">",
"      Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/15\">",
"      Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/16\">",
"      Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/17\">",
"      Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989; 25:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/18\">",
"      Ay H, Furie KL, Singhal A, et al. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005; 58:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/19\">",
"      Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke 2007; 38:2979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/20\">",
"      Arsava EM, Ballabio E, Benner T, et al. The Causative Classification of Stroke system: an international reliability and optimization study. Neurology 2010; 75:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/21\">",
"      Witt BJ, Ballman KV, Brown RD Jr, et al. The incidence of stroke after myocardial infarction: a meta-analysis. Am J Med 2006; 119:354.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/22\">",
"      Homma S, Di Tullio MR, Sciacca RR, et al. Effect of aspirin and warfarin therapy in stroke patients with valvular strands. Stroke 2004; 35:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/23\">",
"      Alberts MJ, Bernstein RA, Naccarelli GV, Garcia DA. Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke 2012; 43:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/24\">",
"      Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/25\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/26\">",
"      Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. Circulation 2006; 114:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/27\">",
"      Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med 1996; 334:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32281/abstract/28\">",
"      Fujimoto S, Yasaka M, Otsubo R, et al. Aortic arch atherosclerotic lesions and the recurrence of ischemic stroke. Stroke 2004; 35:1426.",
"     </a>",
"    </li>",
"    <li>",
"     Aortic Arch Related Cerebral Hazard Trial (ARCH). www.clinicaltrials.gov/ct/show/NCT00235248 (Accessed on February 01, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1119 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32281=[""].join("\n");
var outline_f31_33_32281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H491172207\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LARGE VESSEL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Carotid stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Carotid occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Extracranial vertebral artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intracranial large vessel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SMALL VESSEL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CARDIOGENIC EMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Myocardial infarction and left ventricular thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rheumatic mitral valve disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other mitral and aortic valvular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PFO and atrial septal aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      AORTIC ATHEROSCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      BLOOD DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antiphospholipid antibody syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H491172207\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24782000\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1119\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1119|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/43/21181\" title=\"table 1\">",
"      Cardioaortic sources embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/45/40668\" title=\"table 2\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33415?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/66?source=related_link\">",
"      Carotid artery stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/61/2010?source=related_link\">",
"      Intracranial large artery atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37801?source=related_link\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/18/20772?source=related_link\">",
"      Patient information: Transient ischemic attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21960?source=related_link\">",
"      Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/16/9482?source=related_link\">",
"      Treatment and prognosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14328?source=related_link\">",
"      Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_33_32282="Restless legs syndrome and periodic limb movement disorder in children";
var content_f31_33_32282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Restless legs syndrome and periodic limb movement disorder in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32282/contributors\">",
"     Daniel L Picchietti, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32282/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32282/contributors\">",
"     Ronald D Chervin, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/33/32282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/33/32282/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/33/32282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21806611\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restless legs syndrome (RLS), also known as Willis-Ekbom disorder, is a common, complex, and treatable neurological condition. A substantial body of literature about pediatric RLS has emphasized its impact on sleep, as well as frequent comorbidity with attention deficit hyperactivity disorder (ADHD), mood disorders, and anxiety disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Consensus diagnostic criteria for children were updated in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], and pediatric-specific treatment data are emerging.",
"   </p>",
"   <p>",
"    Periodic limb movement disorder (PLMD) is characterized by clinical sleep disturbance and by repetitive limb jerking in sleep (known as periodic limb movements of sleep, PLMS), that is not better explained by another condition, medication use, or substance use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/7\">",
"     7",
"    </a>",
"    ]. In children, PLMD appears to be closely related to RLS, although they are distinct diagnostic entities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the similarities of pediatric RLS and PLMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/9\">",
"     9",
"    </a>",
"    ], especially overlap in the approach to treatment, they are presented together in this topic review, with important differences noted when applicable. The following topic reviews have related content:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5929?source=see_link\">",
"       \"Assessment of sleep disorders in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32554?source=see_link\">",
"       \"Restless legs syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4711?source=see_link\">",
"       \"Nocturnal leg cramps\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806618\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of RLS in adults is approximately 5 to 10 percent, based upon population-based studies in Europe and North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the prevalence of moderate-to-severe or clinically-significant RLS is lower, estimated at 2 to 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. The severity of symptoms is directly relevant to clinical care and is an important component of treatment decisions. The prevalence of RLS in Asian populations is less, with most studies finding overall rates of 1 to 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/10\">",
"     10",
"    </a>",
"    ]. In all ethnic groups, women are affected about twice as often as men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/10\">",
"     10",
"    </a>",
"    ]. Onset of symptoms prior to age 20 years is reported in approximately 40 percent of adults with RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of RLS in children and adolescents is 2 to 4 percent in population-based studies from the United Kingdom, the United States, and Turkey, and the prevalence of moderate-to-severe RLS is 0.5 to 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. This approaches the prevalence of obstructive sleep apnea in children but exceeds the prevalence of both pediatric epilepsy and diabetes. Boys are affected as often as girls in younger age groups; the female predominance noted in adults emerges in the late teens or early twenties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/10,19-21\">",
"     10,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Population-based studies of RLS in adults report high incidence rates (annual new cases) of 0.8 to 1.7 percent, as well as high remission rates (about 50 percent of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. A single pediatric study found similarly high incidence and remission rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/26\">",
"     26",
"    </a>",
"    ]. These findings are in contrast to clinical cohorts, in which remission is much less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/16,27-29\">",
"     16,27-29",
"    </a>",
"    ]. As an example, a large study in a clinical cohort reported that RLS was progressive in 36 percent, was stable in 41 percent, diminished in 15 percent, and remitted in 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/30\">",
"     30",
"    </a>",
"    ]. Together, these observations suggest that mild, non-clinical cases that are captured in population-based studies are more likely to remit spontaneously than are those cases that come to medical attention and that are captured in clinical cohorts. Nonetheless, the potential for remission should be considered when a treatment plan is discussed.",
"   </p>",
"   <p>",
"    The epidemiology of PLMD is less understood, because no well-constructed studies are available using the current definition for PLMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/7\">",
"     7",
"    </a>",
"    ]. However, two large case series suggest that this diagnosis is not uncommon in pediatric sleep clinics in which children are routinely evaluated for PLMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/9,31,32\">",
"     9,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806625\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetics, brain iron deficiency, and brain dopamine have been implicated in the pathophysiology of RLS and PLMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A genetic mechanism is suggested by the high familial prevalence (40 to 92 percent) among individuals with RLS onset before age 40 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/28,30,34,35\">",
"       28,30,34,35",
"      </a>",
"      ]. Similarly, in a pediatric population-based study, a family history of RLS was reported in 71 percent of affected children between 8 and 11 years and in 80 percent of those between 12 and 17 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/19\">",
"       19",
"      </a>",
"      ]. Both parents were affected in 16 percent of these cases. In addition, several genome-wide studies have found an association of RLS with genetic variants of",
"      <em>",
"       BTBD9, MEIS1,",
"      </em>",
"      and",
"      <em>",
"       <span class=\"nowrap\">",
"        MAP2K5/LBXCOR,",
"       </span>",
"      </em>",
"      as well as a possible association",
"      <em>",
"      </em>",
"      with",
"      <em>",
"       PTPRD",
"      </em>",
"      and",
"      <em>",
"       A2BP1",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/36-39\">",
"       36-39",
"      </a>",
"      ]. A single study of 23 children with RLS found an association with variants in",
"      <em>",
"       MEIS1",
"      </em>",
"      and",
"      <span class=\"nowrap\">",
"       <em>",
"        MAP2K",
"       </em>",
"       /",
"       <em>",
"        LBXCOR1",
"       </em>",
"      </span>",
"      but not in",
"      <em>",
"       BTBD9",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/40\">",
"       40",
"      </a>",
"      ]",
"      <em>",
"       .",
"      </em>",
"      Thus far, two of the variants,",
"      <em>",
"       BTBD9",
"      </em>",
"      and",
"      <em>",
"       MEIS1,",
"      </em>",
"      appear to influence expression of PLMS, as well as iron homeostasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/36,41\">",
"       36,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iron deficiency is implicated in the pathogenesis of RLS and PLMS, as suggested by the association between these disorders and low iron stores found on autopsy data [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/42\">",
"       42",
"      </a>",
"      ], magnetic resonance imaging (MRI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/43\">",
"       43",
"      </a>",
"      ], brain sonography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/44,45\">",
"       44,45",
"      </a>",
"      ], and cerebrospinal fluid analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/46\">",
"       46",
"      </a>",
"      ]. Iron is important in brain dopamine production and synaptic density, as well as in myelin synthesis, in energy production, and, probably, in norepinephrine and serotonin neurotransmitter systems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/47-49\">",
"       47-49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A role for brain dopaminergic signaling in RLS and PLMS is supported by the efficacy of dopaminergic drugs in treating these disorders, demonstrated in multiple randomized clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21806751\">",
"       'Medication'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806632\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children presenting to our pediatric sleep and neurology clinic who were ultimately diagnosed with RLS or PLMD, we have observed the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Chief complaint:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sleep concerns &mdash; 46 percent",
"     </li>",
"     <li>",
"      Behavior concerns &mdash; 46 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sleep problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restless sleep &mdash; 86 percent",
"     </li>",
"     <li>",
"      Sleep onset problems &mdash; 81 percent. Sleep onset problems are somewhat more common in children ultimately diagnosed with RLS as compared with children without RLS.",
"     </li>",
"     <li>",
"      Sleep maintenance problems &mdash; 65 percent. Sleep maintenance problems are somewhat more common in children ultimately diagnosed with PLMD as compared with children without PLMD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surprisingly, leg symptoms rarely are the chief complaint. We think this is because parents are more likely to be aware of and concerned about the behavioral impact of these disorders, rather than the more specific leg or limb symptoms. These observations underscore the importance of asking specifically about leg and arm symptoms, if the family does not spontaneously relate concerns. (See",
"    <a class=\"local\" href=\"#H21806680\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We also noted a high prevalence of attention deficit hyperactivity disorder (ADHD) in this sample (78 percent), which reflects our clinical focus on ADHD. The prevalence of other comorbid conditions probably vary among clinical centers that see children with these disorders. Leg discomfort may be a more common presentation of RLS in a pediatric rheumatology clinic, and limb jerking during sleep may be more common as a presentation of PLMD in an epilepsy clinic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806639\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;To evaluate for RLS, the key clinical characteristics that should be elicited by the history are (",
"    <a class=\"graphic graphic_table graphicRef86837 \" href=\"mobipreview.htm?20/49/21276\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An urge to move the legs, usually accompanied by uncomfortable or unpleasant sensations in the legs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      These symptoms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      begin or worsen during rest or inactivity (eg, lying down or sitting)",
"     </li>",
"     <li>",
"      are relieved by movement",
"     </li>",
"     <li>",
"      occur exclusively or predominantly in the evening or night",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      These symptoms are not solely accounted for by another medical or behavioral condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms are subjective but follow typical patterns that are described in different ways by children. Therefore, it is important to have the child describe any leg-related symptoms in his or her own words rather than by the parent or caretaker and to make these inquiries with open-ended questions, using age-appropriate vocabulary (",
"    <a class=\"graphic graphic_table graphicRef86838 \" href=\"mobipreview.htm?21/49/22299\">",
"     table 2",
"    </a>",
"    ). Descriptive responses should be encouraged, instead of",
"    <span class=\"nowrap\">",
"     yes/no",
"    </span>",
"    responses. Sufficient prompts should be used to determine whether RLS diagnostic criteria are met, but, once the child starts describing symptoms, &ldquo;tell me more&rdquo; is often the best way to elicit further diagnostic information.",
"   </p>",
"   <p>",
"    The interview may start with nonspecific prompts, such as, &ldquo;How did you sleep last night?&rdquo;. More specific prompts to assess the urge to move the legs are &ldquo;Do your legs bother you?&rdquo;; &ldquo;Do your legs bother you at night?&rdquo;; &ldquo;Do your legs bother you at school?&rdquo;; and &ldquo;Do your legs ever hurt?&rdquo;. It is very uncommon for young children to understand or use the word &ldquo;urge.&rdquo; If given the opportunity, most children with RLS will use more than one descriptor for the RLS sensations. Common descriptors used by children are &ldquo;want to move&rdquo;; &ldquo;have to move&rdquo;; &ldquo;got to kick&rdquo;; &ldquo;bugs&rdquo;; &ldquo;ants&rdquo;; &ldquo;tingling&rdquo;; &ldquo;wiggly&rdquo;; &ldquo;itchy&rdquo;; &ldquo;pain&rdquo;; and &ldquo;hurts&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/8,19,51,52\">",
"     8,19,51,52",
"    </a>",
"    ]. If &ldquo;pain&rdquo; or &ldquo;hurts&rdquo; is the initial descriptor, it is important to probe for additional descriptors, since many of the conditions in the differential diagnosis are described as painful but lack additional RLS characteristics. Another helpful prompt to identify discomfort is &ldquo;Is that a good or a bad feeling?&rdquo;.",
"   </p>",
"   <p>",
"    To identify the temporal characteristics of the symptom, useful prompts are &ldquo;What are you doing when you get those feelings?&rdquo; or &ldquo;Do you get those feelings more during the day or at night?&rdquo;. To probe for relief with movement, a useful prompt is &ldquo;When you move, your legs are the feelings better, worse, or about the same?&rdquo;.",
"   </p>",
"   <p>",
"    An additional technique that we find useful diagnostically is having the child make a drawing of symptoms (",
"    <a class=\"graphic graphic_figure graphicRef87631 \" href=\"mobipreview.htm?40/62/41957\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef87694 \" href=\"mobipreview.htm?29/59/30643\">",
"     figure 2",
"    </a>",
"    ). We have found that children will often talk about their RLS symptoms in detail if they are asked to draw a picture of the feelings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, the clinical significance of RLS or PLMD is determined by assessing for significant distress or impairment in social, occupational, educational, or other important areas of functioning. Parental input is helpful in this assessment. The impact of the symptoms on sleep, mood, and schoolwork are typically the focus of concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/19,53\">",
"     19,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Periodic limb movement disorder (PLMD) is characterized by repetitive limb jerking in sleep, with clinical disturbance of sleep. The possibility of PLMD may be raised by the history but must be confirmed by polysomnography, because parental or child observations for PLMS are not reliable for diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/8,9,54-56\">",
"     8,9,54-56",
"    </a>",
"    ]. Parents report children with PLMD as &ldquo;restless in sleep&rdquo; in 70 to 90 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/9,31,54\">",
"     9,31,54",
"    </a>",
"    ]. However, this descriptor is not specific for PLMD and can be seen in a similar percentage of children with obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/31\">",
"     31",
"    </a>",
"    ]. Observed &ldquo;leg kicking in sleep&rdquo; is reported in 40 to 50 percent but also has a low specificity. Conversely, absence of restless sleep and of leg kicking in sleep has a high negative predictive value. Other findings that can raise the index of suspicion for PLMD include a family history of RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/9,31\">",
"     9,31",
"    </a>",
"    ], a personal history of some but not full diagnostic criteria for RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/8\">",
"     8",
"    </a>",
"    ], and a history of frequent parasomnias, such as confusional arousals, sleep terrors, or sleepwalking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/9,31,57\">",
"     9,31,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6963820\">",
"    <span class=\"h2\">",
"     Polysomnography and accelerometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;For PLMD, polysomnography is essential for diagnosis and helps to rule out sleep apnea as the etiology for leg movements. Polysomnography should be considered for children with clinical sleep disturbance (for which another cause is not evident) and with a history suggestive of PLMD.",
"   </p>",
"   <p>",
"    Night-to-night variability of periodic limb movements of sleep (PLMS) can complicate the assessment by polysomnography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Therefore, in cases in which we have a high index of suspicion for PLMD and in which polysomnography is negative for PLMS, we monitor for PLMS by five nights of ankle accelerometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/59,62,63\">",
"     59,62,63",
"    </a>",
"    ]. In the scoring of pediatric PLMS, it should be appreciated that the intermovement intervals may be quite variable, resulting in irregular appearing clusters, as shown in the bottom panel of the figure (",
"    <a class=\"graphic graphic_waveform graphicRef87701 \" href=\"mobipreview.htm?31/32/32266\">",
"     waveform 1",
"    </a>",
"    ), rather than the highly stereotyped &ldquo;runs&rdquo; seen in adult RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Of note, periodic limb movements in sleep (PLMS) greater than five per hour are usually abnormal in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/64,67-70\">",
"     64,67-70",
"    </a>",
"    ], whereas PLMS greater than five per hour are common in apparently asymptomatic adults over age 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Interestingly, the cardiovascular lability associated with PLMS in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/73,74\">",
"     73,74",
"    </a>",
"    ] has also been found in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/75\">",
"     75",
"    </a>",
"    ]. PLMS typically occur during stage N1 and N2 sleep, decrease in frequency in stage N3, and are usually absent during rapid eye movement (REM, also known as stage R) sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6963429\">",
"    <span class=\"h2\">",
"     Iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency is associated with both RLS and PLMD, and iron supplementation improves symptoms in a subset of patients. Therefore, laboratory evidence of iron deficiency supports the diagnosis of RLS or PLMD. However, iron deficiency is neither necessary nor sufficient to make the diagnosis of RLS or PLMD, because each of these disorders is common. (See",
"    <a class=\"local\" href=\"#H21806625\">",
"     'Pathophysiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21806744\">",
"     'Iron supplementation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806680\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, restless leg syndrome (RLS) is closely related to periodic limb movement disorder (PLMD), although they are distinct diagnostic entities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. Periodic limb movements in sleep (PLMS) are central to the diagnosis of PLMD but also are a common and supportive finding in RLS. A diagnosis of RLS supersedes a diagnosis of PLMD. Thus, a child can have RLS with PLMS but cannot have RLS and PLMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/7\">",
"     7",
"    </a>",
"    ]. Some children (especially those who are young or who are developmentally delayed) are diagnosed with PLMD but cannot be adequately assessed for the possibility of RLS because they lack the language skills to describe the sensory component of RLS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806687\">",
"    <span class=\"h2\">",
"     Restless legs syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RLS is based primarily upon the clinical history. In atypical or equivocal cases, such as those in which RLS sensations are worse during the day, polysomnography is useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/76\">",
"     76",
"    </a>",
"    ]. PLMS determined polysomnographically are a supportive feature of RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/5,7,77\">",
"     5,7,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Criteria for the diagnosis of RLS in children were developed in 2012 by a pediatric RLS expert panel in collaboration with the International Restless Legs Syndrome Study Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The criteria previously used for diagnosis of pediatric RLS were simplified and integrated with the newly revised adult RLS criteria (",
"    <a class=\"graphic graphic_table graphicRef86837 \" href=\"mobipreview.htm?20/49/21276\">",
"     table 1",
"    </a>",
"    ). Specific recommendations were developed for pediatric application of the criteria, including consideration of typical words used by children to describe their symptoms (",
"    <a class=\"graphic graphic_table graphicRef86838 \" href=\"mobipreview.htm?21/49/22299\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H21806639\">",
"     'History'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The five diagnostic criteria for RLS are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An urge to move the legs, usually accompanied by uncomfortable or unpleasant sensations in the legs",
"     </li>",
"     <li>",
"      The symptoms begin or worsen during rest or inactivity (eg, lying down or sitting)",
"     </li>",
"     <li>",
"      The symptoms are relieved by movement",
"     </li>",
"     <li>",
"      The symptoms occur exclusively or predominantly in the evening or night",
"     </li>",
"     <li>",
"      These symptoms are not solely accounted for by another medical or behavioral condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This final criterion is important to the specificity of RLS, which ensures that &ldquo;mimics&rdquo; are not misdiagnosed as RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21806701\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additionally, clinical significance of RLS is assessed by determining whether the symptoms cause significant distress or impairment of function. The domains of impact have been defined for both adult and pediatric populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/19,53,79,80\">",
"     19,53,79,80",
"    </a>",
"    ]. For children, the impact of RLS symptoms on sleep, awake activities, and emotions is prominent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806694\">",
"    <span class=\"h2\">",
"     Periodic limb movement disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PLMD in children is based primarily upon findings on polysomnography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/76\">",
"     76",
"    </a>",
"    ] and requires each of the following (see",
"    <a class=\"local\" href=\"#H6963820\">",
"     'Polysomnography and accelerometry'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Periodic limb movements during sleep (PLMS) greater than or equal to five episodes per hour, as measured during polysomnography",
"     </li>",
"     <li>",
"      Clinical sleep disturbance reported by the patient (eg, difficulty sleeping or daytime fatigue)",
"     </li>",
"     <li>",
"      Exclusion of other causes of the PLMS",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific criteria for PLMD are described in the table (",
"    <a class=\"graphic graphic_table graphicRef86839 \" href=\"mobipreview.htm?11/36/11852\">",
"     table 3",
"    </a>",
"    ). The presence of clinical sleep disturbance or daytime fatigue is essential to differentiate periodic limb movements in sleep (PLMS) as a polysomnographic finding from PLMD as a disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/7,32\">",
"     7,32",
"    </a>",
"    ]. In addition, other conditions associated with PLMS, such as obstructive sleep apnea, must be ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6965168\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest evaluating the iron status of all children with suspected or established RLS or PLMD, because of the association between these disorders and iron deficiency. (See",
"    <a class=\"local\" href=\"#H21806625\">",
"     'Pathophysiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6963429\">",
"     'Iron deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Serum ferritin is the best single measure of iron stores. However, serum ferritin is an acute phase reactant, and false elevation can occur for up to four weeks after febrile illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/81\">",
"     81",
"    </a>",
"    ]. As a result, we wait four weeks after acute illness before performing this test. If there is suspicion for chronic inflammation, then this can be investigated by measurement of C-reactive protein. Less sensitive iron measures such as percent iron saturation and total iron binding capacity (TIBC) also may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806701\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1419667\">",
"    <span class=\"h3\">",
"     Restless legs symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common and uncommon conditions that may mimic pediatric RLS are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef86840 \" href=\"mobipreview.htm?32/5/32859\">",
"     table 4",
"    </a>",
"    ). Important distinctions are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positional discomfort is easily relieved by simple position change rather that the recurrent movements needed for RLS.",
"     </li>",
"     <li>",
"      Leg pain is a characteristic of several disorders mimicking RLS, but, in most of these conditions, the pain is not associated with a need to move the legs. In a large pediatric case series of RLS, pain was a descriptor for RLS in almost half of cases, but it was never the only descriptor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/52\">",
"       52",
"      </a>",
"      ]. Thus, the other descriptors, including those indicating a need to move, &ldquo;bugs,&rdquo; &ldquo;ants,&rdquo; and &ldquo;weird feelings,&rdquo; are more likely to be selective for RLS and should be the focus in diagnosis. (See",
"      <a class=\"local\" href=\"#H21806639\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Numbness is not a typical descriptor of RLS, helping in the differentiation from positional ischemia and peripheral neuropathy.",
"     </li>",
"     <li>",
"      Nocturnal leg cramps are characterized by sudden painful tightness and by palpable hardening of the muscle. Initially, movement worsens the pain. Nocturnal legs cramps are uncommon in children eight years of age or younger but occur infrequently in about 7 percent of older children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/82\">",
"       82",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4711?source=see_link\">",
"       \"Nocturnal leg cramps\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      &ldquo;Growing pains&rdquo; is a diagnosis of exclusion, and it should not be the final diagnosis if RLS criteria are met [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/19,83,84\">",
"       19,83,84",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20902?source=see_link\">",
"       \"Growing pains\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While is it very important that RLS symptoms should not be solely accounted for as symptoms primary to another condition, it should also be appreciated that any of these conditions can co-occur in an individual who has RLS, including legs cramps or even sickle cell disease. This necessitates a separate focus on each possible condition in the diagnostic process and in the assessment of impact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1419761\">",
"    <span class=\"h3\">",
"     Leg movements during sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PLMD depends upon documentation of abnormal periodic limb movements during sleep (PLMS) on polysomnography (",
"    <a class=\"graphic graphic_table graphicRef86839 \" href=\"mobipreview.htm?11/36/11852\">",
"     table 3",
"    </a>",
"    ). However PLMD is also a diagnosis of exclusion, so it is important to determine whether the PLMS are attributable to some other cause, including RLS, sleep apnea, narcolepsy, and some medications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is evidence of RLS or obstructive sleep apnea, these diagnoses take precedence over PLMD because they are probably the cause of the abnormal PLMS. (See",
"      <a class=\"local\" href=\"#H21806687\">",
"       'Restless legs syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link\">",
"       \"Evaluation of suspected obstructive sleep apnea in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testing for narcolepsy is recommended when PLMS are accompanied by moderate-to-severe daytime sleepiness, because this level of sleepiness is uncommon in children with PLMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/8,9,55,76\">",
"       8,9,55,76",
"      </a>",
"      ]. The diagnostic evaluation for narcolepsy includes a focused history, physical examination, polysomnography, and multiple sleep latency test (MSLT). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5929?source=see_link&amp;anchor=H13#H13\">",
"       \"Assessment of sleep disorders in children\", section on 'Narcolepsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=see_link&amp;anchor=H376017#H376017\">",
"       \"Clinical features and diagnosis of narcolepsy\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some medications can induce or exacerbate PLMS, particularly serotonergic antidepressants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/85,86\">",
"       85,86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/61/15320?source=see_link&amp;anchor=H11019011#H11019011\">",
"       \"Medical disorders resulting in problem sleeplessness in children\", section on 'Medication-induced sleep disturbance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      REM sleep behavior disorder (RBD) is rare but can occur in children, and it is often associated with PLMS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/87\">",
"       87",
"      </a>",
"      ]. RBD is characterized by aggressive motor behavior as part of dream enactment, resulting from loss of muscle atonia during REM sleep. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28473?source=see_link&amp;anchor=H27172907#H27172907\">",
"       \"Sleepwalking and other parasomnias in children\", section on 'Rapid eye movement sleep behavior disorder (RBD)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myoclonic epilepsy can be associated with nocturnal limb movements and myoclonic jerks. Myoclonic epilepsy is usually distinguished by daytime seizures, by myoclonic movements upon awakening,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      by abnormalities on the electroencephalogram (EEG) recorded during a sleep study. However, distinguishing epilepsy from PLMS occasionally is difficult in a child with only nocturnal symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=see_link&amp;anchor=H15#H15\">",
"       \"Epilepsy syndromes in children\", section on 'Juvenile myoclonic epilepsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some normal movements during sleep may be confused with PLMS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypnic jerks (sleep starts) are typically limited to the transition from wakefulness to sleep, are not periodic, and are briefer than PLMS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28473?source=see_link&amp;anchor=H17023943#H17023943\">",
"       \"Sleepwalking and other parasomnias in children\", section on 'Hypnic starts'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Movements associated with normal phasic rapid eye movement (REM) sleep are limited to REM sleep and typically occur in irregular bursts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806716\">",
"    <span class=\"h1\">",
"     COMORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention deficit hyperactivity disorder (ADHD), depression, and anxiety occur more frequently in children and adults with RLS than in the general population. About one-quarter of individuals with RLS meet criteria for ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/19,88\">",
"     19,88",
"    </a>",
"    ]. Conversely, 12 to 35 percent of children with ADHD meet criteria for RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Similarly, RLS frequently is associated with depression and anxiety in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/92-94\">",
"     92-94",
"    </a>",
"    ], as demonstrated in a large population-based study that reported odds ratios of 4.7 for major depressive disorder and of 12.9 for panic disorder in individuals with RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/95\">",
"     95",
"    </a>",
"    ]. Similarly, children with RLS have increased risk for depression and anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/8,19,96\">",
"     8,19,96",
"    </a>",
"    ]. A study at a pediatric sleep center found that two-thirds of children with RLS have comorbid psychiatric conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with chronic kidney disease have an increased prevalence of RLS as compared with healthy children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/97,98\">",
"     97,98",
"    </a>",
"    ], similar to findings in adults with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32554?source=see_link&amp;anchor=H5#H5\">",
"     \"Restless legs syndrome\", section on 'Secondary RLS'",
"    </a>",
"    .) In addition, children with sickle cell disease have an increased prevalence of symptoms of RLS, sleep disruption, and frequent PLMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806723\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment reviews and algorithms for RLS and PLMD have been published for adults but not children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50,103-108\">",
"     50,103-108",
"    </a>",
"    ]. Because there is limited direct information for children, the pediatric recommendations discussed below are based upon empirical data from adults, pediatric case series, pediatric case reports, and our clinical experience. When considering treatment options, the following should be taken into account: certainty of diagnosis, severity and impact of symptoms, comorbidities, and potential risks of individual treatments. For both pediatric RLS and PLMD, the focus of treatment is typically improved sleep, rather than leg symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806730\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing healthy sleep habits is an important aspect of a comprehensive treatment plan. In milder cases, these interventions alone can be sufficient (",
"    <a class=\"graphic graphic_table graphicRef52760 \" href=\"mobipreview.htm?39/24/40331\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36806?source=see_link&amp;anchor=H16#H16\">",
"     \"Behavioral sleep problems in children\", section on 'Behavioral interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Families may need specific advice on recommended hours of sleep for age (",
"    <a class=\"graphic graphic_figure graphicRef82604 \" href=\"mobipreview.htm?14/0/14351\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2 years of age &mdash; 12 hours (with one nap included)",
"     </li>",
"     <li>",
"      5 years of age &mdash; 11 hours",
"     </li>",
"     <li>",
"      10 years of age &mdash; 10 hours",
"     </li>",
"     <li>",
"      Adolescence &mdash; 9 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical exercise should be encouraged. It has been shown to increase deep sleep in children, to improve RLS symptoms, and to be of benefit for mental health, especially depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. On nights when RLS sensations are particularly bothersome, the symptoms may be improved by leg massage, which acts as a counter-stimulus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806737\">",
"    <span class=\"h2\">",
"     Exacerbating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing for factors that may aggravate RLS or PLMS and working to reduce these are important. Known or suspected exacerbating factors include insufficient sleep, irregular sleep, pain, caffeine, and nicotine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50,112\">",
"     50,112",
"    </a>",
"    ]. Some medications, including sedating antihistamines, serotonergic antidepressants, and dopamine blockers, can aggravate RLS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PLMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50,85,112,113\">",
"     50,85,112,113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806744\">",
"    <span class=\"h2\">",
"     Iron supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with evidence of iron deficiency and of RLS or PLMD, we suggest a trial of oral iron supplementation. This suggestion is based upon evidence for a role of iron deficiency in the pathophysiology of RLS and PLMD and upon evidence of benefit with iron supplementation. Treatment with oral iron is recommended for adults with serum ferritin &lt;50",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50,104\">",
"     50,104",
"    </a>",
"    ]. Iron supplementation also is supported by pediatric case reports and results from trials of oral iron in children with RLS or PLMS, with or without ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/4\">",
"     4",
"    </a>",
"    ]. In three pediatric studies, treatment with iron supplements by mouth was associated with symptomatic improvement, accompanied by a rise in mean serum ferritin. Serum ferritin rose from 26.6 to 83.5",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    in an uncontrolled study in children with RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/114\">",
"     114",
"    </a>",
"    ], from 40.8 to 74.1",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    in an uncontrolled study in children with PLMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/115\">",
"     115",
"    </a>",
"    ], and from 29.1 to 55.7",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    in a randomized study of children with",
"    <span class=\"nowrap\">",
"     RLS/",
"    </span>",
"    or PLMD symptoms and with ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For treatment of RLS and PLMD, it appears to be important to target optimal iron status, rather than typically defined &ldquo;normal&rdquo; ranges for tests of iron sufficiency. Thus, we target a serum ferritin concentration between 50 and 100",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    which generally reflects adequate body iron stores, unless this value is falsely elevated by an inflammatory state. (See",
"    <a class=\"local\" href=\"#H6965168\">",
"     'Laboratory tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For children with RLS or PLMD and with serum ferritin &lt;50",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    we recommend:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children six years and older &mdash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/62/15334?source=see_link\">",
"       Ferrous sulfate",
"      </a>",
"      45 to 65 mg of elemental iron once or twice a day",
"     </li>",
"     <li>",
"      Children younger than six years &mdash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/62/15334?source=see_link\">",
"       Ferrous sulfate",
"      </a>",
"      3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      of elemental iron (to a maximum of 150 mg elemental iron daily), divided into two or three daily doses",
"     </li>",
"     <li>",
"      Recheck serum ferritin in two to three months &mdash; Target serum ferritin levels are 50 to 100",
"      <span class=\"nowrap\">",
"       mcg/L,",
"      </span>",
"      as noted above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We encourage administration of the iron supplements with vitamin C (contained in many fruit drinks) to enhance iron absorption. We also advise parents about safe storage of iron supplements, to prevent accidental ingestion, which can be lethal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2970?source=see_link\">",
"     \"Acute iron poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once iron stores have been restored, we continue to monitor the child&rsquo;s iron status by checking serum ferritin periodically. In many children, it is difficult to attain and maintain a serum ferritin level above 50",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    due to growth, due to decreased iron absorption once levels get to the low normal range, and, in adolescent girls, due to blood loss with menses. In some children, we continue therapeutic doses of iron in anticipation of growth spurts. It is important to monitor children during treatment with therapeutic doses of iron to avoid the rare but serious complication of iron overload, which can occur in individuals who carry hemochromatosis genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806751\">",
"    <span class=\"h2\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;No medications have been approved by the United States Food and Drug Administration (FDA) for pediatric RLS or PLMD. This is also true for other pediatric sleep disorders, despite evidence of long-term negative impact when sleep problems in children are not treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/118\">",
"     118",
"    </a>",
"    ]. Therefore, the interventions discussed below are off-label uses of medications, based upon evidence extrapolated from studies in adults and from limited experience in children.",
"   </p>",
"   <p>",
"    For adult RLS, multiple, large, randomized, controlled trials support use of dopaminergic medications and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"     gabapentin",
"    </a>",
"    , with lower levels of evidence for other treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/108\">",
"     108",
"    </a>",
"    ]. For pediatric RLS, we generally emphasize nonpharmacologic interventions for mild cases and reserve medication for chronic, moderate-to-severe cases in a setting of long-term specialty care.",
"   </p>",
"   <p>",
"    The following recommendations apply to children 6 to 18 years of age:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417013\">",
"    <span class=\"h3\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"     gabapentin",
"    </a>",
"    as a first-line medication for children six years and older with RLS who require pharmacotherapy. Gabapentin has been shown to improve sleep quality and to reduce the sensory symptoms of RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. It is approved by the FDA as an anticonvulsant for children as young as three years.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/12/1222?source=see_link\">",
"     Gabapentin enacarbil",
"    </a>",
"    is a pro-drug with more linear pharmacokinetics that is FDA approved for adult RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/121-123\">",
"     121-123",
"    </a>",
"    ]. We prefer gabapentin to dopamine agonists because of concerns about impulse-control issues with dopamine agonists. (See",
"    <a class=\"local\" href=\"#H1417177\">",
"     'Dopamine agonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children 6 to 12 years of age &mdash; Begin",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"       gabapentin",
"      </a>",
"      at 100 mg, one-half to one hour prior to bedtime, and increase every one to two weeks by 100 mg, until symptoms are suppressed or to a maximum of 600 mg.",
"     </li>",
"     <li>",
"      For children older than 12 years of age &mdash; Begin",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"       gabapentin",
"      </a>",
"      at 200 mg, one-half to one hour prior to bedtime, and increase every one to two weeks by 100 mg, until symptoms are suppressed or to a maximum of 900 mg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417021\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adult treatment algorithms, benzodiazepines are considered second- or third-line agents for treatment of RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50,104\">",
"     50,104",
"    </a>",
"    ]. Several pediatric case series have reported benefit with benzodiazepines for RLS and PLMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/8,9,31,55,114,124\">",
"     8,9,31,55,114,124",
"    </a>",
"    ]. A paradoxical alerting reaction is the most common adverse effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/31\">",
"     31",
"    </a>",
"    ]. Although the possibility for next-morning &ldquo;hangover&rdquo; sedation should be monitored, we have found this to be very uncommon in RLS and PLMD, probably due to the hyperarousal seen in these disorders. Benzodiazepines are particularly useful for children with disturbed sleep or comorbid anxiety. (See",
"    <a class=\"local\" href=\"#H21806765\">",
"     'Children with anxiety and/or depression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11383?source=see_link\">",
"       Clonazepam",
"      </a>",
"      &mdash; 0.25 to 0.5 mg, one-half hour prior to bedtime",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/44/27334?source=see_link\">",
"       Temazepam",
"      </a>",
"      &mdash; The initial dose is 7.5 mg, one-half hour prior to bedtime. For children 6 to 12 years of age, the dose may be increased to 15 mg, if needed. For children older than 12 years of age, the dose may be increased sequentially by 7.5 mg every five to seven days, to a maximum of 22.5 mg, if needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417167\">",
"    <span class=\"h3\">",
"     Clonidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"     Clonidine",
"    </a>",
"    was developed for the treatment of hypertension but was subsequently found to help ADHD and sleep onset in children. It is the most commonly used prescription medication for sleep in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/125-127\">",
"     125-127",
"    </a>",
"    ] and is particularly useful when there are severe sleep",
"    <strong>",
"     onset",
"    </strong>",
"    problems in pediatric RLS and PLMD. However, because clonidine has a relatively short duration of effect, it may not be effective for problems with sleep",
"    <strong>",
"     maintenance",
"    </strong>",
"    . Adverse effects include vivid dreams or nightmares, which are dose-related and which occur in about 5 percent of children treated with clonidine. Because of a risk for rebound hypertension, clonidine should not be stopped abruptly.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children 6 to 12 years of age &mdash; An initial dose is 0.05 mg, one-half hour prior to bedtime. The dose can be sequentially increased every three to seven days in 0.05",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      increments, until sleep onset is improved or until a maximum of 0.3 mg per dose is reached.",
"     </li>",
"     <li>",
"      For children older than 12 years of age &mdash; An initial dose is 0.1 mg, one-half hour prior to bedtime. The dose can be sequentially increased every three to seven days in 0.1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      increments, until sleep onset is improved or until a maximum of 0.4 mg per dose is reached.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417177\">",
"    <span class=\"h3\">",
"     Dopamine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest using the dopamine agonists",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    for children with definite, moderate-to-severe RLS who have failed other treatments. These drugs are considered first-line medications for adults with RLS, and multiple published studies have shown that they also are effective for pediatric RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/8,9,31,40,124,128-131\">",
"     8,9,31,40,124,128-131",
"    </a>",
"    ]. However, in adults, dopamine agonists have been associated with augmentation (paradoxical worsening of RLS sensations) and with problems with impulse control. In addition, dopaminergics have a limited effect on disturbed sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/132-134\">",
"     132-134",
"    </a>",
"    ]. Therefore, we do not use these as first-line agents for treatment of RLS in children, and, when we do use them, we monitor the children carefully for augmentation and changes in behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       Pramipexole",
"      </a>",
"      &mdash; We initiate treatment at 0.125 mg once daily. We advance, if needed, to a maximum of 0.25 mg daily in children 6 to 12 years of age or to a maximum of 0.375 mg daily in adolescents.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"       Ropinirole",
"      </a>",
"      &mdash; We initiate treatment at 0.25 mg once daily. We advance, if needed, to a maximum of 0.5 mg daily in children 6 to 12 years of age or to a maximum of 0.75 mg daily in adolescents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children with RLS, these medications should be given two hours before the RLS symptoms start, which is usually in the evening. For those with PLMD, they should be given one to two hours prior to bedtime.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417528\">",
"    <span class=\"h3\">",
"     Combination drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In refractory or severe cases of RLS or PLMD, the first step is to reassess for possible alternate diagnoses or comorbidities, for iron status, and for compliance with nonpharmacologic and pharmacologic therapies. If this reassessment does not lead to an alternate strategy, then we suggest a trial of the combination therapy of a dopamine agonist and a medication that will consolidate sleep, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"     gabapentin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    . An alternative combination is",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    (for sleep onset), with gabapentin,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11383?source=see_link\">",
"     clonazepam",
"    </a>",
"    , or temazepam (for sleep maintenance).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417573\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single, open-label study has reported benefit of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/0/25608?source=see_link\">",
"     levetiracetam",
"    </a>",
"    for children with RLS and comorbid ADHD with interictal epileptic discharges on EEG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/135\">",
"     135",
"    </a>",
"    ]. Melatonin was found to have a detrimental effect on motor symptoms in a small study of adults with RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/136\">",
"     136",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Levodopa/carbidopa",
"    </span>",
"    was of benefit for children with RLS and PLMS in a small, double-blind, placebo-controlled study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/128\">",
"     128",
"    </a>",
"    ]. However, for clinical use in RLS, this medication has been supplanted by dopamine agonists in RLS, which have fewer adverse effects. For severe, refractory RLS in adults, opioids are considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50,108\">",
"     50,108",
"    </a>",
"    ], but evidence is lacking for children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417583\">",
"    <span class=\"h3\">",
"     Special populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special considerations apply to pharmacotherapy in the following populations:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417651\">",
"    <span class=\"h4\">",
"     Young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children younger than six years of age, we emphasize nonpharmacologic interventions and optimization of iron status. However, for those who have a clear diagnosis of RLS or PLMD and who continue to have substantial impairment despite optimal iron supplementation and nonpharmacologic interventions, we sometimes treat with low-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11383?source=see_link\">",
"     clonazePAM",
"    </a>",
"    (not",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"     cloNIDine",
"    </a>",
"    ) or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"     gabapentin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H1417021\">",
"     'Benzodiazepines'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1417013\">",
"     'Gabapentin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806758\">",
"    <span class=\"h4\">",
"     Children with ADHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;As long as the effect has worn off by bedtime, the stimulant medications used for treatment of attention deficit hyperactivity disorder (ADHD) do not adversely affect RLS, PLMS, or sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/64,137,138\">",
"     64,137,138",
"    </a>",
"    ]. Conversely, treatment of the sleep disorder may improve ADHD symptoms to some extent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/131\">",
"     131",
"    </a>",
"    ]. Interestingly, iron supplementation may benefit RLS, PLMD, and ADHD, suggesting the possibility of a common mechanism underlying these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806765\">",
"    <span class=\"h4\">",
"     Children with anxiety and/or depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with comorbid anxiety or depression, treatment of RLS or PLMD may improve the mood symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/93,139,140\">",
"     93,139,140",
"    </a>",
"    ]. However, if the depressive and anxiety symptoms are prominent, specific treatment is typically needed. In this case, family or individual counseling should be considered.",
"   </p>",
"   <p>",
"    If pharmacotherapy is needed for depression, we suggest using a non-serotonergic medication such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/11/39096?source=see_link\">",
"     bupropion",
"    </a>",
"    , because serotonergic antidepressants can worsen RLS or PLMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50,93,139,141-144\">",
"     50,93,139,141-144",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21806737\">",
"     'Exacerbating factors'",
"    </a>",
"    above.) Bupropion also has significant anti-anxiety properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/145-147\">",
"     145-147",
"    </a>",
"    ]. Bupropion sustained release (SR) or extended release (XL) is given in the morning.",
"   </p>",
"   <p>",
"    Other options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-dose benzodiazepines, such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11383?source=see_link\">",
"       clonazepam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/44/27334?source=see_link\">",
"       temazepam",
"      </a>",
"      , given at bedtime &mdash; For children with comorbid anxiety. Potential adverse effects include paradoxical hyperactivity or irritability. (See",
"      <a class=\"local\" href=\"#H1417021\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/63/33785?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (10 mg) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      (20 mg) &mdash; For children with comorbid depression, if the response to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/11/39096?source=see_link\">",
"       bupropion",
"      </a>",
"      or a benzodiazepine is incomplete. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=see_link\">",
"       \"Psychopharmacological treatment for adolescent depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dopamine agonists, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       pramipexole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"       ropinirole",
"      </a>",
"      &mdash; These drugs are effective for RLS or PLMD and also have some antidepressant properties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/33/32282/abstract/148-152\">",
"       148-152",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1417177\">",
"       'Dopamine agonists'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806772\">",
"    <span class=\"h2\">",
"     Psychosocial considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family support is very important for children who are affected by chronic medical problems such as RLS and PLMD. Because RLS is highly familial, the entire family may benefit from effective treatment for an affected parent. Furthermore, parents often need specific guidance to help the child establish and maintain a good sleep schedule to minimize RLS and PLMD symptoms. As adolescence approaches, it is important to foster self-awareness and self-management skills. (See",
"    <a class=\"local\" href=\"#H21806730\">",
"     'Nonpharmacologic interventions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Advocacy for appropriate school accommodations may be needed when the disorder interferes with a child&rsquo;s ability to function in the classroom. Accommodations may include allowing physical activity during recess, avoiding long stationary positions in the classroom, and giving permission to move around if leg sensations are bothersome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21806603\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restless legs syndrome (RLS), also known as Willis-Ekbom disorder, is a common and treatable neurological condition. It is characterized by an urge to move the legs, usually accompanied by uncomfortable or unpleasant sensations in the legs. The symptoms begin or worsen during rest or inactivity, are relieved by movement, and occur exclusively or predominantly in the evening or night (",
"      <a class=\"graphic graphic_table graphicRef86837 \" href=\"mobipreview.htm?20/49/21276\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21806687\">",
"       'Restless legs syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of RLS is based primarily upon the history, which must be carefully targeted to capture relevant information from the patient (rather than just the parent). Other causes of similar symptoms should be considered and excluded (",
"      <a class=\"graphic graphic_table graphicRef86840 \" href=\"mobipreview.htm?32/5/32859\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21806639\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1419667\">",
"       'Restless legs symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodic limb movement disorder (PLMD) is characterized by periodic limb movements during sleep (PLMS), accompanied by clinical sleep disturbance or daytime fatigue. The diagnosis is established by documenting abnormal numbers of PLMS during polysomnography and by ruling out other causes for the symptoms, including RLS and obstructive sleep apnea (",
"      <a class=\"graphic graphic_table graphicRef86839 \" href=\"mobipreview.htm?11/36/11852\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6963820\">",
"       'Polysomnography and accelerometry'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1419761\">",
"       'Leg movements during sleep'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, restless leg syndrome (RLS) is closely related to periodic limb movement disorder (PLMD), although they are distinct diagnostic entities. Periodic limb movements in sleep (PLMS) are central to the diagnosis of PLMD but also are a common and supportive finding in RLS. Both conditions have been associated with relative iron deficiency and have a familial tendency. (See",
"      <a class=\"local\" href=\"#H21806625\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conditions associated with RLS and PLMD include attention deficit hyperactivity disorder (ADHD), depression, and anxiety. Recognition of these comorbid conditions is important to treatment decisions. (See",
"      <a class=\"local\" href=\"#H21806716\">",
"       'Comorbidity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1417583\">",
"       'Special populations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest evaluating iron status of all children with suspected or established RLS or PLMD, because of the association between these disorders and iron deficiency. A serum ferritin level of 50 to 100",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      <span class=\"nowrap\">",
"       (ng/mL)",
"      </span>",
"      is optimal. For children with ferritin levels below this range, we suggest iron supplementation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6965168\">",
"       'Laboratory tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21806744\">",
"       'Iron supplementation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that may exacerbate RLS or PLMD include insufficient sleep, irregular sleep, pain, caffeine, nicotine, and some medications, including sedating antihistamines, serotonergic antidepressants, and dopamine blockers. (See",
"      <a class=\"local\" href=\"#H21806737\">",
"       'Exacerbating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Establishing healthy sleep habits is an important aspect of a comprehensive treatment plan for RLS or PLMD (",
"      <a class=\"graphic graphic_table graphicRef52760 \" href=\"mobipreview.htm?39/24/40331\">",
"       table 5",
"      </a>",
"      ). Regular physical activity also may be helpful. In milder cases, these interventions alone can be sufficient. (See",
"      <a class=\"local\" href=\"#H21806730\">",
"       'Nonpharmacologic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pediatric RLS, we generally emphasize nonpharmacologic interventions for mild cases and reserve medication for chronic, moderate-to-severe cases in a setting of long-term specialty care. For children six years and older with RLS who require pharmacotherapy, we suggest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"       gabapentin",
"      </a>",
"      as a first-line medication, rather than dopamine agonists or benzodiazepines (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other considerations that affect choice of treatment include the severity of symptoms, the type of sleep disturbance (sleep onset or sleep maintenance), and the presence of comorbid depression, anxiety, or ADHD. (See",
"      <a class=\"local\" href=\"#H21806751\">",
"       'Medication'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/1\">",
"      Picchietti MA, Picchietti DL. Restless legs syndrome and periodic limb movement disorder in children and adolescents. Semin Pediatr Neurol 2008; 15:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/2\">",
"      Simakajornboon N, Kheirandish-Gozal L, Gozal D. Diagnosis and management of restless legs syndrome in children. Sleep Med Rev 2009; 13:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/3\">",
"      Khatwa U, Kothare SV. Restless legs syndrome and periodic limb movements disorder in the pediatric population. Curr Opin Pulm Med 2010; 16:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/4\">",
"      Picchietti MA, Picchietti DL. Advances in pediatric restless legs syndrome: Iron, genetics, diagnosis and treatment. Sleep Med 2010; 11:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/5\">",
"      Picchietti DL, Bruni O, de Weerd A, et al. Pediatric restless legs syndrome diagnostic criteria: An update by the International Restless Legs Syndrome Study Group. Sleep Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     International Restless Legs Syndrome Study Group, 2011 revised diagnostic criteria. Available at: file://irlssg.org/diagnostic-criteria/ (Accessed on October 01, 2012).",
"    </li>",
"    <li>",
"     American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed: Diagnostic and coding manual, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/8\">",
"      Picchietti DL, Stevens HE. Early manifestations of restless legs syndrome in childhood and adolescence. Sleep Med 2008; 9:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/9\">",
"      Picchietti DL, Rajendran RR, Wilson MP, Picchietti MA. Pediatric restless legs syndrome and periodic limb movement disorder: parent-child pairs. Sleep Med 2009; 10:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/10\">",
"      Ohayon MM, O'Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev 2012; 16:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/11\">",
"      Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011; 26:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/12\">",
"      Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Med 2010; 11:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/13\">",
"      Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/14\">",
"      Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/15\">",
"      Berger K. What is clinically significant RLS and who decides about its treatment? Sleep Med 2010; 11:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/16\">",
"      Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology 1996; 46:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/17\">",
"      Whittom S, Dauvilliers Y, Pennestri MH, et al. Age-at-onset in restless legs syndrome: a clinical and polysomnographic study. Sleep Med 2007; 9:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/18\">",
"      Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997; 12:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/19\">",
"      Picchietti D, Allen RP, Walters AS, et al. Restless legs syndrome: prevalence and impact in children and adolescents--the Peds REST study. Pediatrics 2007; 120:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/20\">",
"      Yilmaz K, Kilincaslan A, Aydin N, Kor D. Prevalence and correlates of restless legs syndrome in adolescents. Dev Med Child Neurol 2011; 53:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/21\">",
"      Turkdogan D, Bekiroglu N, Zaimoglu S. A prevalence study of restless legs syndrome in Turkish children and adolescents. Sleep Med 2011; 12:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/22\">",
"      Picchietti DL, Picchietti MA. Restless legs syndrome: what have we learned from prevalence studies and how will incidence studies further clinical knowledge? J Clin Sleep Med 2012; 8:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/23\">",
"      Budhiraja P, Budhiraja R, Goodwin JL, et al. Incidence of restless legs syndrome and its correlates. J Clin Sleep Med 2012; 8:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/24\">",
"      Szentkiralyi A, Fendrich K, Hoffmann W, et al. Incidence of restless legs syndrome in two population-based cohort studies in Germany. Sleep Med 2011; 12:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/25\">",
"      Kagimura T, Nomura T, Kusumi M, et al. Prospective survey on the natural course of restless legs syndrome over two years in a closed cohort. Sleep Med 2011; 12:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/26\">",
"      Goodwin J, Vasquez MM, Quan SF. Prevalence of restless legs syndrome among adolescent children in the Tucson Children's Assessment if Sleep Apnea Study (TUCASA). Sleep 2012; 34:A268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/27\">",
"      Bassetti CL, Mauerhofer D, Gugger M, et al. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol 2001; 45:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/28\">",
"      Winkelmann J, Wetter TC, Collado-Seidel V, et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000; 23:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/29\">",
"      Trenkwalder C, Seidel VC, Gasser T, Oertel WH. Clinical symptoms and possible anticipation in a large kindred of familial restless legs syndrome. Mov Disord 1996; 11:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/30\">",
"      Xiong L, Montplaisir J, Desautels A, et al. Family study of restless legs syndrome in Quebec, Canada: clinical characterization of 671 familial cases. Arch Neurol 2010; 67:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/31\">",
"      Gingras JL, Gaultney JF, Picchietti DL. Pediatric periodic limb movement disorder: sleep symptom and polysomnographic correlates compared to obstructive sleep apnea. J Clin Sleep Med 2011; 7:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/32\">",
"      Gaultney JF, Merchant K, Gingras JL. Parents of children with periodic limb movement disorder versus sleep-disordered breathing report greater daytime mood and behavior difficulties in their child: the importance of using ICSD-2nd Edition criteria to define a PLMD study group. Behav Sleep Med 2009; 7:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/33\">",
"      Trotti LM, Bhadriraju S, Rye DB. An update on the pathophysiology and genetics of restless legs syndrome. Curr Neurol Neurosci Rep 2008; 8:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/34\">",
"      Lazzarini A, Walters AS, Hickey K, et al. Studies of penetrance and anticipation in five autosomal-dominant restless legs syndrome pedigrees. Mov Disord 1999; 14:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/35\">",
"      Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994; 17:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/36\">",
"      Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007; 357:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/37\">",
"      Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007; 39:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/38\">",
"      Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008; 40:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/39\">",
"      Vilari&ntilde;o-G&uuml;ell C, Farrer MJ, Lin SC. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2008; 358:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/40\">",
"      Muhle H, Neumann A, Lohmann-Hedrich K, et al. Childhood-onset restless legs syndrome: clinical and genetic features of 22 families. Mov Disord 2008; 23:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/41\">",
"      Catoire H, Dion PA, Xiong L, et al. Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis. Ann Neurol 2011; 70:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/42\">",
"      Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003; 61:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/43\">",
"      Earley CJ, B Barker P, Horsk&aacute; A, Allen RP. MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. Sleep Med 2006; 7:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/44\">",
"      Godau J, Klose U, Di Santo A, et al. Multiregional brain iron deficiency in restless legs syndrome. Mov Disord 2008; 23:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/45\">",
"      Godau J, Wevers AK, Gaenslen A, et al. Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med 2008; 9:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/46\">",
"      Earley CJ, Connor JR, Beard JL, et al. Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep 2005; 28:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/47\">",
"      Beard JL, Connor JR. Iron status and neural functioning. Annu Rev Nutr 2003; 23:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/48\">",
"      Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004; 5:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/49\">",
"      Burhans MS, Dailey C, Beard Z, et al. Iron deficiency: differential effects on monoamine transporters. Nutr Neurosci 2005; 8:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/50\">",
"      Garcia-Borreguero D, Stillman P, Benes H, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol 2011; 11:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/51\">",
"      Mohri I, Kato-Nishimura K, Tachibana N, et al. Restless legs syndrome (RLS): an unrecognized cause for bedtime problems and insomnia in children. Sleep Med 2008; 9:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/52\">",
"      Picchietti DL, Arbuckle RA, Abetz L, et al. Pediatric restless legs syndrome: analysis of symptom descriptions and drawings. J Child Neurol 2011; 26:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/53\">",
"      Arbuckle R, Abetz L, Durmer JS, et al. Development of the Pediatric Restless Legs Syndrome Severity Scale (P-RLS-SS): a patient-reported outcome measure of pediatric RLS symptoms and impact. Sleep Med 2010; 11:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/54\">",
"      Martin BT, Williamson BD, Edwards N, Teng AY. Parental symptom report and periodic limb movements of sleep in children. J Clin Sleep Med 2008; 4:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/55\">",
"      Picchietti DL, Walters AS. Moderate to severe periodic limb movement disorder in childhood and adolescence. Sleep 1999; 22:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/56\">",
"      Hilbert J, Mohsenin V. Can periodic limb movement disorder be diagnosed without polysomnography? A case-control study. Sleep Med 2003; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/57\">",
"      Guilleminault C, Palombini L, Pelayo R, Chervin RD. Sleepwalking and sleep terrors in prepubertal children: what triggers them? Pediatrics 2003; 111:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/58\">",
"      Picchietti MA, Picchietti DL, England SJ, et al. Children show individual night-to-night variability of periodic limb movements in sleep. Sleep 2009; 32:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/59\">",
"      Trotti LM, Bliwise DL, Greer SA, et al. Correlates of PLMs variability over multiple nights and impact upon RLS diagnosis. Sleep Med 2009; 10:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/60\">",
"      Sforza E, Haba-Rubio J. Night-to-night variability in periodic leg movements in patients with restless legs syndrome. Sleep Med 2005; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/61\">",
"      Hornyak M, Kopasz M, Feige B, et al. Variability of periodic leg movements in various sleep disorders: implications for clinical and pathophysiologic studies. Sleep 2005; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/62\">",
"      Gschliesser V, Frauscher B, Brandauer E, et al. PLM detection by actigraphy compared to polysomnography: a validation and comparison of two actigraphs. Sleep Med 2009; 10:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/63\">",
"      Sforza E, Johannes M, Claudio B. The PAM-RL ambulatory device for detection of periodic leg movements: a validation study. Sleep Med 2005; 6:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/64\">",
"      Picchietti DL, England SJ, Walters AS, et al. Periodic limb movement disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder. J Child Neurol 1998; 13:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/65\">",
"      Ferri R, Manconi M, Lanuzza B, et al. Age-related changes in periodic leg movements during sleep in patients with restless legs syndrome. Sleep Med 2008; 9:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/66\">",
"      Ferri R, Bruni O, Novelli L, et al. Time structure of leg movement activity during sleep in attention-deficit/hyperactivity disorder and effects of L-DOPA. Sleep Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/67\">",
"      Montgomery-Downs HE, O'Brien LM, Gulliver TE, Gozal D. Polysomnographic characteristics in normal preschool and early school-aged children. Pediatrics 2006; 117:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/68\">",
"      Traeger N, Schultz B, Pollock AN, et al. Polysomnographic values in children 2-9 years old: additional data and review of the literature. Pediatr Pulmonol 2005; 40:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/69\">",
"      O'Brien LM, Holbrook CR, Faye Jones V, Gozal D. Ethnic difference in periodic limb movements in children. Sleep Med 2007; 8:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/70\">",
"      Picchietti DL, Underwood DJ, Farris WA, et al. Further studies on periodic limb movement disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder. Mov Disord 1999; 14:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/71\">",
"      Pennestri MH, Whittom S, Adam B, et al. PLMS and PLMW in healthy subjects as a function of age: prevalence and interval distribution. Sleep 2006; 29:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/72\">",
"      Claman DM, Redline S, Blackwell T, et al. Prevalence and correlates of periodic limb movements in older women. J Clin Sleep Med 2006; 2:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/73\">",
"      Walters AS, Rye DB. Evidence continues to mount on the relationship of restless legs syndrome/ periodic limb movements in sleep to hypertension, cardiovascular disease, and stroke. Sleep 2010; 33:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/74\">",
"      Walters AS, Rye DB. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 2009; 32:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/75\">",
"      Walter LM, Foster AM, Patterson RR, et al. Cardiovascular variability during periodic leg movements in sleep in children. Sleep 2009; 32:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/76\">",
"      Aurora RN, Lamm CI, Zak RS, et al. Practice parameters for the non-respiratory indications for polysomnography and multiple sleep latency testing for children. Sleep 2012; 35:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/77\">",
"      Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/78\">",
"      Hening WA, Allen RP, Washburn M, et al. The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions (\"mimics\"). Sleep Med 2009; 10:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/79\">",
"      Earley CJ, Silber MH. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med 2010; 11:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/80\">",
"      Dodel R, Happe S, Peglau I, et al. Health economic burden of patients with restless legs syndrome in a German ambulatory setting. Pharmacoeconomics 2010; 28:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/81\">",
"      Eskeland B, Baerheim A, Ulvik R, Hunskaar S. Influence of mild infections on iron status parameters in women of reproductive age. Scand J Prim Health Care 2002; 20:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/82\">",
"      Leung AK, Wong BE, Chan PY, Cho HY. Nocturnal leg cramps in children: incidence and clinical characteristics. J Natl Med Assoc 1999; 91:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/83\">",
"      Rajaram SS, Walters AS, England SJ, et al. Some children with growing pains may actually have restless legs syndrome. Sleep 2004; 27:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/84\">",
"      Walters AS. Is there a subpopulation of children with growing pains who really have Restless Legs Syndrome? A review of the literature. Sleep Med 2002; 3:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/85\">",
"      Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005; 58:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/86\">",
"      Sal&iacute;n-Pascual RJ, Galicia-Polo L, Drucker-Col&iacute;n R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/87\">",
"      Lloyd R, Tippmann-Peikert M, Slocumb N, Kotagal S. Characteristics of REM sleep behavior disorder in childhood. J Clin Sleep Med 2012; 8:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/88\">",
"      Wagner ML, Walters AS, Fisher BC. Symptoms of attention-deficit/hyperactivity disorder in adults with restless legs syndrome. Sleep 2004; 27:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/89\">",
"      Oner P, Dirik EB, Taner Y, et al. Association between low serum ferritin and restless legs syndrome in patients with attention deficit hyperactivity disorder. Tohoku J Exp Med 2007; 213:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/90\">",
"      Wiggs L, Montgomery P, Stores G. Actigraphic and parent reports of sleep patterns and sleep disorders in children with subtypes of attention-deficit hyperactivity disorder. Sleep 2005; 28:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/91\">",
"      Silvestri R, Gagliano A, Aric&ograve; I, et al. Sleep disorders in children with Attention-Deficit/Hyperactivity Disorder (ADHD) recorded overnight by video-polysomnography. Sleep Med 2009; 10:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/92\">",
"      Sevim S, Dogu O, Kaleagasi H, et al. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry 2004; 75:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/93\">",
"      Picchietti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005; 28:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/94\">",
"      Winkelmann J, Prager M, Lieb R, et al. \"Anxietas tibiarum\". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol 2005; 252:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/95\">",
"      Lee HB, Hening WA, Allen RP, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 2008; 20:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/96\">",
"      Pullen SJ, Wall CA, Angstman ER, et al. Psychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study. J Clin Sleep Med 2011; 7:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/97\">",
"      Applebee GA, Guillot AP, Schuman CC, et al. Restless legs syndrome in pediatric patients with chronic kidney disease. Pediatr Nephrol 2009; 24:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/98\">",
"      Davis ID, Baron J, O'riordan MA, Rosen CL. Sleep disturbances in pediatric dialysis patients. Pediatr Nephrol 2005; 20:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/99\">",
"      Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis 1996; 28:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/100\">",
"      Mucsi I, Molnar MZ, Ambrus C, et al. Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant 2005; 20:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/101\">",
"      Rogers VE, Marcus CL, Jawad AF, et al. Periodic limb movements and disrupted sleep in children with sickle cell disease. Sleep 2011; 34:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/102\">",
"      Rogers VE, Lewin DS, Winnie GB, Geiger-Brown J. Polysomnographic characteristics of a referred sample of children with sickle cell disease. J Clin Sleep Med 2010; 6:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/103\">",
"      Hening WA. Current guidelines and standards of practice for restless legs syndrome. Am J Med 2007; 120:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/104\">",
"      Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004; 79:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/105\">",
"      Hening WA, Allen RP, Earley CJ, et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004; 27:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/106\">",
"      Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999; 22:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/107\">",
"      Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006; 13:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/108\">",
"      Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep 2012; 35:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/109\">",
"      Aukerman MM, Aukerman D, Bayard M, et al. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2006; 19:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/110\">",
"      Deslandes A, Moraes H, Ferreira C, et al. Exercise and mental health: many reasons to move. Neuropsychobiology 2009; 59:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/111\">",
"      Dworak M, Wiater A, Alfer D, et al. Increased slow wave sleep and reduced stage 2 sleep in children depending on exercise intensity. Sleep Med 2008; 9:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/112\">",
"      Gamaldo CE, Earley CJ. Restless legs syndrome: a clinical update. Chest 2006; 130:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/113\">",
"      Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008; 43:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/114\">",
"      Mohri I, Kato-Nishimura K, Kagitani-Shimono K, et al. Evaluation of oral iron treatment in pediatric restless legs syndrome (RLS). Sleep Med 2012; 13:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/115\">",
"      Simakajornboon N, Gozal D, Vlasic V, et al. Periodic limb movements in sleep and iron status in children. Sleep 2003; 26:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/116\">",
"      Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol 2008; 38:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/117\">",
"      Barton JC, Wooten VD, Acton RT. Hemochromatosis and iron therapy of Restless Legs Syndrome. Sleep Med 2001; 2:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/118\">",
"      Mindell JA, Emslie G, Blumer J, et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics 2006; 117:e1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/119\">",
"      Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/120\">",
"      Happe S, Sauter C, Kl&ouml;sch G, et al. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 2003; 48:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/121\">",
"      Lal R, Ellenbogen A, Chen D, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol 2012; 35:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/122\">",
"      Inoue Y, Uchimura N, Kuroda K, et al. Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/123\">",
"      Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011; 7:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/124\">",
"      Kotagal S, Silber MH. Childhood-onset restless legs syndrome. Ann Neurol 2004; 56:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/125\">",
"      Newcorn JH, Schulz K, Harrison M, et al. Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am 1998; 45:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/126\">",
"      Owens JA, Rosen CL, Mindell JA. Medication use in the treatment of pediatric insomnia: results of a survey of community-based pediatricians. Pediatrics 2003; 111:e628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/127\">",
"      Prince JB, Wilens TE, Biederman J, et al. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996; 35:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/128\">",
"      England SJ, Picchietti DL, Couvadelli BV, et al. L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children. Sleep Med 2011; 12:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/129\">",
"      Cortese S, Konofal E, Lecendreux M. Effectiveness of ropinirole for RLS and depressive symptoms in an 11-year-old girl. Sleep Med 2009; 10:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/130\">",
"      Konofal E, Arnulf I, Lecendreux M, Mouren MC. Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome. Pediatr Neurol 2005; 32:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/131\">",
"      Walters AS, Mandelbaum DE, Lewin DS, et al. Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD. Dopaminergic Therapy Study Group. Pediatr Neurol 2000; 22:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/132\">",
"      Manconi M, Ferri R, Zucconi M, et al. Dissociation of periodic leg movements from arousals in restless legs syndrome. Ann Neurol 2012; 71:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/133\">",
"      Saletu M, Anderer P, Saletu-Zyhlarz GM, et al. Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. J Neural Transm 2010; 117:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/134\">",
"      Ferri R, Manconi M, Aric&ograve; D, et al. Acute dopamine-agonist treatment in restless legs syndrome: effects on sleep architecture and NREM sleep instability. Sleep 2010; 33:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/135\">",
"      Gagliano A, Aric&ograve; I, Calarese T, et al. Restless Leg Syndrome in ADHD children: levetiracetam as a reasonable therapeutic option. Brain Dev 2011; 33:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/136\">",
"      Whittom S, Dumont M, Petit D, et al. Effects of melatonin and bright light administration on motor and sensory symptoms of RLS. Sleep Med 2010; 11:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/137\">",
"      O'Brien LM, Ivanenko A, Crabtree VM, et al. The effect of stimulants on sleep characteristics in children with attention deficit/hyperactivity disorder. Sleep Med 2003; 4:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/138\">",
"      Sobanski E, Schredl M, Kettler N, Alm B. Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep 2008; 31:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/139\">",
"      Hornyak M. Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management. CNS Drugs 2010; 24:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/140\">",
"      Hornyak M, Kopasz M, Berger M, et al. Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. J Clin Psychiatry 2005; 66:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/141\">",
"      Kim SW, Shin IS, Kim JM, et al. Bupropion may improve restless legs syndrome: a report of three cases. Clin Neuropharmacol 2005; 28:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/142\">",
"      Malek-Ahmadi P. Bupropion, periodic limb movement disorder, and ADHD. J Am Acad Child Adolesc Psychiatry 1999; 38:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/143\">",
"      Nofzinger EA, Fasiczka A, Berman S, Thase ME. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000; 61:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/144\">",
"      Bayard M, Bailey B, Acharya D, et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2011; 24:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/145\">",
"      Trivedi MH, Rush AJ, Carmody TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001; 62:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/146\">",
"      Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001; 25:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/147\">",
"      Zimmerman M, Posternak MA, Attiullah N, et al. Why isn't bupropion the most frequently prescribed antidepressant? J Clin Psychiatry 2005; 66:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/148\">",
"      Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/149\">",
"      Rektorov&aacute; I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/150\">",
"      Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/151\">",
"      Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med 2011; 12:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/33/32282/abstract/152\">",
"      Benes H, Mattern W, Peglau I, et al. Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. J Neurol 2011; 258:1046.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16995 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32282=[""].join("\n");
var outline_f31_33_32282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21806603\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21806611\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21806618\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21806625\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21806632\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21806639\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6963820\">",
"      Polysomnography and accelerometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6963429\">",
"      Iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21806680\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21806687\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21806694\">",
"      Periodic limb movement disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6965168\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21806701\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1419667\">",
"      - Restless legs symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1419761\">",
"      - Leg movements during sleep",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21806716\">",
"      COMORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21806723\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21806730\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21806737\">",
"      Exacerbating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21806744\">",
"      Iron supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21806751\">",
"      Medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1417013\">",
"      - Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1417021\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1417167\">",
"      - Clonidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1417177\">",
"      - Dopamine agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1417528\">",
"      - Combination drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1417573\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1417583\">",
"      - Special populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1417651\">",
"      Young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21806758\">",
"      Children with ADHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21806765\">",
"      Children with anxiety and/or depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21806772\">",
"      Psychosocial considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21806603\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16995|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/62/41957\" title=\"figure 1\">",
"      A childs drawing and description of RLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/59/30643\" title=\"figure 2\">",
"      An adolescents drawing and description of RLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/0/14351\" title=\"figure 3\">",
"      Typical sleep time in children by age group",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/49/21276\" title=\"table 1\">",
"      Diagnostic criteria for restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/49/22299\" title=\"table 2\">",
"      Considerations for the diagnosis of pediatric RLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/36/11852\" title=\"table 3\">",
"      Diagnostic criteria for periodic limb movement disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/5/32859\" title=\"table 4\">",
"      Differential diagnosis of pediatric restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/24/40331\" title=\"table 5\">",
"      Sleep hygiene child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16995|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/32/32266\" title=\"waveform 1\">",
"      Recordings of periodic limb movements of sleep",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2970?source=related_link\">",
"      Acute iron poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5929?source=related_link\">",
"      Assessment of sleep disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36806?source=related_link\">",
"      Behavioral sleep problems in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=related_link\">",
"      Clinical features and diagnosis of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20902?source=related_link\">",
"      Growing pains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/61/15320?source=related_link\">",
"      Medical disorders resulting in problem sleeplessness in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4711?source=related_link\">",
"      Nocturnal leg cramps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=related_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28473?source=related_link\">",
"      Sleepwalking and other parasomnias in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_33_32283="Signs of autism PI";
var content_f31_33_32283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs of autism spectrum disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       A child with an ASD might:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Not play \"pretend\" games (pretend to \"feed\" a doll)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Not point at objects to show interest (point at an airplane flying over)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Not look at objects when another person points at them",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Have trouble relating to others or not have an interest in other people at all",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid eye contact and want to be alone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prefer not to be held or cuddled or might cuddle only when they want to",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Appear to be unaware when other people talk to them but respond to other sounds",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Be very interested in people, but not know how to talk, play, or relate to them",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Repeat or echo words or phrases said to them, or repeat words or phrases in place of normal language (echolalia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Have trouble expressing their needs using typical words or motions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Repeat actions over and over again",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Have trouble adapting when a routine changes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Have unusual reactions to the way things smell, taste, look, feel, or sound",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lose skills they once had (for instance, stop saying words they were once using)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. National Center on Birth Defects and Developmental Disabilities. \"Learn the signs. Act early.\" campaign. Available at: www.cdc.gov/ncbddd/autism/actearly/autism.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32283=[""].join("\n");
var outline_f31_33_32283=null;
var title_f31_33_32284="Allergen reduction PI";
var content_f31_33_32284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Basic measures to control exposure to indoor allergens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Indoor allergen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Recommendations for reducing exposure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Animal dander",
"      </td>",
"      <td>",
"       Remove animal from house, or at minimum, keep animal out of patient's bedroom. Keep pet in a room with a HEPA filter and replace the filter as recommended by the manufacturer.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cover air ducts that lead to bedroom with filters. Replace filters as recommended by the manufacturer.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use air filters and vacuums with HEPA filters. Replace the filter as recommended by the manufacturer.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"7\">",
"       Dust mites",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Less costly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Encase mattress, pillows, and boxspring in allergen-impermeable covers. Finely woven covers for pillows and duvets are preferable.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Wash bedding weekly in warm water with detergent or use electric dryer on hot setting.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Reduce indoor humidity to &lt;50 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       More costly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Remove carpets from the bedroom",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Replace old upholstered furniture with leather, vinyl, or wood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Cockroaches",
"      </td>",
"      <td>",
"       Use poison bait or traps to control. Consult professional exterminator for severe infestation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Periodically clean home thoroughly.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Encase all food fully and do not store garbage or papers inside the home.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fix water leaks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Indoor mold",
"      </td>",
"      <td>",
"       Clean moldy surfaces with dilute bleach solution.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fix water leaks.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reduce indoor humidity to &lt;50 percent. Avoid use of humidifiers.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evaporative (or swamp) coolers should be avoided or cleaned regularly.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Rodents",
"      </td>",
"      <td>",
"       Consult a professional exterminator.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Periodically clean home thoroughly.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       All food should be stored in sealed containers. Do not store garbage inside.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Repair holes in walls, doors, floors, and block other entry points.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The measures that can effectively reduce exposure are different for each indoor allergen. Those listed are suggested, but have not been verified to be effective in isolation. Studies showing greatest benefit from indoor allergen remediation were those that adapted the measures to each patient's individual sensitivities, and addressed all of a patient's allergies simultaneously.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: The Allergy Report. American Academy of Allergy, Asthma, and Immunology (www.aaaai.org).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32284=[""].join("\n");
var outline_f31_33_32284=null;
var title_f31_33_32285="First dose diuretic response";
var content_f31_33_32285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peak diuresis after first dose of loop diuretic",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 248px; background-image: url(data:image/gif;base64,R0lGODlhsAH4ANUAAP///4CAgAAAAEBAQMDAwP8AAP+AgKCz/9DQ0AAz//+goPDw8LDA/3BwcDAwMCAgIBAQEFBQUKCgoP/AwBBA/2BgYP9AQPDz/+Dg4DBZ/7CwsMDN/5CQkHCN/1Bz/+Dm/yBN/4CZ/9DZ//8wMEBm///g4P9QUGCA///w8P8gIP+wsP9wcP9gYJCm//+QkP/Q0P8QEN8GH99mgLCw76+Pz8Ct348mgK+Av885X788bwAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACwAfgAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsaoECLK2t5MIAQIDuL6/igMCvMDFxoIExMfLzHjJvUkEAdPUBM3X2F7PStLUAQMB2eLjVAgcAg4EC07T5O7vS8LDAtZN7fD4+VX3+v3+S/z+CRwIICDBg/kMIlxITiHDh9ccQpxoTCLFi7gsYtwISyPHj6s8ghxpSiTJk6FMolzJSSXLl5S6gYNJ05PMcDVztsSps+cl/5c+gxoCKrRoIKJGk/JBqrTpHaZOo8qBKrVqG6pWs6LBqrXrGJUMGHgdWwYshQ9k04Jx2SGDWrW6AtQyomEaBnY8m2To8HasBgEPHgjQUKQCOgj07OVl8oGC2L5aHQhAgABdkWELdi1GQpTBWchZhwkRTcTwAwcO1jFB2hY0ygUcqEmAQpr0kHOSIcwt0o3aTCl7XZOUNwyaE8QLFgiAQKRyr3PGifSe9jtK48fCOaIjwH13E8PTBFQAkCwAhuUaDI9fvdmJZ7TZB3JAXNyIg/ZNFkQYFmFdeQASCAZBBaoBhF8TrcUn0HIDNNiAEQ08IJsbWAWnoD8SKkGcMmxgdf/dhf0QIOE0sxWBAHfdUXige5+BiI9k80RnB1cAJOjiOwJEgKJ39GwoYxo0AmDhjeQ0sJ4RAyDQQIMOqpjFh0SO46MeQQIQVpTjLMnkg7xFsKWTWOZEX31XrRjmQhJ4UyIREHAJR5VnijNlERIMsCOYXFwZpzEncgfBmkMYFiOeW7y3JzMDRGAEOhOW+YWNh+KSZgANcDjEAG6ycRMYQ0Zqy4aEFQbBl2ps+gWUnsrSJwF3ITmPpWrAaYShqb6izqq0UGnmFZDWukqPr/5Ih6xHdOprKuZNSiIRDbQ61a5XoHrsLcUBSigYtE57yquDDgGbgBV4twaxSPSq7SgNQuD/QLpHSlcBYg5IUCCQ0GZh7LmjQFCPkUksIIFk9cRaLxbS4iuKeADoJ6yJztJ7RrYGh1LpPJvhmuK4A2dhbsSecNAgB0dsSKbAadzL8SkRVDDNAypbewa5SxR8sib6LZfpEPoKEUC7TcQl7hB1maeYGnrOzIkwA0i2mboEaLAuFH8FNlgRC0iGWsBKwGy0KlMDsKQRErwaqhOSUWZZaQKA/ITWAhXdFQTh6KeoET5HUZsARSAmjAMNJ8F2Exts0IxnF4w18TBjE1EXBnLRhjcAto1Gj3pHTPdNxl50EMI1HpxAlscRJD7ExASkDAVyyjHHJt7bGGF5dUsooIAXnonQ/8wFFAjelQTymm7EgOl8AwV4u4z3H3jgDd2EAgXM3kUIGRTOTAsgSJ/VAxwIqjYRPRJQwcJI1JyjfwLEvZ8AN/s9MPPOc+GBB8YEPgQJfGlFz7pfF5H0A/ttjzEU7OvCBTKwOWB44ABDaIzurAK38gnPRPRJzbWYEEAuiMAxv7hAAuAjhBa4JSukcwDPhpCrNyClgoWigO1wcYAPEoGAWYGNBjLzM9g0qkOYEwIKtQA968niBC0wgggSsMK+CKZbOKTCDrPwPly0qAjQA02O7uQoJTaPCwMsYCwY4EIjZCCIfeFXHLCyxCtcEDuvOEH9jrCBJ6YlbEj8nxXKaIXaxf9ChUroAAmkggAvNekyo/pjEq9Axyr08BUiAMESLgACMDbliCMbQobGmMMjFJIKTXRFB9aYhDb60Cg5UkKEbihHLFxSCll0BQgWqIQTwK8pEUgfEeY0yCycMgpnZMUFnYA7NBblXaRqDopKWEtbXlELbkNFCDznHl8KhZZ0MNUWbsmMDDhza1WQ5jSPSY7GQCZZatLVF6hZjBYw8y3AiuOMKrk8bl4hmaPIAAKnAE+a3GqYPxsCAuQ1wW22r454LIUGP/kEBlRvLMmA27y2wk4nkJMJhyTFAV5JBRJosSvSgB1Dx/DQJZxgj6SQXxWGyMGqrCqfL2voEzqahAFyshj/HaBoTxagDnVAKFj99AJLkdCYeRoDd6ysCRwJ4ID0LYeUJCvDTtkYUGMcQJE9Oc0DMmqESb5JpVFYqhEOQAGC+gKGOule/phlp4sVkwxaLcIJurgJkWbBkzph2X3a5Cp1OgwNaX3hOTdBAp9m4QR7hclfhgGBvgEonFXEqzungDu/YuIDCfBqFYCqE11wwLBYqNsRMEBMA60hr0K4YFAtsUwvRFGovRthwvZDV6gBRjCiS5hkwFeEvykBtADgakktAYJrYgEEjl0J9rTnqqSVDwplq4wDbgor9bWBeSuYQAmq0BbJQiKRYIArTO6HqR91baxNuBtvytdczmCVkCyw/wAMCjACExhABROAAgkCOwk1hsEDL0VJA6nzO/PNzQni9dYDGtA613njcnJAwQQUYAALjKAAKbDAClwwARS0FKyVaKoXIFvElYRwhIfr2nEEkJzlSIdbwnrdecPwAhUYIL0FKIAFWPDeFxAhl1yYgI4nYAADKMDCb2jhGEIAUpbIkIZHAF1sl0A8hJWHpgTADUpru2IzKNgFK7BACthrAR/fYAZN2DGPe9xgC5g5xjEegZklbAATFMAEP26DBxwJBkb6FiQn5YL4+kOe4wqhwJ4txARcbIIHw4DNZT4zmtVs5hWQGb46BjISUOCCB5tABWoYKBnqCZIQRydJWhJkKf8TUYIxv3fHktZCCSoNAxZg2gwtkGl8RlW+AXOPANBM6i1WPYJWv1oM8nQRPUgcgP8+pcpzOEBwyfCCFaQABiuw8Rd2KWwNJOpp+sNJA4yta0UcIAHLLkOzU5CCaHehA/Td9J0p0oAADBZQjHsAOAKA7bMm4tvhNkOzYVBuaf+2w2YwqHUxQpnxcgvZU7AtG/ANBxWwAAYjcMF0q2BQNliUJAgAGPaIQFMRmtXe3ga3HBwOcYlP4QQXRQNkd4sRB0BAX+AFmnkal1hHMHwOKnBzxFO9yA22gcgjGYydHsisYZROtSmVxM3ngAIFuNm9ZI661A0gAxtM/epkpjAWewv/Egh4TAMs+10FgkdbMig8yCK3Q9Oxzva2S50FW5awCiYOUJZPZBfzwNpocO29sn8F4XhY+iVQ4GILQNi98aWCHkGi5JA5gH9py2kjBK+JFyiABQ8ewQoUQPcmpHIjvFMCAiK40LtSgvKcUHCDYXBoA1SYCaLdiJeY0Nk0aHMSqP9ECRSwgsyzQAH+NgL1Bk6QAFFxln4fw+1xn3Y/uJUMPDZB3N/L80xSJNcFSX5ZAM+H3OPhgGsogQqyDOHfT5eRdH6IsgLgskoFc9SW8H4dNP2GCbhA5y6ogYYZUhcAMO5n2LdRmqBsfTBRdNB0DxcDORB8CzFJiSJOFwF+d6AC/zgQAyngagyRGNlnBBGwXBgAN5JHEPR3B41BA87WanE2ECyTHCK0KKESc6YHEQaoB3rCa2/Gef+Ad0bngkIAgwLYCQR4BxIICLuHf50HD3USOkcQAW1SKf7TbZsgf20wgoKAgPxmbvCQZyZyRBJUc5wghWswg4jgcOSGgVmCU5UzZUkHCmCYBkPYB5w2BOOGgjx3DEe1LEXQAKqBAbK0hmzYfG9AhXwAMUlgg+4FX3UIBqW2Y0lQZstjAQz4BlYVMvpCAKMSgpnQhmUghn+wMYXIe4qmZo6mANLlBQaAZgWABMzjXmFmAEf4BktyfEOAATDCN1GgWRw3KZh1BGf3B/+aOAZv+Acm8wQ61mNmtl4RRmMUFolRMAEypkPvZQIm8AIlYHgsUIzTxWPTlXMzho0AgAJZxgLS5mMuMGOJ+AUBODF9mARRA1u1NQ+FpTyj8It1FlmDIDNX8AL212ZaVgCHBnU6RozPCACGlwIPlgIvsGUjwGAFEF+nuGBv1mY91pAA0GsG0GvTlWZbxgJmsH4usx/hwW1LkFxnQ0J3AZLyOI+AmAacGAiE+AWlxmDp9WAy1mWJdwTOaAFCYHhC8GAA8JA/SZEP6QLs5WNBOQEvUAArAAAqUAAuAADPiAIDKQYY4B1VyYGhUjqOIzlIYBguw4vcd28reQbBGAieSAb/CuZiN2kEObmTqUiQqQiUcimUhqeUD+mMBgAAeAmVOsmXZhcdROctNEVTu4gEAWYiJckbB6ZRKplvYSCIgjCMcLBq7BVfPAmXRwkARDkCBrBl9hddqwiU/DYBbmZjAzmVYaCDdjVURXU6JJY6YKMupfdnixmWIeeYX9CS94hBdnCKaIaZmAmUKGB47dWQKrBlb4YCQPkCB+k8p9mXYqCakSQEUkVVT9BkxnNc59Am7JeSpkCPbzVag/CS4xCYgbl3duKD/XI+fPYfAWgEvVgI4DkKZ4kNVzmLPyNXAdBaIFcK8ykKkvkPg7Uchbl9rRCEsYCPA2FZBWqgHEOebxGf/4vAALhJBc+3CPVJFhKqCAYFXF3QV5AQoGOxoYvwVB76JPb4CAqqobYZfyBwolYQa5IQhyPaopdgohWqBNaETXNAopCAo1NAbTxKScsApFCAbpdAo1bho7j3ojkqBKuUpF0VoTbqCUaqBBsAVZdgfSwqDia6bvaFCb2EUNRRpaFwAOu2f5VAOF6xfPnARZzApV3BpJ2wAQdgPXPGCbjTAnYnFXTKCRuQARRwAiKgQX26ph6QAF8EcFHxp50gAidAASBQZJ1wAQwQqSDQAeJpFI7qCRdwAJsKqB0AAoPKAMRXE52aHSLgQQngAaGKqmYaKR8Aql0QOIFjXYtXnrF6LP8bwKdXkADAmgC5gwQkkAANsau+sgEeIKkncKdTAKw1kgAF1AIk4AGPUawA8AEhIDjaKjgM4AHz9aqskKpnIgJEpqgdsG5GAKzQAwJo0QEJEFMJIBbYugHSCgD2GgLf5gEhwK++QK6HwgBtkQAWxajrSrAgcK8U4BYaBD/1eq/52gKKqq+/ALCe8qknQKqumgTQCgDQSrBCALIPuzn5CgDnGq//iqzY9AEtEKrA2qsJoEiJygAhkABBhK1DRAHnGgItoKn7Kgr+wn6zaV5DGgfBSrC2cwGJSgH1g63RCgInIK0GBawecKqWMFuJGWhFGxR/oSj7sWRgubVCoRkF4Wf/7CG2QUG2ZFs5izlvB/a2cBu3cju3dFu3dnu3eJu3eru3fNu3fvu3gNu3emcL5/AgTogEr+O2gesbiru439C4i9sgjusNkju51AG5gVu5lqu5m4u5gMuYsnAeUyUYDToE5HK63Ie6XqC6XQAzrPsLAQIYX0m0rZu6tru6t1u7uPsFr6sPvasFv5sFwYsFw0u8udsPxWsFybsPx7sFy8u8u+sPz5twzQu81Su814u90Rsig4sF3KEN3XsF39sF48sF5bsF56sF6au+4WsF64u28Bu/8ju/9OstacJPHIdPV8BZQ1sOeGi+NrUFQYtVGBAb1sJZKFK6ShA0CswEhGm//0LrvrtRwAHAAf1LEVi7XCdmV0+wAE6jgVrwKus4BUO1BaPHCw9gBWEzKtymmg1lGC4HwlRQOmabwf7LIcShwSDRtQDwtSeWDrUHBcmwg1swG5XxOFnwgUScBYKhhk0gurNZPNzRwEeAGWtbBRQjBDzsw1IgD8YxQwsgGO0LEWprtn02KhVAxUggDGNMBaK7BUwiw1ZQGVIjkk+AG4jxhLsgbwFwwUwGGKjhx/bgZ2XMToBGnQKgxgNRyM2hMntzBWzsBVyMBfOBAZGcBcmQDpIxu6shHhqAGA0jAe0mGCO8BLixHE48yDjByFNwyIVLEq98uFWMxFRwyVqwAMLAyf9dzC1t7ATOUbbsdA7hYMsnpn10QwzQQbx+FsuR18qWUilIdxGiKyKJDDm9UGzfUF5O0HFpk8pOQIu8YBdZ0CeSYcFaAFsA48aA8ckQQFPHlTIBIBjsdB4QkB4I477qYQ3TTLpTYA7bsQ77MSK9zBCx+wAlQgxgxx+CHA1o6L28zAXEfAUZtxy6zAQFXQv/sZ82o8LgstBKwC1CUNAVnQQbYg0HV78ondIqvdIs3dIu/dIwHdMyPdM0XdM2fdM4nQcWs09JkgXqmdPNIDJDp8hrTMtAnQ0nks8nIjRpYm16+D1zUTqYMrTCoAEREAFz0XiHFdLhkCYFjAELoCUqe9TgR0HIiSEMUkNrKdy1lWLHAIDWkpHClbJtUyMMQmDXwoAYIgI3EULWqLC2u2ANdu2eeAOS8WzUl/I4kgEA6pIwoWTXb403wqAaL6cyRO3XlQDYZ806x4XXDiQRkG3XykAMoS3ZSNxHAnLZmC0Jmi3YnD3MeHMOOpIeAHAOWFPaPTwYuwAy+xFLiBHZlyIBuDYZq00KrQ3chK0zR+S1KTxLj2PXNdNaCCAYHWjaQ3A+Bl3czfAn2k0SGODW3R3e4j3e5F3e5n3e6J3e6r3e7N3e7v3e8B3f8j3f9F3f9h0pQQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increase in urinary sodium excretion (UNa) after intravenous bumetanide, given as a continuous infusion (solid line) or as a bolus (dashed line), in patients with stable chronic kidney disease. The continuous infusion produced a 30 percent greater increase in sodium excretion than bolus therapy due to a more favorable rate of diuretic excretion. In addition, the natriuretic response declined over time with both regimens. With the bolus, for example, the peak natriuretic response to the second dose was 25 percent less than that to the first.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rudy DW, Voelker JR, Greene PK, et al. Ann Intern Med 1991; 115:360.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32285=[""].join("\n");
var outline_f31_33_32285=null;
var title_f31_33_32286="Migraine prevalence";
var content_f31_33_32286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Migraine prevalence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 370px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lipton, RB, Bigal, ME, Diamond, M, et al. Migrane prevalence, disease burden, and the need for preventative therapy. Neurology 2007; 68:343.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32286=[""].join("\n");
var outline_f31_33_32286=null;
var title_f31_33_32287="Diagnosis of dysphagia";
var content_f31_33_32287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Diagnosis of dysphagia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 448px; background-image: url(data:image/gif;base64,R0lGODlhPgLAAdUAAP///wAAAIiIiERERLu7uwBmMyIiIpmZmd3d3REREWZmZu7u7jMzM4i4oMzMzAAz/0SPabvWyVVVVSJ6TmajhXd3d93r5JnCrRFwQaqqqjOFXIig/z8/P8/Pz5+fn9/f37vJ/8zg1u718SJO/1WZd0Rp/2aF/3etkt3k/zNc/5mt/+/v7w8PD39/f19fXxFB/+7x/8zW/1V3/6rMu7+/v3eS/6q7/x8fH6+vr09PT29vbwAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAA+AsABAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6cBrq+wsbKztLW2t7i5uru8vb6/v6zCw2YBxKDGx8rLWcnMms7P0tNL0dSU1tfa1Nnbj93e4cTg4ork5eitbgEEWQMCgwIDTOxS9Vzn6fqi2QsBBmXuFSGQD8A7IQfdwTO4cElCegQICpEH0V67JxSVFNzHkVM2AQwSXBQjkIhEhwsfXlHZhOWSkxk1jnxSslnHm6SyGRCgQIGQ/wAMXB0wGDSAT3kCAiAY4GrAAgSvGCwAIMFVAgBAhRIx4Aog0wBOhxx4dWBAUZ8IzhbJGmCoArJjhR5M+s8B1qIH4rYdUkECEZBYCXD9J8AAV6lE0r4ioGCewQoHErgSQDCoAbtsh+pFW5QdxbdaiWzESXqSNYILCCSYGgCegKsD/DoI4KBwu8ILFjBoCDVDYQRDWgMobDIZbt0NGSKcRxCBBLQJ7AZ3fXWIAgbKGTqIDqAvVtdekwPIcLUxVXjsYBpAsCDB0CESHLODioD+gApDCNqV4Fc4cbEBLCABdoHFBMB1a5WmoEdFgKZVPc0l1FZGPU2kgANftVVhcO0cAP9QfslsyBMRCR1E32Ch/dROc691ld07ev0TGAAeZjeEPxncFxlmERnnmAHvCQGkigxV4BMBQQ3ggHoz1nhAZwgMWeA8Lcoo2oJYYhJNexlMhF09FYQ3nlIZHbcTgv4c8BuHNH4oBGrDGZDbTiTipxx9zyEB5noBdBnmYwgJsJ10RNZ4nxESuLdddekFONyPQVIlG4QGcAefAicx4FM9NRqAXwZK8QfAbATI01t3bv6U5arYEBHZEFDN1lU7GbrmmEFNpSYZV0N9dRWnqeom41dhAdiWiUop5gpwwc2K6z8AxVWWa69s2mG0KQ63GgCaqijsTpAS4cBh9zDg2FeXEeT/CgPAATtcV0qN+49n86CbKlas5gtJQSW59EdNf7Q3E4hUzMZsNfomzAi/M/nrB8B+VECgESc9oa5wTYym8MZ6aMwxGx5/LLIcIY98Rskmp6wGyiqT1PLLdrAMsxcyz2zzFjXfbJPOPKcBzM9ABy300EQX/XPPSOebc9JMN03H0k5HLfXKU1dtdR5QX6311ldkzfXXYGcc9thk01z22WhX4XXabFu9dttwO/123HSvYfTdeOet9958B103q3P/TZPgWQZOOD2HL2h44kkszrg6jxcTOU6OTx6c5R1VjrnmmG/yQQeqAtDBB51r8Xnoo5euzQoBcOBBAB5wEMAKqmPB/7rrsMtOe+3UuBCLC7xj4TsswAc/TQexgG58FcjDovzyz8juCgfQWyF969VL87orHmRPxfawe/8MCwGwID4V5Jt//jItBNDC+lK0/z78x3wQAOn0P2E//vkPQ0P/UPgfAAdIwAIa8IBw6JsCF8hAXiCigRCMoARtIbebcW4MF8xcBW2WwTB0cB8fREcIpzHCLpSwHCf0RgqXscKdbZBpLTxGDLsmtRmScApRao26BoaEil1CIgaagg3VJogc8oYr4lFCEPfgsNDBMAkokgBwKFIBx+zmUUwA4q162A0tTmSLQyhREs/gRSsMkQrdcEBRGBApKpQJjFKoYhHkCIUlVv9jRcnwoRT0mIQm4qtp5BjSUuQEn4WIxGLGsGMd4VgEP5IxkYyEwhmFeAQG2GlEV1DkFCQgHk5GQZN6wqMW+IgEP06ShVAMUgJ8MwC9oIsigpkMnejTnFcwBY9TeVMiDQOU1CilWp+BC1kOkhkAxNIVRRjMZVwlmdZ4Zwgggcq6fIlF1QTAPdxKjgTsZIRTRqEb5ioCXZZZzMhMZjPSNAosJYNNs7jCJyZhZ15ewSy9LCVX7wKKXegCliJUZTL5vIyDXmEAIPISMf/EmBDM2RpljkUIFeInhuBxnYNdDpCpDKMAKCKh28wjAQ2ZpVLKWKEN6TJO7HFPGQ2EIDF+J07/AEgAfkgJAE/VaQjkOdA8PCmE3ngRpDRajXcG4BNLdfOBR3AAaJQ0qO70BzyAKsJYFvDGmMIjMgsYAHOUQgSgYpUlc5ETcmZjl8aQCovQTABw3tFU70Aoj7tMqZrUaqOoGjMZDz3QhQTyDvMcwZsyzKgQVsnRhdTDVFwVEjxoCck3qTWxJ80IkFZKpWaKSTnAos9dibAAB8HzTUlyAI50FB0MkUWLmsUKAsijJgbkVE9IVcJ1YgQQdyEJLA54Ej3fmFqlIOtgvV2KeA4iIgXUyJhA+hBL4QkjWNRWlJuV7AE2pJLbKukkee3JcRGSALr+9YVGEOQAAFJYIlEEqAg5/8pIEzkxs/ilOGidLHu/eKo/HQqz17Lqu1zlqG4hyieJOsCiDoSdNP2UOlPpLgJe897vHgKc7zGrUZuUqufYFFQLJtB5EfzbrnJ4uOCZk6BoQxUlkTg+fxHrTpoanC7BqYxAMtMYn/PiZGnqrAgx0noc/EQkRHEq5Z3ROiejrqAgQCLbMcqYBgbjAyBZMgrgaFewdSz05DcuXElMUQzw2Wct8zVT6ZY1eeVFa2KzxABIU+NiO8eoTLFaFPZybeCFgCRHmTnyvBNkjZlnsKYEn3RhQFnXtUVhESafSgaNGv/RZEPTKYxdEa1lcJWAbkmUuMtMEEbfAMoy/GcPgB0cKf8WICUskLqNYAj1MFaIgFWygS6H5IOqxcaPpjTD1gEB78tmjbio8XoVv+YHmzfd4z/Q9CWG6zTOhv3JSHbh2FhoNaq34EhxIvObujaDHR0JbQ6dpNtVMBC40chsiBEMrWMYNxUUwM0vVPtG9Xj3RYsdB25r7NvJdrYJmZ1FH5VB3VKASi7BIO9RJaPgf6T3EtIplUUHQAJZtQqfrzmUY250Hg6ap1COWXEUEeG1QpiNP45Z0KxMWFl+IdZTbOvxwhyGmi7vJVVeMcZeG8IajQrKhJUZc8SMk1DI1UoFXuEAZeGnMJKRSmWuOWitHNMYfgWSwxtMIwJF/JpB34vFzTz/lJ5PJaECuHp1ehoVUsvCyYPplTxSFexUlKw3gNHlwL26GvSim8DZwWZOgepDf+R2PQLoT490Sasuo3giYt0NVPIr0+iupz1OjivkX7PWmiPswWvpUeHhi1LIt5Xqev9Vl4Qgqu2USsWUiXeXEdR4iUS9tUfAJJwGO5S9N4TuVH28e9b0jtkfwacHN2TtYcMuTStcCaYVinOAMpShgzS4kKVIlcSUzmVxVY+7YaMCPNmok+p1K0Eq7uLbpNkmN5m6ltdIuQf//XNLl7awisWCuaKAUyNETefCVIiOYtnyQx1Sy8dGf/FZzicA1fdLzBJc0oV+3XFNyZF8bXESyAIL/8J1VMTGBGiyF4g3BAYDVGBmd4jlJ15hJ2c2WNQiTglQVNzRKFNxEiaFZognYljRKwDhgY1VU5EXX2qCetoycDZXCDjHfi8IJ9LFYkVQgl11AKVHLwAgbS6oAPVVgydIHKoRJJ9WdUXQgZFidx64GtIlYxwIWRmYg1GFhC7Rdqhwb7syIacFZ1w3ca0hZdBCIxunTHSYFVm4J95iGU+oZa6QcoC2LlSWZdLVaFsGDzzlBGjIYyrShzdiGdKFaF1Gcu0xTUaHaH7Rh/Zyh1mWQyGhJmSRGI5yMUdih9akQ3kmXcKSADtBivE0L2QoLSRXV06UNIs4B1f4BKfWHj74g/+EMEnKhgS5iIHtBoTZxgqwxkPVgGv2wG9wEIx/YRXKqATS5ow6c4udgI1X4mvHmDLaOG8XiDTnAEoAtw7TGAjfWIurUEZNEHcY1I1fpAQ+VI4nc45cEGRG4FKSZI1bYEdB5i/3YG7/doNOgHDkFo7ipG/0CDL26AUOY5DbeHNv4EgCiQbs2AQZcC9fkI6hcBqDsVEHNRUqh2StuEsvN3MABStFMVPsoIFx8nIMtwBTV1ORNiMaNV7KwhmLkV2b4iGY0nKtRBYZpxfTkk+CdhfZknDGKAYcpRbyQJQHoUxKRU85x3SItkUxSQRD5wpqpE0VEJNeFGiiRWJD4Gp+947/4QiCureDubEb+lFQjidXlFdXpScSBCEevwF58ecbE7MV+NEvxZcnreYAA6IiPIkV79V6jcUSLZUSI1ZW8+Af98KRlcNRW7Vg9eKYfmmTjVJ4s9EldnQqLcYXKVdUhAJ8j0JWOpVNUSJgYweXLnOBqaWDxUUQjRddkMKAQyAlrcRHRZghBxCAB9BZcNYvC4EibSEl7HCY9eB/WJQQ0/ciAnBcghFnEbmUYVBe9PGPYedZnCmExqVcWwSBkVIYRrEArAUSOUWeWkSdANEXCpCRgbebDYkFHIkMR9gQX4h6BKEa8NBkYAgfk8J+f5GbBeaShTFV3GItJLIQeSKgBtcj//XRLfdgg8+JH1EYVWx1YpGZX9f5i2OgnWRSL3bSXGG2KaPXfXqlmocHUQc6bdikYAyGdwYGSSw6D9sBEImyEGcZmwp3ihcnJL2SK0+mfzroaMlxib4JKWPGhsq3ZQyqUT0FJfLCFbRyTRR6EVjWWNKyiV1KLfpkneAIokyZmU04onc4LcrCZQdifeDZpv+wRU0aJJUocyimZnMalusiHUCFYUKQkWRwn5/QQfbHBwbjBMO4kfw4CA9KBxDZjAiZasyIBxeTfhMhjbmGeYjwFcVHB+7oo7ZoQYsqqpHqjaPKQfA4MpRZQ6kqMqvKjaVqMq86CQIkCYLqCROUq7qKN/8PtKu++qu8ikCQKqyMSKzCZqwWiKzHqqxjyqzZ6KzNCq3QIK1KSa2WcDp/lDrCiq3JoK3WOgm38zqxMzvEGq65Q67fSgnD8wrFQ6zr6grtmq6S0Dyv8DzCSq+uYK/yGgnXQz3K2q/7Wgng0z3KOrABWwnpA60Je7CUID/Q6rAMOwn7A60TG7G0Sq21arEau7Ec27EqA6wgG0HCELIkGwyWc6v/MrLXgLIipDgqyw2b47KswLJ2E7MKQrOKCrMnK7PAtrI2uwUg8ABu8AAgcARBKwVHu28zywVJuwUlsAFIQLRS8LRKOznZsAEv8AAPIAMwEAVNuwZSawRf6wRjywT/VKt+S0sEI6C1WosCXiu0XHC2RhC2UCC3TVC2xhc51mADD6ACAIACKSADbzu0RSu2cAsFeEtDaTsEI+C3VJC4VWC3REC3TyC59vmzQiADNTAEMfAAMPC0JTACgKu1mxu0KfAAIxADpvsALxADAGACbOu3oDsCIwC1MPACNrABtPsAKdC1MsC2ULsBWpu6ALC2qOu6lAsCxiu0tQsAt2sDNcC2MaC7Wdu7q9u6xTu8riu8WlsCAEC1xku8H5qGRdC4RBC9WhsDo/sAm0u9vAsD1+u6sKu1fqu8bPu3p/sAJvC6sfu9UDsE60u0JuC931sDMZC/gsu79Pu9+bu/KsC2//sbwCBwtA+stfs7voljDc0rBCjwAChQAingtjIguDHwAhP8AK47wkFbtCVwwUJgAinAwG6rAiMAADQMALqLArerAljrtk9bwq5bA4LLuJtLuS8AtRRcwzf8ADYwBLoLAzBQuyv8vS5cvAbMxDjsvXY7ApuLwaagwWzrwVicuSRswk8cxRswxS1MBDAMAC9QukIrAxGMvS8cw3YrAwRMtB2MAnu8ATE8BA8QvC/wvd4btG4rBA8MAzLwx0T7tYnsxYRjDZrLuZ57tub7vSqQtLqbtCawv1g7vP4rBLcLAingtxtAwI3byULwtBU8vDAwv/oLAHS7xwBwtKNcyji8tv8mAAOnvMomwMm7DMsmcMNZ7L+vDMF563bl67hCoLv6G8WOWwI8TMAtDMw4nLWoS8tHu7x9+8moG8qM67hS+7Q1EMG/i8tSa8hUu8cqkL8efMmNLLTtzLaHrI6MYw0P7LeAK7hnO8IA0LknLAQp8Mtw28kd3MQ1UMNy68eDXMzFy8MjAMW1C8RD8MgDLcuFKwRHjMNwy9BF8ALT/LcgDcwWbQKdm8JavAElnczkq7bMTAQg7c8A3csoMNIFbQIHDQAJ7cbBG8cunNM7fccknM4jQMfNXMNSG9RQu8dcDAB8iwIyHc9W7NQeDMmCc7XYzLXgvL5wrLUhbM0lMLwK/b//zhvIzYzKKgAD+du83Ku/6zsC+0u5FXy6omzWt+vVvMy2ggvMb72/8zsCKd3XLA05jBvGJYzXXM3RWrvXN/29Ym3Dwyu0AfzBj223MbC2p1u4KUDAbe23bDsCLLzUHsy9a4sCl426Uk3aVR2th5MzkHu3L9C1SgDNWgACsX0EvTwFcqyIL0sFuS0FuqsFoxy1GQ0FnVvPaGu1V/DaTJACXRy13bsFzo0Ev+0EYc27yJ3cqlAz1d0E3GvCWlADf3wElMsEQau1ZH15yn2zvS0NOBsO790x7f0M8b0N9Y0H960F+R2omEs5880M+31D7L247r05JXvgejOyCL7gFOSx/w7O2g8e4U8j4RSO3xV+4ROO4Rr+BgG+4QDU4R6ePyAe4vAz4iR+PiZ+4t6T4ioeBwz+4jB+4C2+MAXE4h5r4zeB4xyr4xzB4xrr4/oA5BEr5C074+ZQ40ZuCNwqBN7qPUsuOvyT5H5gruO6O+JD5boj5YHwrgEQr+LD5V6u5XyArwGgr95D5mYu5nsAsPnD5mr+BwabP3H+5n+wsP1j53TuBxDbP3ue531Qsf0D6H7eBxnbP4U+6Iie6Iq+6BkT4yX7MSKr4kTui/qSQZMOq6sG6SfT4peu3Qlj6ZweWBwD6pIu6htD6ideMttmqU5QMdXZBAuZeZ5e6VLgL6YU6v+c5StjhI+0SAUVE2WtTpDyGISzrjRZuEbTRkwNk36dHo4Ss1CMtOpZcBLtYVHD3jX22OxtYA2WZCFHYOvMjut80amORXHPiYg0J3aiOE1Lxx1PB+2XGqbJ+Vll5nGvJxHKwg4zadVYwu1g9IbKjpKtoe78TuHW0FlJNxS4V1i8l3q9KIoZ0J8GUVT/mQyuZXCQiZgD0Vh8939CKhGH5xl9WfADzoFLZRe4p+wN73skH+HkMBaHqlqFxYAFKC7A+YTOuR0L9SHVWROodX0ej4MSoZwEIJyDDThJUFGJ5VtWRvMOePQYbg08hVVdSFWZGaAGdzBj2IcWWgF2cqM2STD/G7ZfVKhSxrCEI5GL2g4yRSCAq1n1Ks+DIbdnay+O4qRMK5KKmbmKJflOr0hm+3eHQRFThCKWYR9Z87ClTXgYZj8q5FIqodjypGENWwkUwAHwVsb3qef3ku/g3pQBI18FsV6stC45pT4Jo5+sCoPqJF73UF84m376mT7qsZ/qpr76td/6t//puR/irt/5Od77Hu7ojz7qEMToaPD79I38oEZAyg+tz49KzI81zj/91D9A0c+s2b/71v8GT97k1fP9Ud79a4Dl6Oo95m/l5M8GYA4/7b/+boDm8CP/8O8Gbr4+91//azDn6wMEnsDQAzAekUnlktl0PqFR6ZRatV6x/1ntltu9sgIs75hcNp/RWLA43Xa/4XH5nP5sBVp1/Z7fP97z/AQHCQsN/T4CPg4ZGx2TEhcfJykrLQlpLjU33zI5P0FDRUdJS01PUVNVV1lbXV9h/YZmaWttb3FzdXd5b2PheoOFh4mLjXt/k00DXpmV05yfoaWpOaNZr6u9srW3u78fuVPFwa/Iy83R1QfPl9e12t+j4uXrzehH8e2T9Pf5/QFOmxOAgBYBA6b0A6iQycEzBJ04LMQwYEUo2QIYMLIggUYlEq0QBFll5BOK9q4RCKDAiEqWT0peLGhyZkOETFRakRjTpEWfXTAGyADgQMYlPOfVvIJ0ycl6KYcsAP+gYCUUpvCUfry5JCfJrSF/hs2CcQBCBgM0ImAwpAKCWQrUsgVwUEAABEfiDiHgsMIsB3krAFCp8kDdIQgJGBhyAECAAwZeGnEqD+oAARwZsEy8WLDiAAIEGFDMYIHbIaRVrk3goHFBCUMSAPBsgDXEIwQSBEjAOHRu0gdyf5492DHEx52HGF7pELduxgPWVkUyWaxPjAISZDAQGoAECQAcJNh70zt48aGzSrgpEqHQI+XDE1ApADxEh7sBZIgd4Pu/6kqgekwABQZgCT/9AEiAPiNCQ4AjxoxwK4PBACiwtQaVMCAw24xQkKgEFghtgQW2GyCwlpyZDwC3CjrOQwb/b7qPPuAWKEswu6b7T8d5+DmAKtA0MgDCAQq7SUgjiIzpyAsRCm0lEoc8oKvj5hrAtFlYBHDHHG+zSzEHCrxyCLfugtEIIcGcRUpnFGCJoDaPWICqIdysiUzJEJCoQALWGsCBrrrK8rE7zaySULssWxHHI6jbch+MDggvRI3gE4kBIyodT4lMR9ot064cCIA19RKEULKsGnNUMiRUyhMhC/E74sUqz/Tx0gUc6wpOkQwosyipMmsNCQ+xCxEhBGLtTgGVpOqqsec0mlWAS2klFsRECV1V1W21ZdRU7gAzb6VwY3JgNPY4Oq206AJzds6zkDOKQ0a3harMCjWbTbDg/0AzUsrcFFvTiF0LGgC2vCAT9rbc8FPuO4MzcmCBtQxw1jAGNGrus/CWQ4zh5+jLNlVu622mZG4bJVmdlCdhuRyX0YFZ5W5kZqRmbW6meWZHc57o5J93/q9nQoZ+pmhpjg7aZFeS/qXpZJ5WepWo9aCaaZKtlvqUY7jumut6vQ5b7LHH1trsLbI+25C01W77DbbdliXuud2hWxm47c4bHr2d5ttvS/D++23BCW8k8MLROBzxxUdmfGvHIa868ronr9wNxS0fK3NryO7c889Bz8Xu0EkvnZjNtYQcc6SrW10s1ykbvXXU/XMcdqhnp51e1WV/Xffdbe89rNuti5z4WP+Ob5n2DzrQtgNJCk9+Feadh94e6kd+3vIVAuBACA84CGAFwTvIIRNmaMihea259z4A8MUHqP3vwx/fchdqcaHwGwLg33+18UcL/QUkgLMYoOU6UIv1CU4ItCjC2RJIiwX6I4KzmGDlwjcEDiBuBWAYAgvsd7YMds8nI9wg6hr4vsXpYBY6cFsKH1gRGOpuDYxLxBCsd7Ya/mSHtAOE48J3Qrf98CdEXJ4iHIeDAOBgbpEIixN/5wkg2k2KP6ni77CYRS1ukYtd3JLpwCi9yoWRjMF4Wxk9Bw4x9qQZaOwc4O42uE+s8XL5gAUdU0cJPAJFjtZQox2X5sdK7JELSSP/JPBwBsirzRGOuKsjI79xyNq1QpKNU54j21DJSpJhk92iJCjo2EmwPFKQOuuSUZTgrKW8akGJikJMRMkjSOoxCQYL2bwMoUpZZrKWs1jQG67SlD+yihy6xIIrXWmVr3gSG71MThyCmcdLHgEtdsnS40iJJM2IyhGxLGQSugIdOslmCL2KDkvoUhzFJOA1AQjMQYqyGDVtxjGNic4BrhQZSzYTCRZSCWsM10hqEshKEIHYABaQGt2wRpxVSScCDiqVdn7mWZChJ2P6MgQHACc5OdkOADgyIc+YipkPqeVLdvPQiHbHlxVd1kgBkFFRcfQzB3ELa5h10UlWIxvhRIxd/7oiAZYgywHouVFBDICQotAKmQs60H7owx1Y3vGkHSpSXSB6GIm21DEWhalMN8ovm3IzpzDlEi37uazP8GpEDBAAhSw0gO+EqqgVm4sB2gqaBNwlUfyxan72MxQknehGdzXsU3dq0rQSxS5GFdHE9MpX+vi1VIBtjGArRFiHWEiolUXQWRNJTCTdEgFd8cxiJBJO+uRks628JS0EpZGpBlKbjM2TXR/rVuxItjH9Qax7BnuEzbKks4gFbTiq2k4CwGkuah0YS1zpGIkwd0DM7WtBxNRYxSggoX36EzM4wid81uJe+1QsNdVEq6m8pLovua6iYOsk7vIpAH5izl6tSf/e41Kjp87AFlADIFF9pta/q2XGZk9kor8yqkWypdZ+VZENiNVzuuxtk3sni13yyre79S2qx8iU3fKGsqqm2QteSfRWNkGXPhlobIxQvJ3HftQ2yRqWqYSqKwOAqLLCzCa+kLCTGANpRDSeiY1lhWMFSEQ0N0EyInlKTKP810EUy8uLUTTawjokngfoMj01YhyNcEyf3mTjQIMM4yITOcUKe3KPlcXkpC5Ymshd7FQMqlVdQbelIInoxMqZ4ZbMJl0BIA3EaBMoisbLI1A+b22Fu5U/R8fIgy5noQ9dzg8boSgzAXNiWScKMztBwgOWtFYBnRFBMxrTNdK0RDptaVT/OjqgXEimFKA0kD5mIddyGLXmRE3VLfQ6DiS29S8vchg6GBIeytZ1JBX5ybE429cCRd6uNfFrLIhS2z4u5TSv/eNLdHuUoSA3qAdpbWHzcpahNfe6N2Hsvolb3fyNNj+/bed5szvf/HXj5+CdbcD9m+CzOGPBvWa2c/sa4Ql/VO6wuPBSSBzcxcsixe/dNow/WncbfzfdPF6GkON7cSNfG8R/Z/J4C+8nKh8H79qGPWdozyIuR4XN6y21+b2vfhaPOMzbVsAhHLAiOD94w8WmI6ProYJDuODEkf41U2Y8H1EPHTpMODVQQpsU2j730o8wwwhvferBvjnJv9HDl7fb/95dX/vY0WHEt6+87B/HJtzLAUW8093dZr/73MFxxbOz/RcyNwLNL2F4ACDe74D3ohEUz/hGRD6Hrtg5/EJoicv33O2noPzjjbD5+E1C9JmHhdADQPRLoF71m/j8KErPDqsT/Ayst4TtldH0ADy9Errn/SViTwrcC8LmOfO9JY7/jKyDYvmiGP4okk/8KJ+h+ZWofjLE/onshyL6pLh+H4qPhu1TYvzJUPsnzh+K74ui/HwIPxrST4n4/0Lun6h/KNovivnv4f1nuD8l/q/wkEgU9I4U9i8UApD/6CCaqgCXLiINCtASIvAZBO8TKhAB8UAVJhD8qkBMGm0KGJAKHP/wzM7gAinBBEFPEzaQFFBQcqhAZLxC5FCFBFMQ9FoQZTpwUUAKYmKjOfCjodBJNAytNGaBNFjqmQyDNsgpYhQmIS5u9k6HUaBwGGoQwpzAA5lFVmbkWuZKVBrkQfBCKHarQgQgPFijAvrjTDZkBkltOqYQF9zwDXmBk9pNkjxODsNGChhCZPpCQQ4FohZEuvwlTRbDugQgni5tTqpiBNuQ1k7OEfWNj77NDucBD2uBBjvvAV9QB48gVJAlqq6lxbBMNmwFpKRryMzwCH4FAIKFEZvgGsQIFvttbyaR8LytmzCR6m4xCrDwLfbFOSqkz/ylOQIm1T5KOeCC0uqkAa3/0GcgERfHgBKfERpz8RFf0fGY4GhubQqITeSakWi+sda8oRZnsc5sphrtDh29YBuTrb4EoqQOQRb5ThLn0WogoAHQZpeoMRuxcRcxybyggB3fESCl4NYEsp+QLR2iUQogoAAcEh+RoAEg4NngMQQ0wCE14ALI4B7zURMj0R910Rz3jSCDbBYkABCz4CD5cRrDcBY0wiATUglUUg/pMAoggAIAIAIKIAQ4kNY04ASMoAFwcgw4khbVkQlm0hsbUQqfqQxYa5kiTctEkCa7IDHkwJgKyyNJ0ggqQAkhigCSsibhcQlEBiafICyPkhltcigx4ALuEQImQCIBAC4dki4x/8ACAGACHHICeLIALmACGjICcrIAREAfxUEDJhIJIkAv/TInGbMBIgADCqAtAaABJkAvNaAwScAhCwAfGZMvAcAvAbMABFMnCxPdUFO4TBIljykml3IlvSU/AgwNkCIEQfI2yXAKlswK0DKVMEI+DgwqQSsesqOWzqlKsGqlDI0zEkU5AAo2txIJypI+JiqqNM2lLING5uLBqHIcoeAmAeACCsACIEAD8FIuIWAixVMw4xIJJgAoC4AEjIACcJI+uxMgQ4AC6pInKXMGMAAAMAAiARQfLwADRMAyLUAE2hJB51JA8xI+5RMA7NM+RbJCj6ArWeMre5MeofNZ5iI2jv/QCKsztsgQLa4MOPMJEeHiLZrzNBjqOMORJaOAI8rLDbASK6UpHjixQn7qtgoityYrql6yDF1xOKXAA8kQQywjFdGwt7TsSJbECRfSJjlTI4sSPfFRJ43gHkVAPx0SJ0nTCCLTAsbzPuOBAsyTMx2STPESANjUCMZTLvPyAiiUS720AMBUMHPyLsvUQsOxOPvpOFVKq+yJOa1To15zF4vwR41Qt/aKDEkUOu5CAqiFIJ4yCX5FT4iUNQiER29kxO4TOyfrnuLFGQ4gRq7zYs7QL/qKVMllx4ZQoVajNS6VnpBNHpsAyaiswhhkGY8jOz/wNfVhOg0REeVlJppzALT/o9w41AnA8wiudCI5UksbVDwLUwPyFFo1IEINcwkycj4nkjKPIEDHFR8bwEDldAIuwDJFQATi0loBAFtDU0/ncls79F75oUZtpFUcC8XcqjGElAxDhQ1Tc58cIzyGQhFXwhAjdUGWxFKDk9OiYxSBddByU2T0ASP6o68CNgHaxRkYYCiYVALoairaA7M41rDg4zyGDK7q5FJnxUidoCuxawDAkrSEbM2E5VeJlGBlFgqmc8bKcFYZTMswAxSlQh+/aS2RIFobdDC3tAEs4CILYAKy1QhmIEzNdAlOgDPN0zH3ck8fMjInUyPT9QJE4CIxIC6ndi+vFgCyll4LdiyT/6yWcPYmqMtXh5RKtFJRGUM/isoIGWTIPBQtcrM7uhA4t1MNZTNPqGVJuYlUqCxGmck23mtQcCQnwoPTaEFIPMIqOexygyRK9MS51otWgxMGPYkeFBEudvXU6ksqxCw3nVNYj7RzyRDQOuJQFxFZF6QCeEwCXBNfga0P5HRrGeF4/XQaaXZFbPZ1B1dnZxdyfXYaIWVwEWCiDsAYDxVjDtdcMgJixWXJyskuyKxFDY2hSItyDdZ3dzZarDOmTiQVjaBkSSXJRBdx60NTkEVgTld8ZeQWY5F9zSBROCJplbYj+cACMGAGplJG6YCBHZh457Z1UZJM/IxQp5d3nxM36f/2CbrRCTwR265xOtx3duNJMRLkOZFxLly01fKXXEwyKwmmVvnlZ/cxbVwMgR/YOwUOgq0xUc9RiNtROMGppUiYgq3CADKAO2nTiLeNgBUQiMFxSuvRFpdX+oi48bY4ImCjesfANrsV3A5JZmSGWsdAeS3pjAugDNQYHwa4i8mub/8xG8T4FcF4jJ1SL+5BLLsAjb3gjaUYCgC5CwSZjuMxLasyGqyS40o41Jjpjk34VDgUjvM4Uf5VknE0OtXSCwqZCw75g63gk7cglBNVkpsijxF5kLHAXYZ3aVc5DVBZKSMZimWCkmGZk69APLJgk804CdoWTwGgax0yBIIZKC3/UzIzUyfVlifvVCMXkzPdlGrrs0orMzERKRuCGSeJeSePuTInQJlFgJkn05mtOZodcpq/VEKt2ZQfuVDMYSaKVErfOQ26gkYTJ1SByZZTGVAaBVcHdzS2agivBDUIgryWs54+CoMtozhUo4PXeAkcIDq+AyKqs1DryTLmpETi5RB9MTQEWl+yuIeNgARwkoFDoAAmGABIQD5DAAMigF3dFTLD9FnnUwMAFCi11KTdFAN48qaveZKygadRWqWPoKUB4KVjegLaNS51UjBtWkJxGgN0uo2J2qePAE2DmnLtmJ9JTZ5V+SipYzZqg1TpyVRvwgdBxnCjOIHdAJU3mVnt/7hXHmRagOWXJERFFIaisEM2cNauXFaoj4I7ReJRU5Y73iuAMTXAvnA3fNmP81JN11UvKcBdNXIu1zUxb5Ja7fNc9/JNtZQxHXJdJbNqtzqbk0C0/dIy8dSytzSzt5QCOBsnPbtqQbuNVZu0w9adOxSkhzBEiVBdiAO2EpoxFvrF6qIoHrpgWUZDAPawDMwIQrZDtrBGGKBGO1mRkyAJHWCih+A7VLVCBFUISaOgB5qiCGI4mIGmXhk6u7pWFFYBCDFXosE2IKJVjttVsux0cRgvXoMBGONNMOx9c9M+CupeDmBi9ZsUH9uKS3ook6AtkTqlY3oiGfgCZptMHfgEJv9gQCvTqiFcw4e5w015qCEcCSTcpUlTLi88w42awz28AUD8CEQcxnl7Fxu7MBoVr4VCr+0bFP1aUXz0qIAsHCdDTnxRzO5Ec0H0DzdUiQd5ZKelE7mpU+WqPurKQZJFQsbwuvw5s9q6lmvFro9AAW6FvhlFsCCiK4EMqwjsuQS7CbiDrdpsg4VFsWUjMFxswYUkCz2YWdW5mEs7M79Zxh1SPmd7Lveyw8Wzats4mMezIauWxLF5dYGZandy0EWg0DkT0dtYQnFS0i8zPPfy0TGdPBf9tEVZzEkxvufbf/e6IPD7bvebuaw3C1axFRssQeK3AgjLWmqkvd36z5XAWHv/5b+97HOHVDKKpFZe3RBRN8voy0+y+71J8QhzBWDQfGDGxCVl/TRGcc/ifLvTiyC4l8AT22OSIwlHUUgALVhXnaStQI2nwDLDXJebgN6lwN4VkgaZTMcR2MxNEdaBa81fEp3CfcWYOwsQRm8ZazlXeGGA8cmJPd6RgH6DjDYil5Ua998FHlcKg3AhtlmuobNIOo4tHglCuNocfN4rPQoMHabvnTr03QliXm7lvbf9Bdv/JXxhfU6uBLDBfcHF3cjloInpreLJnU6UgzdcNBiRcBi1fXspLcPePScQDaK1EuXxXTKorQ5+mRznsZ6HmOxDcm63gOI3IkppueunOOWr/9iHx42VtVi73c/uc07pU1LYAeTr257ryxiy0aAoKxkOCD+XzT6I9T7vR1rrqNgF4T4g+X6e5RjQ//jTsXReSZme3V4KqDXzSXPz9XnxIR/Ky7Hx9w7wr0Agb82YKD/x792TPx1aBVT09XgMCpnwbT+W6Z4iTX8sqvf1Ob/ypS3ywb73kRLZXD+sUX/YlUAn9RIDNrMAgPKbPxP00dlqNRsob98JoH8yp7/6qRYor19a8ZE0P5MCtn/0m7/0SV8GBf/3Hd/rLdHgEAlXOjg7dAp93REIBoxAQAEwEA2AJSBAAAyIg8UiGkhUiQnmMsD9gsNgr/gbKUQAEwjgUgCQSP+AECZyXjbYkAYAfQdYFFgEWpR9kXUZcp2lrbW9xc3V/eUB7PXZvQEKEioyIRqCeo6SljYpioIJDAgEIEgQMSwcJBAJEAQMGTg0EeDiHiAF7CoQuVpNNQVHPeEuhJKmmk5TV5dKW4dhZx9+MQggGBw4bCUcAGRssToEZACsQg0A4CLgjhEIGFB9Oy/1j3EDOOrPpTsTLiyBcIGSHj5+NFlqcILCNS7bzGgq+OZgwoWaKl16yGTPxIqejKFMqXIly5YuW6JSlO+JAFkAvg2owAQXLwkSeuES8MWATifv9C341uQnAAVGnMYc9XIq1apWr04NGFWrGFEVJCjIYECABAT/KRGwCrYEHisAZuulcgL1nZEKV4TaTSDUItdPpAjyuRMpxEMRAEA6zGQYQIQJGEKYTDQwY2BIcggrPtwQ05nFjR9H7htN9GhD8JqiVEBgyAAH9o4CJbOgGBEjRucKsP1kXoK3W0kDDy7c2kWtosgpkaAXgDku6wL0lNf27b9P+JCOZcIOwZLtfEUXZwKY8RsLGgoUOAFAxPkJiDGxLzBhiQY2ocMvGX/HPHr18d1vhsZ/9NlX2nBl4EdacafV9MwXYL3GgG6vHRDAMxI24U4+VGRn1BJCMAXNgSOSWKJkw6WyXAauzCOMEm3RZoB0Qr2V1DAWPYHMArjUxmMR3YBn/6IhItRhCigJHkhkGqEJeUqTTpZxGgCwEHGAFbv4yAB3TryGwBDDPEUEWlI84yE6ZiL4pJprUoNkNW6WAZaQcP7G5gkaTHMkm1zcmSebdAYEaBivCSeliHsimuh3KHJjhZZzKqjom4tKyiSkTwoKBqHAIZCAOydVGqqQH3QgWQcfBJfpnqoKJKpUlLp6KKZqshprrbHiCsYKAXDgQQAecBDACqnmKqtxpvyRzSXc6FlKstYsm82tpJBqKqolThtqtsXm6kJKLgi3rXN7QXEOV9u6eUcl1URLHKyKqFvgNO1OKuSuvf4a7LDYcltvv/9W00FKpRIrXFtuYdEXushCBP8tH8y+a8iz7D4s7ZPeogSuieIasmm4AINMTbBEcMCowXvlFqTK8E6A3huVnOByCPylp1kDgpDgMh83ywdZARdMQNFv+DXmsmYAxIzezOfVnMfNFuSM3s7oTeAz0EIbS6LAKBHMr5AeFxyy2J74SoQHJpNSYW1HIWETlQHsZcBuOv4SgLmvrmwIBpUdXcAMTAxWRwMTpDF4IXvQAdkJchQgB94n6s13JX4DfpnghB82weENJI40446D+uTIvDYZngNfSkDLMzXhgkQCVOqUTy2yuAgFma1fATsAtNgS+ti/l8FCACwcCGiFC+SDwALmJA+FUBkwsBZS/MDtZ95idBL/b+YFUCACR5ZcsC4FQu/hhsvzoWEglGVk/zIbg3PvPULgi09+A+ZTjYn6Jpb9a+me1IQL4jjCAX5xBHlU6CgcugUZNpQUBj5BRrvzQk4sBbwLAqAFAWhB8UxxgC+54jTimEtbJLAX3KiGTgvzxN4O4z4uYOACg0HDugYnAu9xDjRMSN/j1leGFt7saEyI4QwjUMMJ3NA9ndvhknzXJOER73+KeEUuzrEKscyDDG2xx2kGkMIloPA1W/TCagLQGidiEIMfCMC1PlYKopwJASI8gAPHsgALSW+BYENjoEZhvvNohkjo0YAIaKaedcUHA+5xIXoowkMn4ueP7hNkAQhp/0ghJnKRPOOe/nooJA1yUIqjyAcAlqcUMQqFi/LoVAHxWEcGfiiVoJBTndJ4QRqMyE2tGEYI5UFAGyVgLGRxzu1UGKnfNWtsHPPEGtu4MQAaw1wVSBgqs/gOY/zERi8qZiyteSVe1NKW4gTOMpnAgE9dr4/IjNi/yqkIXM6KGgczjS9FOc57HlNsK1QmO/vlTlfRaUUOoiet8EkrrCAUK11ZZzoBlkx9GjRrtvxnRIFUKWxQNGznAt5DQyaNhII0pFXp5wUzWlHIKQqjDFUYR0larI+Os6PDIRQBlODGk5LIpPvzy5rQZKR8QpSn/GxVGmUqHEIpgFzkxKnXLrrQof8qTKRSFalFpmpVhGojpi7ty2uWx52bMhVtklLpKMwSix3l4gq8qGmVoCCMAbhuSwQway4GGs6w4tWiRd2qIVzEi7TarUXGWIKV/FGL5rACrhbLK1hT+tRSmCUDBvQic86RjnhMMIJCMVNkd8rYz+o0l3z1BByrR8rlROhTy1GdEL7qrs8u1RAQ0NkolkWvuybIAVaw22ucQlcxjbGbTtBtND0LW7zC6bZ/aVjeMjUbY+hmdwbwjT3IsQTfNAEtSvXXcTcqW4qcATKKUK4nhaoIBUTvjq0EoxGaw4TgOq8X6C1lYMvb3bCK4gIYQA8ExMsF8npiYiw17zSOd5PoqmX/Oa0AQAV0sgQFY2Ger73vsb67hBjyrGp9YNoF8HeBS2zSv1kdsScIUAskrLcpRmDrjeDbFi6duL58pDBOQSECyomABPP7b8WmIWDvotQUXkoCgpWgtiEwB5y8ucI5JMxdGk9YDBCgiBs6t7g+7AwDEUkI5x4pUR86FMp5tXEBeszIAoQAxFQLASN+FoH9xpAxLUMPIJhGEaf9TD4FwEDU1IM/rEEutNDLqZghJluXddhl8tHfGSxg2/vNx75gbmeh8fuFDzdSBJgZSQ4VR4IzPKyF+iUS30hAEQs8ZnBpYIQa2OAGLrhhMYGOaGhpPV6sLXEJ6TvBfCCgnohsesaT//ZnpZmKDfacAGg8xp98/tCJPrRPDYoOn33084YLME0QlKp1U4v9UwszYZOOpFoazPfhqSnty9yusLdtLZ7+rkcDXW4i4nRIniFmmdQuhAOg12VtNahnBto277pF2+5vZ8PLhiYqyAp+8A4yAWouc1yI1dzIZL15zwiRZJ1dZgF/U+beGR74rGcaHkOp8+GSLoXCF8vwMKv8ng4Haq326DEno3zhMf/ynx7r0Z1rVZxG5aoocF5PdgPd547VxlWbTpWkTzToQebCV7gQQCrJwh5DJoIv0poAB6hNxvAwMZN3Vwu48a56aYK60hNV8JmzHVdwH/DUmXBZBcjDhA26Cf8sJRC92OTICEZnjlBY62AoHJ7nUL/IuhbB3Hvr3J5xL/TcgTzsJdwxAzmhhQNo0yMvDDA27I2v1QeAXVeUsTWpVzKJJ0/gLzQeXo+3XkFdX+nKI704yhlHArawd394wScAYEfXR1/B0hP+HQlbAi2nZIS12x6lSUOzyyiA51fTjARzPogmxteHqxXtZ3qVfPTvi/uUX34tCcPQlKJZXSQgofgqnqDY5UF2xCaBuMNg/csnLwrK4YF9qNq9kUCB/MGrAYD3Nc6FIcQMaNloxVb50ZjTUaBCvZ5WeEdPSaAPwU/31FC1bcSOHWD3OVIaBIKiFcIFdtsGsqBTEV3v9Jz/BGIDhuGJEAmGARaAYTSaeZQgA7bdgVSLk5xKCxIhopwf3UWfje1XJWnaflkfCHZc4wzIbGGABvSgnOUPBGrFvfgKsAhLEYJh7eHTEULVWF3Mt4RhGl7KGG7gEdba1hhD16jhHDaW0LWhqHDb6JQMHfKhRkldEuKhmvTP2fRhIUZVBSKiVdyhtqwJFBniI/4cJEae260JKEniJb4UJkbZ0j1JM2niJzIiKBpJIoIUm8CTKKJiDKbiKrJiK46fK8JiLF4iGcqiVJDiLbpELUJiEJLBEOoisRkULf5iRHFhvnzhMGZiMCJjIWKMMWjMMsqdu0HjHMIhEcjhNIYiG2Lj/xzq4TbaijR6IxgOYjgGYnD8GDdEi0K0HjkSoSOyowuCwZyhRwo6y+yh48Ogmqxp4TsCnSXyIyd+wfdUwzkqy8M0AKDt4z+qnCcqpBGKgUAijcxc0uDsFyGdwXmAxvZBxiaxQfghBAUg2papQRO9YkPa3imapAaGgTwKAgDCgeUYERLhEKtNGRdMwAkQxt9UQpw5IBdQAJ5cwgzU4DqmZFFCIzZAZAfKT0esy5T9wfiIAEg2krJpxgl6XAMsYa/xAQmYWUIa5VeCIlLuGAzJ0GXQEBugmkcswfjEGgBYIWFARgECQJwtQSD8Da9FxI3pY0mCJa3hIlX1JfQFpKLRwf8gFRLTHNLEQd740EzQJCDVdOT2WQLVaGUDgA5RBqYy5oowGuKtxJ4pmFopaMDfCGZmgiNAmSZmUsNnesJsVRI9Il1qamM0yqZXcgtn1qbLfWNu1h0G4SZvtkky8matAJgYAmfUmUJxsuaTySZxJgZAHqdvgsGNRRoYKKe8iMFy2iY/Omc2Rqd0wp4GFIl1diUXaCft5aYohN/9VJ/N4AxtoYFVEtIizBl7NlLmtMx8Ro2WZZjVOKYKfmck2uRBCk3F2dkj3GclSKX4TV8IKGhIbuc7ikILXVoODqDhbNkj2SUMdWWsGQ6RhI/mLIGVfU7/BaiA5kcOvpmmPRIEdCT/yXmovPxkH5CmEK3lUPZmYILCs7VBtn2cfXhfhkZAmkHoJtAjtl2lfRxEkCJo/rTcb55onSzoz1Allxkpks5jJWBl/iillmYlX2bmhFbMTQKAwP0oHsjkIqHBjN7YWFIowJWpIKzLQWCoJIjYk0ZpSXEBkZBmA2hAsG0ZIZCpmebBhuLlEFGboVZnjvalei5hA4zcmcbbnqmpHexXy4xlxpVZpM4pQrgmf7YnnubpSrXBA26Cg8rMJRACp+oBZVISIYEEZYKpjp7mqMIcbQ5nrdoqMOJqeurqrgrnbuaqZgLrrQqrrxJrsfLqsdYmlAanslLaZh6ns6IntErrtQ7nOF9qK0pYqz9ta0J1a7iK67iSa7ma67mia7qq67qya7u667vCa7zK67zSa73a673ia77q677eVxAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_33_32287=[""].join("\n");
var outline_f31_33_32287=null;
